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Abstract

GENE EXPRESSION PROFILING: A FAILURE SIGNATURE
PREDICTIVE OF RIGHT HEART FAILURE
By Jennifer I. Drake, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011

Major Director: Paul M. Fawcett, Ph.D.
Assistant Professor, Department of Internal Medicine and Director of Research
Resources, Massey Cancer Center at Virginia Commonwealth University

Pulmonary arterial hypertension (PAH) is a disease of the lung vessels that causes severe
effects on the right ventricle of the heart; ultimately, most patients with severe PAH die
as a result of right heart failure. However, little is known about the causes of right heart
failure.

Here, we describe a pattern of gene expression that differs between the normal rat left
ventricle (LV) and right ventricle (RV). These genes are known to be involved in the

xviii

development of the heart as well as adaptations to the heart during stress. This gene
expression pattern is used as a baseline to describe changes in gene expression the occur
in the RV as a result of adaptive hypertrophy, stimulated by chronic hypoxia, or right
ventricular failure (RVF), caused by administration of Su5416 and hypoxia. The genes
differing between RVF and hypertrophy encode glycolytic enzymes, mitochondrial
electron transport chain complexes, cell-growth promoting proteins, and angiogenic
capillary maintenance proteins. Additionally, we show that RVF is associated with an
increase in the serum cytokine production of IL-1β, IL-10, TNF-α, and VEGF. Finally,
we show that treatment with the β-adrenergic receptor blocker carvedilol partially
changed the gene expression pattern seen with RVF. The most profound effects were on
the genes encoding glycolytic enzymes and mitochondrial electron transport chain
complexes.

Together, these results show that the normal LV and RV have a distinct pattern of
expression and that the failing RV is characterized by changes in cell growth,
angiogenesis, and energy utilization. Treatment with carvedilol can partially reverse
these gene expression changes in the failing RV.

xix

Chapter 1: Pulmonary Hypertension, the Heart, and their Interactions

1.1

Pulmonary Hypertension

1.1.1 Overview

Pulmonary hypertension refers to an increase in pressure in the lung circulation
frequently causing in patients symptoms of dizziness, fatigue, peripheral leg edema, and
shortness of breath.

It is diagnosed by measurements obtained during right heart

catheterization. Patients with pulmonary hypertension have a mean pulmonary artery
pressure of greater than 25 mmHg at rest or greater than 30 mmHg with exercise[1]. A
normal mean pulmonary artery pressure is 8 – 20 mmHg at rest.

1.1.2 Classification schemes

Pulmonary hypertension is categorized according to a World Health Organization
classification scheme, the first of which was proposed in 1973 at an international
conference on primary pulmonary hypertension. Based on the presence or absence of
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identifiable causes and risk factors, patients were classified as having either primary or
secondary pulmonary hypertension[2, 3]. In 1998, the second world symposium on
pulmonary arterial hypertension (PAH) was held in Evian, France. Here, five major
categories of pulmonary hypertension were created based on shared pathological and
clinical features and therapeutic options[4]. The third world symposium was held in
Venice, Italy in 2003. During this conference, the primary pulmonary hypertension
group was subdivided into idiopathic pulmonary arterial hypertension, familial
pulmonary arterial hypertension, or associated pulmonary arterial hypertension[5].
During the fourth world symposium held in Dana Point, California in 2008, modifications
of the Venice classifications were made to reflect current publications and treatments[5]
(Table 1). The groups as described following are based on the Venice classification
scheme.

1.1.3

Pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) may arise spontaneously and have no familial
connection (idiopathic PAH), have a familial connection (familial PAH), or be associated
with other diseases such as connective tissue disease or HIV (associated PAH). The PAH
subgroup of PH adds an additional diagnostic criterion of a mean pulmonary wedge
pressure, an indirect measure of left arterial pressure and an indication of left ventricular
failure, greater than or equal to 15 mmHg[1]. Idiopathic PAH has an estimated incidence
of approximately 2 cases per million per year.[6, 7] The mean age at presentation in
adults ranges from 36 – 50, although individuals of any age can be affected.[7, 8] In a
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Table 1: Venice classification scheme of pulmonary hypertension
Reprinted from Journal of the American College of Cardiology, vol. 54, G. Simonneau et
al., “Updated Clinical Classification of Pulmonary Hypertension,” S43-S54,
Copyright 2009, with permission from Elsevier.

1. Pulmonary arterial hypertension (PAH)
1.1 Idiopathic PAH
1.2 Heritable PAH
1.2.1 BMPR2
1.2.2 ALK1, endoglin (with or without hereditary hemorrhagic telanglectasia)
1.2.3 unknown
1.3 Drug- and toxin-induced
1.4 Associated with
1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
1.4.6 Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Hematologic disorders: myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis,
lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucer disease, thyroid
disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on
dialysis
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study of 194 patients with PAH conducted by the NIH from 1981 to 1985, the estimated
median life span after diagnosis was 2.8 years with 1-, 3-, and 5-year survival rates of
68%, 48%, and 34%[8]. A more recent study estimates 1-, 2-, and 3-year survival rates at
77%, 69%, and 35%.[9].

Irrespective of the causes, most PAH patients die from

intractable right heart failure.

Histological findings of PAH are: intimal hyperplasia, medial hypertrophy, adventitial
proliferation and fibrosis, occlusion of small arteries, in situ thrombosis, and infiltration
of inflammatory and progenitor cells. Plexiform lesions are a hallmark of PAH and are
found only in patients with PAH Group 1 and also in patients with myeloproliferative
disease and patients with sarcoidosis (Group 5), but not those with other PH categories
(Figure 1). These complex vascular lesions are typically composed of proliferating
endothelial cells and perivascular inflammatory cells and are located downstream from
the occluded arteries. They express growth and transcription factors observed in tissues
undergoing angiogenesis, including vascular endothelial growth factor (VEGF) and
hypoxia inducible factor 1α (HIF-1α)[10]. It is hypothesized that widespread early
endothelial apoptosis seen in PAH culminates in selection of apoptosis-resistant
endothelial precursor cells that proliferate and eventually form plexiform lesions[11].

In familial PAH patients, bone morphogeneic protein receptor type 2 (BMPR2) germline
mutations are seen in 70% of patients[12, 13]. In addition, 11% - 40% of idiopathic PAH
patients also have BMPR2 mutations[14, 15]. It has been suggested that patients with
BMPR2 mutations may present a subgroup of PAH patients with a more severe form of
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Figure 1: Plexiform lesions of pulmonary arterial hypertension
Pulmonary blood vessels in the normal (left) and pulmonary arterial hypertension (right)
lung. The plexiform lesions seen in the pulmonary hypertension lung are formed due to
increased cell proliferation and decreased apoptosis leading to occlusion of the
pulmonary vascular lumen.
Reprinted from Journal of the American College of Cardiology, vol. 54, P.M. Hassoun et
al., “Inflammation, Growth Factors, and Pulmonary Vascular Remodeling,” S10S19, Copyright 2009, with permission from Elsevier.
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the disease and are less likely to demonstrate vasoreactivity than the idiopathic PAH
patients without BMPR2 mutations.[16-18] Other, more rare, germline mutations are in
endoglin and activin receptor-like kinase type 1 occuring predominantly with hereditary
hemorrhagic telangiectasia,[19, 20] also known as Osler-Weber-Rendu disease, which is
characterized by abnormal blood vessel formation in the skin and organs.

A number of risk factors relating to drugs or toxins are included in the classifications of
PAH and were categorized as “definite,” “very likely,” “possible,” or “unlikely” based on
their association with PAH (Table 2). A “definite” association is one defined as an
epidemic or a large, multi-center epidemiologic study demonstrating an association
between the drug and PAH. A “likely” association is one revealed by a single-center,
case-controlled study. “Possible” is defined as drugs with similar mechanisms or actions
as those in the “definite” or “likely” categories, but has not yet been studied. Those drugs
termed “unlikely” have been studied and no association has been revealed.[4] The only
identified definite risk factors for PAH are aminorex, amphetamine, fenfluramine, and
toxic rapeseed oil[4, 21]. Aminorex and fenfluramine are drugs used in anti-obesity
medication. Toxic rapeseed oil is rapeseed oil contaminated with oleoanilide, a chemical
by-product formed when industrial grade rapeseed oil interacts with anilide and
acetanilide[22]. Between 1998 and 2001, the Surveillance of Pulmonary Hypertension in
America (SOPHIA) study enrolled 1,335 patients across the US and determined the
association of fenfluramine or dexfenfluramine intake with the development of PAH[23].
It also studied St. John’s Wort and over-the-counter anti-obesity drugs containing
phenylpropanolamine, both of which were shown to increase the risk of developing
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Table 2: Risk factors for development of pulmonary arterial hypertension
Definite
-aminorex
-fenfluramine, dexfenfluramine
-toxic rapeseed oil
Likely
-amphetamines
-methamphetamines
Possible
-chemotherapeutic agents
-cocaine
-phenylpropanolamine
-SSRIs
-St. John’s Wort
Unlikely
-cigarette smoking
-estrogen therapy
-oral contraceptives
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PAH[23]. While the SOPHIA study showed no increase risk for developing PAH with
intake of non-selective monoamine reuptake inhibitors (MAOIs), selective serotonin
reuptake inhibitors (SSRIs), antidepressants, or anxiolytics[23], a case-controlled study of
pregnant women using SSRIs after 20 weeks of gestation showed an increased risk for
the newborn developing persistent PH of the newborn, a form of PH[24]. As such, SSRIs
have been placed in the “possible” risk category.

Another subgroup of PAH is the PAH associated with other diseases, including
connective tissues diseases, HIV, portal hypertension, congenital heart disease,
schistosomiasis, and chronic hemolytic anemias. PAH occurs in 7% - 12% of patients
with scleroderma[25, 26], a chronic systemic autoimmune disease characterized by
fibrosis and vascular alterations, while the prevalence of PAH associated with systemic
lupus erythematosis (SLE), a systemic autoimmune disease that can affect any part of the
body[27, 28], and mixed connective tissue disease[29, 30] is unknown, but likely occur
less often than with scleroderma. PAH is a rare complication of HIV infection with an
incidence of 1 in 200 AIDS patients, and HIV-associated PAH has clinical,
hemodynamic, and histological characteristics similar to those found in idiopathic
PAH[5]. In the early 1990s before antiretroviral therapy was widely available, 0.5% of
patients with HIV also had PAH[31]. A more recent study shows the percent of HIV
patients with PAH to be 0.46%[32].

Untreated congenital heart disease (CHD), in

particular those patients with systemic-to-pulmonary shunts, presents a significant risk
for developing PAH. Eisenmenger syndrome, defined as CHD with an initial large
systemic-to pulmonary shunt that induces progressive pulmonary vascular disease and
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PAH, presents the most advanced form of PAH associated with CHD[33].

The

prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Europe
and North America has been estimated to be between 1.6 and 12.5 cases per million
adults, 25% - 50% of which have Eisenmenger syndrome[34]. PAH associated with
schistosomiasis, an infection caused by a parasitic worm of the genus Schistosoma, can
have similar clinical presentation to idiopathic PAH[35], including similar histological
findings and the development of plexiform lesions[36]. It is estimated that more than 200
million people worldwide are infected by one of the three species of Schistosoma, of
which 4% - 8% develop hepatosplenic disease, which is characterized by an enlarged
liver and spleen and block of portal bloodflow[37]. Of patients with hepatosplenic
disease, 4.6% also develop PAH[38].

PAH can also be a complication of chronic

hereditary and acquired hemolytic anemias, including sickle cell disease[39, 40];
thalassemia, an autosomal recessive disorder that causes a reduced rate of synthesis or
lack of synthesis of globin molecules[41]; hereditary spherocytosis, an autosomal
dominant disorder in which red blood cells are sphere-shaped rather than bi-concave disc
shaped[42, 43]; stomatocytosis, an autosomal dominant disorder in which the membrane
of the red blood cells leak sodium and potassium[44]; and microangiopathic hemolytic
anemia, which causes destruction of the red blood cells by a fibrin mesh that forms due to
increased coagulation activity[45]. PH has been described most often in patients with
sickle cell disease and presents with histological lesions similar to those seen in
idiopathic PAH, including plexiform lesions. In the largest study of patients with sickle
cell disease, 32% also had PAH[40]. However, a recent study by a French group has
revised this incidence to 6%[46].
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Three classes of drugs are currently being used to treat PAH: prostanoids, such as
prostacyclin, endothelin receptor antagonists, such as bosentan or ambristentan, and
phosphodiesterase-5 inhibitors, such as sildenafil.

These drugs are used to induce

pulmonary vasodilation with the additional hope that they reverse pulmonary vascular
remodeling[47, 48]. While these drugs may be advantageous for the lungs, they can have
negative effects on the heart by increasing the contractility of the RV.

Increased

contractility causes an increase oxygen demand and can reduce RV dilation[48]. In
addition to vasodilator therapy, based on empirical evidence most patients also receive
anti-coagulants, such as warfarin, to prevent thrombosis in situ and diuretics to prevent
edema[47].

1.1.4

While

Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis

pulmonary

veno-occlusive

disease

(PVOD)

and

pulmonary

capillary

hemangiomatosis (PCH) are very rare, PVOD is increasingly recognized as causes of
PAH[49]. PVOD is described as any disease that causes the veins of the lung to become
blocked or narrowed. PCH is characterized by thin-walled microvessels infiltrating the
perivascular interstitium, the lung parenchyma, and the pleura[50]. Pathological studies
indicate that PVOD and PCH are quite similar in terms of development of pulmonary
arterial intimal fibrosis and medial hypertrophy, as well as changes in pulmonary
parenchyma[5]. PVOD and PCH are often included in PAH classifications because they
show similar histological findings in the small pulmonary arteries[5]; clinical
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presentation of PVOD, PCH, and PAH are often undistinguishable[21]; and all three
diseases share similar risk factors, including scleroderma[51] and HIV infection[52, 53].
Additionally, mutations in the BMPR2 gene have also been seen in patients with
PVOD[54, 55].

1.1.5

Pulmonary hypertension due to left heart disease

Left-heart disease may represent the most frequent cause of PH[56].

Ventricular or

valvular diseases of the left side of the heart may cause an increase in left atrial pressure
leading to an increased pulmonary artery pressure because of passive backwards
transmission of the pressure[56]. In this situation, the pulmonary vascular resistance is
normal or near normal, unlike in PAH. In approximately 19% to 35% of patients with
left heart disease, the increase in pulmonary artery pressure is out of proportion from
what is expected by the increase in left arterial pressure, and there is an increase in
pulmonary vascular resistance[56, 57]. Currently, no studies of patients with PH due to
left heart disease using medications approved for PAH have been conducted; as such, the
efficacy and safety of PAH medications in this population remains unknown[5].

1.1.6

Pulmonary hypertension due to lung diseases and/or hypoxemia

Alveolar hypoxia as a result of lung disease, impaired control of breathing, or residence
at high altitude is the predominant cause of PH in this category, although the prevalence
of PH in these conditions is unknown[5]. PH is generally modest with mean pulmonary
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artery pressures from 25 – 35mmHg[58], however some patients can have much larger
mean pulmonary artery pressures (35 – 50mmHg)[59]. Diseases including brochiectasis,
in which recurrent infection and inflammation of the airways destroy and widen the large
airways of the lung; cystic fibrosis, an autosomal recessive disorder that results in
accumulation of mucus in the lungs[60]; and a newly identified syndrome characterized
by emphysema in the upper portions of the lung and fibrosis in the lower portions of the
lung have been shown to cause PH[61]. In those patients with the combined syndrome of
fibrosis and emphysema, the prevalence of PAH is approximately 50%[61]. As with the
left-heart related PH, PAH drugs have not been tested in this patient population[5].

1.1.7

Chronic thromboembolic pulmonary hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is a frequent cause of PH
with up to 4% of patients developing PH after an epsidoe of acute pulmonary
embolism[62, 63].

Prognosis of CTEPH reflects the degree of associated right

ventricular dysfunction and has predictable mortality related to the severity of the
underlying PH[64].

Currently, the only cure is pulmonary thromboendarterectomy,

removal of the blood clot (thrombus) from the occluded artery[65]. Those patients who
are not surgical candidates may benefit from administration of PAH-specific
medication[65, 66], but more studies are required.
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1.1.8 Pulmonary hypertension with unclear and/or multifactorial mechanisms

The final PH group is composed of several subgroups of PH for which the cause is
unclear or multifactorial.

1.1.8.1 Subgroup 1

Several hematological disorders including polycythemia vera, an abnormal increase in
the number of red blood cells; essential thrombocytothemia, an over-production of
platelets; and chronic myeloid leukemia can cause PH[67]. Chronic myeloproliferative
disorders can cause PH by various mechansms, such as high cardiac output; auto or
surgical asplenia, absence of normal spleen function; direct obstruction of pulmonary
arteries by circulating megakaryocytes[68]; chronic thromboembolic pulmonary
hypertension[69]; portopulmonary hypertension; and congestive heart failure[5].
Splenectomy, either as the result of trauma or as a treatment for hematological disorders,
can increase the risk of developing PH[70].

Portopulmonary hypertension is a

complication of liver disease present in 0.25% to 4% of patients suffering from cirrhosis
and in 4% - 6% of those referred for liver transplant[71].
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1.1.8.2 Subgroup 2

This subgroup includes systemic disorders that are associated with an increased risk of
developing PH.

Sarcoidosis is a disease of unknown origin in which abnormal

collections of granulomas form as nodules in multiple organs[72]. PH is increasingly
recognized as a complication of sarcoidosis[73] with a reported prevalence of 1% 28%[74]. Severe PH is common in patients with end-stage pulmonary Langerhans cell
histocytosis,

an

abnormal

increase

in

the

number

of

histiocytes[75].

Lymphangioleiomyomatosis is a rare, multisystem disorder predicominantly affecting
women that is characterized by lung destruction, lymphatic abnormalities, and abdominal
tumors[76]. PH is an uncommon complication in patients with this disease[77, 78].
Neurofibromatosis type 1, also known as von Recklinghausen’s disease, is an autosomal
dominant disorder characterized by cutaneous fibromas and “café au lait” skin lesions
and occasionally complicated by systemic vasculopathy. The neurofibromatosis type 1
gene modulates protein kinase B, which in turn regulates cell proliferation. Several cases
of PH have been reported in patients with von Recklinghausen’s disease[79-82].

1.1.8.3 Subgroup 3

Subgroup 3 is composed of PH associated with metabolic disorders.

PH has been

reported in a few cases of type Ia glycogen storage disease, a rare autosomal recessive
disorder caused by a deficiency of glucose-6-phosphate[83-85]. Gaucher disease is a rare
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disorder characterized by a deficiency of lysosomal β glucosidase resulting in an
accumulation of glucocerebroside in reticuloendothelial cells. In a study of 134 patients
with Gaucher disease, PH was not common[86]. In addition, an association between
thyroid disease, both hypothyroidism and hyperthyroidism, and PH has been reported in
several studies[87, 88]. One study reported that more than 40% of patients with thyroid
disease also had PH[89].

Another study of PAH patients showed that 49% had

autoimmune thyroid disease suggesting a common immunogenetic susceptibility[90].

1.1.8.4 Subgroup 4

Finally, subgroup 4 contains miscellaneous conditions associated with PH.

Tumor

obstruction may cause PH if a tumor grows into the central pulmonary arteries.
However, these cases are rare and occur principally due to pulmonary artery sarcomas
and are usually rapidly fatal[91, 92]. Occlusion of the microvasculature by metastatic
tumor emboli (mostly caused by gastric cancers) may be another cause of rapidly
progressive PH[93].

Patients with mediastinal fibrosis, a late-stage complication of

histoplasmosis characterized by invasive calcified fibrosis on lymph nodes that block
major vessels and airways[94], may present with severe PH because of compression of
both pulmonary arteries and veins[94, 95]. PH has been reported in patients with endstage renal disease (ESRD) maintained on long-term hemodialysis and may occur in up
to 40% of patients in this population[96].

36

1.2

Heart development and physiology

1.2.1 Heart development

The heart is the first organ to form and function in the embryo. The vertebrate heart
forms first from a population of myocardial precursor cells in the primitive streak termed
the primary heart field, or first heart field[97, 98] (Figure 2). These cells migrate
bilaterally into the anterior mesoderm and adopt a crescent shape;[99-101]; this structure
is termed the cardiac crescent and is present at embryonic day (E) 7.5 in the mouse,
which corresponds to week 2 of human gestation[102]. The cardiac crescent fuses at the
midline to form the linear heart tube consisting of an inner endocardial layer and an outer
myocardial layer[103] and is normally present at E8.0 in the mouse and gestational week
3 in humans[102]. Rightward looping and differential growth along the outer curvatures
of the heart tube ultimately generate the multichambered heart[101]. An additional
source of cardiac precursors, the secondary heart field, are derived from the pharyngeal
mesoderm located medially to the cardiac crescent and are progressively added to the
developing heart to form the outflow tract, right ventricle, and atria[99, 100].

Committed progenitor ISL1+ cells are clustered in the right ventricular outflow tract and
right and left atrium, all of which are derived from the secondary heart field. These cells
give rise to the endothelial cells, cardiomyocytes, and smooth muscle cells[104-106].
Endothelial cells form the cardiac valves and the endocardium. Cardiomyocytes form the

37

Figure 2: Heart Development in the Mouse
a) Progenitor cells originate in the primitive streak (PS) and migrate to the anterior of the
embryo. b) The progenitor cells migrate to under the head folds (HF) and form the
cardiac crescent (CC). c) The heart tube forms through fusion of the cardiac crescent at
the midline. d) Rightward looping begins the process of ventricle formation. e) By E10.5,
the heart has well-defined ventricles. f) In the fetal heart, ventricles are separated and
connected to the aorta (AO) and the pulmonary trunk (PT) so that normal circulation can
occur.

Anterior (A)-posterior (P) and right (R)-left (L) axes are shown. AA, aortic arch; AO,
aorta; AVC, atrioventricular canal; CC, cardiac crescent; HF, head folds; IFT, inflow
tract; IVC, inferior vena cava; LA, left atria; LV, left ventricle; OFT, outflow tract; PLA,
primitive left atria; PRA, primitive right atria; PS, primitive streak; PT, pulmonary trunk;
PV pulmonary vein; RA, right atria; RV, right ventricle; SVC, superior vena cava; Tr,
trabeculae.
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Genetics, M.
Buckingham, S. Meilhac, and S. Zaffran, “Building the
Mammalian Heart from Two
Sources of Myocardial Cells,” vol. 6: 826-835, copyright 2005.
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ventricular and atrial myocytes as well as cells of the conduction system. Smooth muscle
cells form arteries and veins.[101]

The transcription factors T-box 5 (Tbx5) and hand and neural crest derivatives expressed
1 (Hand1) mark the primary heart field, whereas hand and neural crest derivatives
expressed 2 (Hand2), ISL LIM homeobox 1 (Isl1), and fibroblast growth factor (Fgf10)
are expressed in the secondary heart field[107, 108]. Natural killer 2 transcription factor
related, locus 5 (Nkx2-5) is expressed in both heart fields[101]. Myocardial transcription
factors are first detected in the cardiac crescent where myocardial differentiation is
initiated; activation of key myocardial regulatory genes, such as Nkx2-5 and GATA
binding protein 4 (Gata4), depends on positive signaling by bone morphogenetic proteins
(BMPs) and fibroblast growth factors while wingless-type MMTV integration site family
members (Wnts) exert a repressive effect[109].

Mutations of Gata4 lead to cardiac bifida where the two halves of the cardiac crescent
fail to converge at the midline[110-112].

In an Nkx2-5 knockout, there is loss of

ventricular tissue and the absence of Hand1 expression at the cardiac crescent stage and
later in the cardiac tube[113-115]. Hand1 mutants have a proliferation defect in the left
ventricle (LV) and die from extra-embryonic defects[116-118]. Similarly, Tbx5 mutants
show severe defects in the left ventricle and atria-inflow regions of the heart, although
Hand1 is still detectable and the outflow tract and RV continue to grow normally[119].
In contrast, Hand2 mutants show right-ventricular hypoplasia[120, 121] and extensive
cell death in the pharyngeal arches where Hand2 is normally expressed[122].
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Although fibroblast growth factors are necessary for proliferation of cells in the
secondary heart field[123], Fgf10 mutant mice have no apparent early cardiac phenotype
and the outflow tract seems to be normal[124, 125]. On the other hand, fibroblast growth
factor 8 (Fgf8) knockout mice die at gastrulation, but an Fgf8 hypomorph dies later of
cardiac failure that is due to malformation of the outflow region[126, 127]. T-box
transcription factor 1 (Tbx1) mutant mice show a similar cardiac phenotype to the Fgf8
hypomorph mice, although the neural crest defect in Tbx1 mutants is more severe[128131]. Targeted deletion of Tbx1 in the secondary heart field causes a proliferation
defect[132].

Isl1 may have several roles in the secondary heart field. In its absence, migration of cells
into the cardiac tube is not observed, proliferation is affected, and cells undergo
apoptosis[107]. In a mutant embryo, the heart tube seems to have only two chambers and
the outflow tract is absent.

Genetic markers show the presence of an atrial and

ventricular myocardium and labeling with Hand1 and Tbx5 probes show the left
ventricular identity of the anterior compartment.
expressed[100].

Right ventricular markers are not

Myocyte enhancer factor 2C (Mef2c) Is regulated by Isl1 and

Gata4[133]. Early expression of Mef2c is medial to the cardiac crescent and continues
into the secondary heart field[133]. Mutants have a reduced outflow tract and the right
ventricle does not develop[134].
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1.2.2

The fetal heart

By the third week of gestation, blood begins forming and the primitive heart tube begins
beating; active circulation begins by the end of the fourth week of gestation. The right
ventricle (RV) and pulmonary circulation begin to separate from the left ventricle (LV)
and systemic circulation due to formation of the interventricular septum and formation of
valves after the fifth week of gestation. At birth, full septation is normally complete[135137]. In the fetus and embryo, the RV is the dominant chamber of the heart, accounting
for approximately 60% of the total cardiac output; however, only about 15%-25% of the
total cardiac output enters the lungs because the embryo receives oxygen from the
placenta. The remainder is shunted to either the systemic circulation via the foramen
ovale and the LV or the pulmonary artery and aorta via the ductus arteriosis[138, 139].
At birth, the increasing left atrial pressure closes off the formen ovale[140]. Soon after,
the ductus arteriosis closes[139], the LV hypertrophies, and the RV involutes becoming
thin walled[47].

The fetal heart has different characteristics than the adult heart. Unlike in the adult heart,
the RV is as thick as the LV in the fetal heart[141]. A disproportionately smaller LV than
RV, which is diagnosed by echocardiography, may be an indication of obstructive leftsided heart disease[142]. The fetal/neonatal RV ejects blood at a higher pressure than
systemic circulation. A few days after birth, these pressures fall[143] and, by three
weeks of age, the pulmonary artery pressure is usually lower than the systemic
pressure[144]. Doppler echocardiography has shown that the RV output in human babies
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is slightly larger than that of the LV at a gestational age of 38 weeks (60 ml/min
compared to 40 ml/min)[145]. The two ventricles pump in parallel to the systemic
circulation and the difference in pressure between the two ventricles is minimal[139].

1.2.3 The adult heart

In adult humans, the right ventricle is the most anterior portion of the heart and is located
directly behind the sternum[146]. The RV appears triangular when viewed from the side
or has a crescent shape when viewed in a cross section; the entirety of the RV muscle lies
between the tricuspid and pulmonary valves.

In contrast, the LV has an ellipsoid

shape[141, 146]. The interventricular septum is concave towards the LV in the normal
RV[141]. The free wall of the RV is normally 1-3mm thick compared to the 10mm thick
LV free wall and accounts for approximately one-sixth of the total mass of the human
heart – on average 26g/m2 compared to 87g/m2 of the LV[144, 146].

Table 3

summarizes the characteristics of the normal RV and LV.

Anatomically, the RV can be divided into three regions: the inflow tract, an apical region,
and the outflow tract, which ends at the pulmonic valves. The main pulmonary artery
originates from the outflow tract[147] (Figure 3). The pulmonary artery is a thin, elastic
vessel that branches to supply the various pulmonary arteries, pulmonary arterioles, and
alveolar capillaries. Once blood travels through the alveolar capillaries and exchanges
CO2 for O2, blood returns to the lungs through a system of pulmonary veins and branches
to the left atrium. From the left atrium, it goes to the left ventricle and is then pumped to
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Table 3: Summary of normal adult RV and LV structure and function
Characteristics
shape [141, 146]

RV
triangular (side),
crescent (cross-section)
2
mass index (g/m ) [146]
26
free-wall thickness (mm) [144]
1-3
ventricular pressure (mmHg) [148] 25/4
PVR vs. SVR (dynes/s/cm5) [149] 123
contraction [144, 150]
sequential
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LV
ellipsoid
87
10
130/8
2130
concentric and twisting

Figure 3: Pulmonary and systemic circulation
The human circulatory system includes the heart, lungs, and blood vessels. Blood leaves
the right ventricle and travels through the pulmonary arteries to the lungs where CO2 is
exchanged from O2. Blood returns to the left atrium of the heart after passing through the
pulmonary veins. After the left atrium, blood pools in the left ventricle where it is
pumped through the aorta to the systemic circulation and capillary beds where O2 is given
to the tissues and CO2 removed from the tissues. It then travels through the veins and
venae cavae to the right atrium after which it returns to the right ventricle.
Reprinted with permission from
at http://www.biomedicalphysics.org.
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the systemic circulation[149, 151, 152]. Almost the entire cardiac output is pumped by
the thin-walled RV through the lung circulation while the oxygenated blood is collected
by the four pulmonary veins and emptied into the LV[141]. The RV contracts in a
sequential manner, starting with the inflow tract and moving towards the outflow tract in
a wave-like manner. In contrast, the LV has a concentric contraction along with a
twisting motion[144, 153].

Normally, the pulmonary circulation is a low-resistance, high-capacitance system
allowing an increase of RV stroke volume by 3-4 fold without significantly increasing
pulmonary pressure[154]. The alveolar membranes of the lung are thin and highly
permeable. As such, the pulmonary pressures must remain low to prevent pulmonary
edema[155]. In humans, a normal mean pulmonary artery pressure is 14 mmHg with an
upper limit of normal of 20.6 mmHg. With exercise, the mean pulmonary artery pressure
can have an upper limit of normal as high as 35 mmHg[154]. The average pressure of the
RV is 25mmHg/4mmHg (systolic/diastolic) and the LV is 130mmHg/8mmHg[148]. The
function of the RV is often determined by measuring the so-called afterload, the
pulmonary vascular resistance (PVR). Pulmonary vascular resistance is defined by the
ratio of the mean pressure drop from the main pulmonary artery to the left atrium divided
by the cardiac output and is given in units of dynes/s/cm5. It can also be measured in
Wood units, which are defined as the mean pulmonary artery pressure minus the mean
pulmonary capillary occlusive pressure (both in mmHg) divided by cardiac output
(L/min). One Wood unit is equivalent to 80 dynes/s/cm5[150]. In a normal human heart,
pulmonary vascular resistance is approximately 1/20 that of the systemic vascular
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resistance – 123 dynes/s/cm5 in the RV compared to 2130 dynes/s/cm5 in the systemic
circulation[147].

1.3

The heart during progression of pulmonary arterial hypertension

Pulmonary arterial hypertension develops as a consequence of lung vascular lesions that
cause an increase in pulmonary vascular resistance against which the right ventricle must
pump (Figure 4). This increase in afterload is the first trigger for RV adaptation in
PAH[48]. Based on the LaPlace relationship, an increase in intraluminal pressure will
result in an increase in wall stress unless the thickness of the chamber wall is increased or
the internal radius of the chamber is decreased. Because an increase in wall stress would
increase myocardial oxygen demand and impede myocardial perfusion, the RV adapts to
the increasing afterload pressure through increased wall thickness, both by hypertrophy
(increased muscle mass) and assuming a more rounded shape[48] (Table 4).
Hypertrophy is largely the result of protein synthesis induced by stretch, which is sensed
by integrins and stretch-activated ion channels in myocytes, fibroblasts, and endothelial
cells of the heart[156]. Integrins are attached to the extracellular matrix (ECM) and the
cytoskeleton allowing them to transduce mechanical stress to intracellular chemical
signals that increase synthesis of contractile proteins and proteins for autocrine and
paracrine signaling[157, 158]. Growth and proliferation of cardiomyocytes is paralleled
by ECM synthesis and supporting capillary growth. Angiogenesis, growth of new vessels
from existing vessels, is part of this process and can be induced by angiopoietin-1 (Ang1)
and vascular endothelial growth factor (VEGF) signaling[48].
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Figure 4: Changes in the Heart in PAH
Schematic representation of the heart and lungs in a normal (left) and pulmonary
hypertension (right) patient. Pulmonary arteries constrict in pulmonary hypertension due
to the formation of plexiform lesions causing an increase in pressure against which the
right ventricle must pump. Over time, this causes the right ventricle to hypertrophy.
Reprinted with permission from Nationwide Children’s Hospital
at http://www.nationwidechildrens.org.
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Table 4: Summary of Changes in the RV and Circulation Associated with PAH
Characteristics
RV shape
septum position
energy utilization [47, 159]
RV mass index (g/m2)
[146, 160]
RV free wall thickness (mm)
[144, 160]
RV systolic pressure (mmHg)
[148, 160]
mean
pulmonary
artery
pressure, resting (mmHg)
[1, 160]
PVR (dynes/s/cm5) [149, 160]

Normal
triangular (side),
crescent (cross-section)
concave towards right
ventricle
varies from fatty acid to
glycolysis as needed
26

PAH
thickened and enlarged

1–3

5–7

25

85

8 – 20

50

123

240
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paradoxical
shift
towards left ventricle
reliant
on
glucose
metabolism
68

1.3.1

Adaptive vs. maladaptive hypertrophy

Hypertrophy can be divided into two categories: adaptive, or pathological, and
maladaptive, or physiological.

Examples of adaptive hypertrophy included athletes’

hearts and exercise-induced reversible cardiac enlargement[141]. Hypertrophy is induced
in athletes’ hearts through aerobic interval training over long periods of time, which
causes increased cardiac dimensions and mass as an adaptation to the increase in physical
stress; they also show improved myocardial contractility[161-166].

This adaptation

allows greater transport of blood and oxygen to the skeletal muscles in order to improve
work capacity.[167] Exercise increases secretion of insulin-like growth factor 1 (IGF-1)
and growth hormones both systemically and locally in the heart[168-173].
Overexpression of the IGF-1 receptor or an activated form of Akt leads to myocardial
hypertrophy with enhanced cardiac function[170, 174]. While exercise training programs
induce an improved work capacity and adaptive hypertrophy, pressure overload induces
reduced contractile function and maladptive hypertrophy[175].

In maladptive

hypertrophy, there can be a doubling of the heart weight, re-expression of fetal genes, and
deactivation of the Akt/mTOR signaling cascade[175]. In contrast, adaptive hypertrophy
does not reactivate the fetal gene program[176, 177]. Fetal gene re-expression is due to
activation of the transcription factors nuclear factor of activated T-cells (Nfat) by
calcineurin and myocyte enhancer factor 2 (Mef2) by calcium/calmodulin-dependent
protein kinase (CaMK) or mitogen activated kinase-like protein (MAPK) [176] and
increased protein degradation by the ubiquitin-proteosome system[178].
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Molecular

markers have been found that distinguish between adaptive and maladaptive hypertrophy
in the LV. Gata4, cyclic-AMP response element binding protein (Creb), and signal
transducer and activator of transcription 3 (Stat3) are markers of adaptive hypertrophy
while phosphate and tensin homolog (Pten), nuclear factor of activated T-cells 3 (Nfat3),
and Mef2 are markers of maladaptive hypertrophy[179].

While it is generally believed that sustained pressure overload is enough to induce
maladptive hypertrophy and cardiace failure[48], recent studies[180] have shown that
increased RV pressure overload alone is not sufficient to cause heart failure. Rats with
only pressure overload did not have heart failure or an increase in long-term mortality
rates.

However, rats with increased RV pressure and angioproliferative pulmonary

remodeling, as seen in human PAH, do have heart failure and increased rates of
mortality[180].

Those rats with RV failure also have an increase in RV fibrosis,

decreased capillary density, and oxidative stress[180].

1.3.2 Transition from hypertrophy to failure

The mechanisms that underlie the transition from hypertrophy to failure in the RV
associated with PAH have not been well characterized.

Similarly, it is not well

understood why some patients with severe PAH rapidly progress to RV failure and others
do not[141]. One hallmark of heart failure is the switch from alpha myosin heavy chain
(MHC-α) to beta myosin heavy chain (MHC-β) in cardiomyocytes[48]. Normally, in the
human RV approximately 25 – 34% of the MHC is in the form of MHC-α and the
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remainder is MHC-β. In PAH-associated RV failure, there is approximately 5% MHC-α
and 95% MHC-β.[181] MHC-β has lower ATP activity than MHC-α and the reduction
in MHC-α causes a decrease in systolic function[182]. Additionally, neurohormonal
overdrive, oxidative stress, inflammation, ischemia, and cell death may all contribute to
the development of RV dilation and failure[48].

1.3.2.1 Neurohormonal signaling

Heart failure is associated with an activation of the renin-angiotensin system.
Angiotensin II (ATII) is the most important factor involved in cardiac remodeling.
Adrenergic overstimulation causes increased expression of several peptides including the
natriuretic peptides atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP)[48].

While ATII, ANP, BNP, and aldosterone reach the heart via systemic

circulation, they can also be produced locally by myocytes, endothelial cells, and
fibroblasts in the heart to affect cardiomyocyte growth, proliferation, and survival[48].

1.3.2.2 Ischemia

Myocardial ischemia occurs when blood flow to the heart muscle is decreased by
obstruction of the arteries carrying blood to the heart muscle itself causing a decrease in
the oxygen supply of the heart[183]. Exercise-related chest pain, often a symptom of
myocardial ischemia, occurs frequently in patients with pulmonary hypertension despite
normal coronary angiograms[184]. Systolic right coronary artery flow is reduced in
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pulmonary hypertension[185] and can lead to RV ischemia[186] because of a mismatch
between the number of capillaries and the size of the cardiomyocytes during development
of cardiac hypertrophy and impairment of right coronary artery flow as a consequence of
RV wall stress[187]. It has been suggested that the RV coronary circulation becomes
more like that in the LV during PAH: greater oxygen extraction at rest and greater
dependence on oxygen and an increase in coronary blood flow to meet the myocardial
oxygen demand[188].

1.3.2.3 Oxidative and nitrosative stress

Excess reactive oxygen species (ROS) and reactive nitrogen species (RNS) induce
contractile dysfunction through suppression of enzymes involved in excitationcontraction coupling. ROS and RNS also favor cardiac remodeling through induction of
cell damage, apoptosis, and inflammation[48].

ATII, endothelin1, and other

neurohormones can stimulate the formation of ROS to induce hypertrophic pathways
within the cardiomyocyte[189].

Activation of ATII leads to ROS formation by

upregulation of NAD(P)H oxidases[189]. Neutrophils are recruited to the pressureoverloaded myocardium and may be a source of ROS because they have significant
quantities of NAD(P)H oxidases[48]. Other sources of ROS production in heart failure
are xanthine oxidase, cytochrome P450, and auto-oxidation of catecholamines[189-191].
RNS in the heart can be hemoglobin dependent and constitutively expressed endothelial
nitric oxide (NO) synthase (eNOS). Desaturation of hemoglobin and uncoupling of
eNOS can also contribute to ROS generation[192, 193]. Decreased expression of eNOs,
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inhibition of eNOS activity, and inhibition of NO by superoxide anions can lead to
reduced NO signaling[194]. NO signals through the guanylate cyclase/cyclic guanosine
monophosphate (cGMP) pathway and acts as a vasodilator and growth inhibitor;
decreased NO activity can cause endothelial cell dysfunction[194].

1.3.2.4 Energy utilization

Otto Warburg proposed that a shift from oxidative phosphorylation to glycolysis and
glucose metabolism was a hallmark of malignant cell transformation.

It has been

observed that, in PAH, the Warburg effect occurs in lung vascular cells[195, 196]. Both
cancer and lung vascular cells manifest excessive cell proliferation and impaired
apoptosis. While in PAH the lesion cells do not metastasize or disrupt vessel boundaries,
lung vascular cells in PAH share a mitochondrial-metabolic abnormality with
cancer[197]. Positron emission tomography (PET) studies have shown that there is an
increase in glucose uptake in lung tissue of patients and animals with right ventricular
hypertrophy[160]. Other studies have shown that there is an increased rate of glycolysis
in right ventricular hypertrophy and that the switch from glucose oxidation to glycolysis
is associated with impaired RV function in the form of reduced RV contractility and
overall cardiac function[198]. This increase in glycolysis is in part due to increased
expression in HIF-1α, which is known to be increased in animal models of PAH[180].
HIF-1α activation causes an increase in transcription of glucose transporter 1 (Glut1),
hexokinase, and lactate dehydrogenase kinase favoring glycolysis and inhibiting glucose
oxidation by activating transcription of pyruvate dehydrogenase kinase genes[199].
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Additionally, animal studies of PAH have shown that mitochrondrial function is
abnormal due to hyperpolarization of mitochondrial memranes in RV myocytes[200].

1.3.2.5 Apoptosis of cardiac cells

In the normal heart, apoptosis of cardiomyocytes is extremely rare: approximately one
apoptotic cardiomyocyte per 104 – 105 cells[201]. In human heart failure, the apoptosis
rate can increase to up to 1 in 400 cells[202, 203]. Apoptosis rates have been shown to
be elevated to 14% in models of ischemia/reperfusion and lower than 1% in models of
chronic pressure overload[204]. Even very low rates of apoptosis (approximately 1/5 that
of human heart failure rates) have been shown to cause lethal dilated cardiomyopathy in
mouse models[205]. Pressure load can induce apoptosis via activation of ATII, ROS, βadrenoreceptor agonists, and proinflammatory cytokines[206].

Ischemia is another

strong activator of apoptosis in the heart[207]. Broad-spectrum caspase inhibitors have
been used to block apoptosis after ischemia/reperfusion resulting in reduced infarct size
and improved cardiac function[208, 209].

1.3.2.6 Inflammation and immune activation

Patients with chronic heart failure have increased serum levels and myocyte expression of
proinflmaatory cytokines: tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), and
interleukin 6 (IL-6). Elevated levels correlate with disease severity reflected in clinical
and hemodynamic parameters[210]. In left-heart failure studies, TNF-α can depress
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myocardial contractility[211] and induce apoptosis of endothelial cells[212] and
cardiomyocytes[213].

TNF-α is upregulated after trans-aortic contstriction, an

experimental model of left-ventricular failure in rodents, and mediates cardiomyocte
apoptosis, fibrotic remodeling through inflammatory cell influx, matrix metalloprotease
(MMP) upregulation, and activation of IL-6, monocyte chemotactic protein 1, and
macrophage inflammatory protein gamma[214]. IL-1 and IL-33 have been shown to be
changed during the development of heart failure. IL-1 has a negative inotropic effect on
cardiomyocyctes[215] and enhances fetal gene expression[216]. IL-33 is produced by
cardiac fibroblasts in response to mechanical strain[217].

In summary, pulmonary arterial hypertension consists of a group of diseases affecting
lung circulation with a fatal outcome due to right heart failure.

As pulmonary

hypertension progresses, there is a shift from adaptive to maladaptive hypertrophy, which
can be characterized by pathways involving energy metabolism, inflammation, and
apoptosis resulting in ischemia such that the right heart can no longer compensate for the
increased strain. While there are some insights into the molecular pathways affected as
the disease progresses, there has not been a systematic study of the gene expression
changes of pulmonary hypertension or adaptive hypertrophy. A better understanding of
the molecular mechanisms of RVF will likely lead to the development of therapeutic
strategies to prevent RVF.

Because RVF is entirely reversible after single-lung

transplantation, other strategies need to be found that will reverse RVF even when the
pulmonary artery pressure cannot be lowered by our present treatments.
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Chapter 2: Materials and Methods

2.1

Rat models

2.1.1 Su5416

Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g
were

injected

subcutaneously

with

SU5416

suspended

in

0.5%

(w/v)

carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 80,
and 0.9% (v/v) benzyl alcohol in deionized water. Rats were given a single injection of
SU5416 (20 mg/kg) at the beginning of the 4-week experiment. The animals were kept at
the altitude of Richmond, VA (sea level) for another four weeks.

2.1.2

Chronic hypoxia

Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g
were exposed to chronic hypoxia (simulated altitude of 5,000 m in a nitrogen dilution
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chamber) for four weeks; thereafter the animals were kept at the altitude of Richmond,
VA (sea level) for another two weeks.

2.1.3

Su5416/hypoxia

Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g
were

injected

subcutaneously

with

SU5416

suspended

in

0.5%

(w/v)

carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 80,
and 0.9% (v/v) benzyl alcohol in deionized water. Rats were given a single injection of
SU5416 (20 mg/kg) at the beginning of the 6-week experiment. The animals were then
exposed to chronic hypoxia (simulated altitude of 5,000 m in a nitrogen dilution
chamber) for four weeks; thereafter the animals were kept at the altitude of Richmond,
VA (sea level) for another two weeks.

2.1.4

Carvedilol only

Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g
were given carvedilol (15 mg/kg; Sigma-Aldrich, St. Louis, MO) dissolved in 20%
dimethyl sulfoxide and water and administered once daily per oral gavage for 4 weeks.
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2.1.5 Su5416/hypoxia and carvedilol

Male Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 200g
were

injected

subcutaneously

with

SU5416

suspended

in

0.5%

(w/v)

carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (w/v) polysorbate 80,
and 0.9% (v/v) benzyl alcohol in deionized water. Rats were given a single injection of
SU5416 (20 mg/kg) at the beginning of the 6-week experiment. The animals were then
exposed to chronic hypoxia (simulated altitude of 5,000 m in a nitrogen dilution
chamber) for four weeks. Carvedilol (15 mg/kg; Sigma-Aldrich, St. Louis, MO) was
dissolved in 20% dimethyl sulfoxide and water and administered once daily per oral
gavage for 4 weeks, beginning after return to room air breathing.

2.2

Isolation of total RNA with mortar and pestle

Total RNA was isolated from approximately 30 mg of snap-frozen rat heart tissue using
the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). Briefly, hearts were homogenized
using a mortar and pestle under liquid nitrogen then mixed with Buffer RLT and βmercaptoethanol in a tissue homogenizer. Samples were then transferred to an Eppendorf
tube and spun at full speed for three minutes. Supernatant was transferred to a new 2 ml
tube and mixed with an equal volume of 100% ethanol, then placed in an RNeasy spin
column. Samples were washed once with buffer RWI and twice with buffer RPE before
being eluted in 40 μL RNase-free water. RNA concentration was determined using a
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NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE) spectrophotometer.
All samples had an A260/A280 ratio between 1.9 and 2.1

2.3 Isolation of total RNA with FastPrep® lysing matrix

Total RNA was isolated from approximately 30 mg of snap-frozen rat heart tissue using
the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). Briefly, hearts were homogenized
with Buffer RLT and β-mercaptoethanol in an MP FastPrep®-24 Lysing Matrix D tube
(MP Biomedicals LLC, Solon, OH). Samples were then transferred to an Eppendorf tube
and spun at full speed for three minutes. Supernatant was transferred to a new 2 ml tube
and mixed with an equal volume of 100% ethanol, then placed in an RNeasy spin
column. Samples were washed once with buffer RWI and twice with buffer RPE before
being eluted in 40 μL RNase-free water. RNA concentration was determined using a
NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE). All samples had an
A260/A280 ratio between 1.9 and 2.1

2.4

Microarray hybridization

The amplification and hybridization process is as follows. 500 ng of total RNA was
amplified and labeled with Cyanine-5 and 500 ng of universal rat reference RNA
(Stratagene, Santa Clara, CA) was amplified and labeled with Cyanine-3 using the
Agilent QuickAmp Labeling kit (Agilent Technologies Inc., Santa Clara, CA) to produce
labeled cRNA following the manufacturer’s protocol. After amplification and labeling,

62

the dye incorporation was determined using a NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific, Wilmington, DE). All ratios were greater than 8.0 pmole dye
per μg cRNA per the manufacturer’s recommendation. 825 ng of sample and 825 ng of
reference RNA were combined and incubated with an Agilent whole rat genome 4x44k
microarray slide (Agilent Technologies Inc., Wilmington, DE) for 17 hours at 65°C.
Following hybridization, slides were washed following the manufacturer’s protocol and
scanned using an Axon GenePix 4200A scanner (Axon Instruments, Union City, CA) at a
resolution of 5 μM. The raw data will be generated using GenePix Pro 5.0 software
(Axon Instruments, Union City, CA) and submitted to the Ramhorn Array Database
(http://ramhorn.csbc.vcu.edu).

Ramhorn is a VCU-specific implementation of the

Longhorn Array Database[218] maintained in the laboratory of Dr. Paul Fawcett.

2.5

Microarray data analysis

Microarray data were retrieved from Ramhorn after filtering the data using a set of spotquality metrics designed to ensure the reliability of the data. Features were included in
the dataset if they have a signal greater than or equal to 1.5 fold above background in
both the red and green channels. Those features with less than 50% good data across the
set of arrays were eliminated. Technical replicates were averaged together using a besteffort averaging procedure.

Statistical analysis of biological replicates was performed using the Significance Analysis
of Microarrays (SAM) algorithm[219] with a two-class paired (for normal RV vs. normal
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LV) or unpaired design (normal RV vs. failing RV) to identify differentially expressed
genes. Briefly, the SAM algorithm for a two-class comparison is as follows. First, the
relative difference in expression between two sets of samples is calculated for each gene;
this is the observed relative difference. To calculate the expected relative difference, data
labels are permuted and the relative difference is calculated for each gene. The expected
relative difference for a gene will be the average relative difference across all
permutations. The observed relative difference is plotted against the expected relative
difference. Genes that fall outside of a threshold value, Δ, will be called significant. Δvalues were chosen to give an acceptable false discovery rate (FDR) of less than 5% and
a 2-fold filter was applied.

The gene list was clustered using hierarchical clustering methods in Cluster 3.0[220] and
visualized in Java TreeView[221].

Based on literature search results and pathway

analysis results obtained using Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
Redwood City, CA) and the PANTHER classification system[222, 223], genes were
selected for confirmation by quantitive RT-PCR.

For prediction analyses, raw expression data files were uploaded into R[224] and
normalized using the marray package[225] by the Lowess normalization algorithm, then
exported to BRB Array Tools. Lowess intensity dependent normalization was used to
adjust for differences in labeling intensities of the Cy3 and Cy5 dyes. The adjusting
factor varied over intensity levels[226]. Genes that were differentially expressed between
the three classes were identified using an F test, using an α-level of 0.0001 for univariate
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testing, and performing 1,000 permutations for multivariate analysis.

The class

prediction model was developed using Diagonal Linear Discriminant Analysis[227],
Nearest Neighbor Classification[228], and Nearest Centroid Classification. The models
incorporated genes that were previously deemed significant. We estimated the prediction
error of each model using leave-one-out cross-validation (LOOCV) as descried by Simon
et al.[229].

For each LOOCV training set, the entire model building process was

repeated, including the gene selection process. We also evaluated whether the crossvalidated error rate estimate for a model was significantly less than one would expect
from random prediction.

The class labels were randomly permuted and the entire

LOOCV process was repeated. The significance level is the proportion of the random
permutations that gave a cross-validated error rate no greater than the cross-validated
error rate obtained with the real data. 2,000 random permutations were used.

2.6

Quantitative real-time polymerase chain reaction

Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) to
convert total RNA (1 μg) to cDNA and the Power SYBR® Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA) along with rat-specific primers (Table 5)
(Invitrogen, Carlsbad, CA). A dissociation profile was generated after each run to verify
specificy of amplification. All PCR assays were performed in triplicate and no template
controls were included. 18S rRNA was used as a housekeeping gene. Automated gene

65

expression analysis was performed using the Comparative Quantitation model of MxPro
QPCR Software (Stratagene, Santa Clara, CA).

2.7

Protein isolation

Protein was isolated from approximately 40 mg of snap-frozen rat heart tissue using
RIPA (radio-immunoprecipitation assay) buffer (Sigma-Aldrich, St. Louis, MO) and
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) in an MP FastPrep®-24
Lysing Matrix D tube (MP Biomedicals LLC, Solon, OH). Protein concentration was
measured using a standard colorimetric protein assay based on the method by Bradford
(Bio-Rad, Hercules, CA). A standard curve was generated by measuring the OD595 of
the protein reagent mixed with bovine serum albumin (BSA) at concentrations of 2.5
μg/mL, 5 μg/mL, 10 μg/mL, and 20 μg/mL.

2.8

Western blot

Proteins were separated by SDS-PAGE on Novex precast 4-12% Bis-Tris gels using the
NuPAGE® system (Invitrogen, Carlsbad, CA). Proteins were transferred to a PVDF
membrane (Biorad, Hercules, CA) in NuPAGE® transfer buffer (Invitrogen, Carlsbad,
CA) for 1 hour at 50 volts. The membrane was blocked for 45 minutes in TBS-T (20
mM Tris-HCl pH 7.6, 137 mM NaCl, 0.1% Tween-20) containing 5% nonfat dry milk
(Carnation, Wilkes-Barre, PA). TBS-T was used for all wash steps. The membranes
were incubated overnight at 4°C in TBS-T containing 5% BSA with appropriate rat
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antibodies (Table 6). The membrane was washed in TBS-T and incubated with a 1/2000
dilution of goat anti-rabbit IgG HRP secondary antibody (Cayman Chemical, Ann Arbor,
Michigan).

Proteins

were

detected

using

Western

Lightning™

Plus-ECL

chemiluminescent substrate (PerkinElmer Inc., Waltham, MA). The ChemiDoc™ XRS+
Imaging System and Quantity One software (Bio-Rad, Hercules, CA) were used to
capture and analyze digital images of chemiluminescent signals.

2.9

Multiplex assay

Levels of 23 cytokines (G-CSF, eotaxin, GM-CSF, IL-1α, leptin, MIP-1α, IL-4, IL-1β,
IL-2, IL-6, IL-13, IL-10, IL-12p70, IFN , IL-5, IL-17, IL-18, MCP-1, IP-10, GRO/KC,
VEGF, TNFα, RANTES) were measured in rat serum samples using the Milliplex® rat
cytokine/chemokine magnetic bead panel kit (Millipore, Billerica, MA) following the
manufacturer’s protocol.

Briefly, a standard curve at dilutions of 1:1, 1:4, 1:16, 1:64,

1:256, 1:1,024, and 1: 4,096 of each analyte were prepared. Serum samples were diluted
1:4 using serum matrix. Standards, quality control samples, and experimental samples
were incubated overnight 4°C with antibody-immobilized magnetic beads. Beads were
washed twice with wash buffer, and then incubated with detection antibodies and
streptavidin-phycoerythrin. Beads were washed twice again before being resuspended in
sheath fluid. The plate was run on a Luminex 100 analyzer (Luminex Corporation,
Austin, TX) and results were analyzed using BioPlex Manager Software 4.0 (BioRad,
Hercules, CA).
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Table 5: qRT-PCR Primers
Name
Ang-1 forward
Ang-1 reverse
ANP forward
ANP reverse
Apelin forward
Apelin reverse
BNP forward
BNP reverse
CAPS1 forward
CAPS1 reverse
CTGF forward
CTGF reverse
IGF1 forward
IGF1 reverse
Irx2 forward
Irx2 reverse
Klf5 forward
Klf5 reverse
Nr2f2 forward
Nr2f2 reverse
Rcan1 forward
Rcan1 reverse
VEGF forward
VEGF reverse
Hexokinase2 forward
Hexokinase2 reverse
18s rRNA forward
18s rRNA forward

Sequence 5’ to 3’
AGAAACTTCAGCATCTGGAGC
CGCATTCTGTTGTATCTGGG
CAAGGGCTTCTTCCTCTTCC
TCTCCTCCAGGTGGTCTAGC
GAATCTGAGTTTCTGCGTGC
CCTTCTTCTAGCCCTTTCCC
CAATCCACGATGCAGAAGC
GCCTTGGTCCTTTGAGAGC
CAAATGGCAGACCAAATAGC
CATGAGTAGGTTGACGGAGG
AAATGCTGTGAGGAGTGGG
TTCCAGTCGGTAGGCAGC
GCTCTTCAGTTCGTGTGTGG
CAACACTCATCCACAATGCC
CCAAGAAAGATGCCAGTGA
GCTTGGCCCTCCTATAGG
CCAAATATCCAACCTGTCCG
GCACTTGTAGGGCTTCTCG
CTCAAGGCCATAGTCCTGT
CCACGTGGGCTACATC
ACGGTGATGTCTTCAGCG
TGAAGTTTATTCGGACACGC
CTGCAATGATGAAGCCCTGGAG
CTATGTGCTGGCTTTGGTGAGG
GAGGTCAACTCCGGATGG
GAGGTCAACTCCGGATGG
AGACGGACCAGAGCGAAAGC
TGTCAATCCTGTCCGTGTCC
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Product size
115bp
124bp
108bp
84bp
107bp
80bp
106bp
73bp
161bp
61bp
119bp
94bp
151bp
309bp

Table 6: Antibodies

Name
α-actinin
AKT
Ang-1
Apelin
IGF-1
p-AKT

Company
Cell Signaling
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz

Product Number
3134
sc-8312
sc-8357
sc-33469
sc-9013
sc-7985
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Species
rabbit
rabbit
rabbit
goat
rabbit
rabbit

Chapter 3: Comparison of the Gene Expression Pattern between the Normal RV
and the Normal LV

3.1

Introduction

Although we have concepts and data to explain mechanisms of left ventricular failure,
there is little comparable knowledge of mechanisms of right ventricular failure. Right
heart failure has not been systematically investigated on the cellular and molecular level
most likely because of the widely held opinion that the conditions which govern right
ventricular failure and left ventricular failure are identical, or at least very similar. As
such, most concepts of right ventricular failure have been shaped by the studies of the left
ventricle.

However, there exist both embryological and physiological differences

between both ventricles that support a hypothesis that the gene expression patters differ
between right and left ventricular failure. We first sought to identify gene expression
differences in the normal right ventricle (RV) and normal left ventricle (LV). While
differences in expression are known for individual genes, there has not been a systematic
study of the gene expression differences of the two ventricles. This study served as the
basis for the studies of right ventricular failure associated with severe pulmonary arterial
hypertension (PAH) in the rat that followed.
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The vertebrate heart forms from two populations of cardiac progenitor cells: the primary
heart field, or first heart field, and the secondary heart field, or anterior heart field. The
primary heart field originates in the anterior splanchnic mesoderm and gives rise to the
cardiac crescent, left ventricle, and atria[99-101]. The secondary heart field is derived
from the pharyngeal mesoderm, located medial to the cardiac crescent, and gives rise to
the outflow tract and large portions of the right ventricle and atria[99, 230]. Progenitor
cells from the cardiac crescent migrate medially and form the linear heart tube, which
consists of an inner endocardial layer and an outer myocardial layer. Right-ward looping
and differential growth along the outer curvatures of the heart tube ultimately generate
the multi-chambered heart[101]. Cells from the adjoining secondary heart field are
progressively added to the developing heart forming additional structures, such as the
right ventricle and atria[99, 100] (Figure 5).

During these embryological processes, transcription factors are regionally expressed in
the developing heart. While some can be found in both the primary and secondary heart
fields, others show specific expression patterns in just one of the developing heart fields.
T-box 5 (Tbx5) and the basic helix-loop-helix transcription factor heart and neural crest
derivatives expressed-1 (Hand1) are both expressed in the primary heart field, while heart
and neural crest derivatives expressed-2 (Hand2), islet-1 (Isl1), fibroblast growth factor-8
(Fgf8), fibroblast growth factor-10 (Fgf10), paired-like homeodomain-2 (Pitx2), and
Tbx5 are expressed in the secondary heart field[107, 108].
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Figure 5: Overview of Heart Development
The heart forms from two different heart fields, the primary heart field (shown in blue)
and the secondary heart field (shown in purple). a) The cardiac crescent is composed of
cells from the primary heart field with cells from the secondary heart field located
medially. b) Cells from the cardiac crescent migrate medially and form the linear heart
tube. c) Rightward looping of the heard tube ultimately generates the multi-chambered
heart (d).

Reprinted from Cell, vol. 127, D.J. Garry and E.N. Olson, “A common progenitor at the
heart of development,” 1101-1104, Copyright 2006, with permission from
Elsevier.
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Natural killer cell-associated antigen 2 transcription factor related, locus 5 (Nkx2-5) is
expressed in both heart fields[101].

Knockout mouse studies of these transcription factors reveal their importance during
development of the heart. Loss of Nkx2-5 was associated with a loss of ventricular tissue
and the absence of Hand1 expression, both at the cardiac-crescent stage and later in the
cardiac tube where it would normally mark the left ventricle[113-115]. Tbx5 mutant
mice show severe defects in the atria-inflow region of the heart and left-ventricular
hypoplasia; however, Hand1 and other left-ventricular markers are expressed. Despite
the abnormal development of the left ventricle, the outflow tract and right ventricle
continue to develop normally[119]. Without expression of Hand1, formation of the left
ventricle is disrupted due to a proliferation defect, and the mutants die from extraembryonic effects[116, 118, 231]. In contrast, Hand2 mutants show right-ventricular
hypoplasia[120, 121]. Isl1 mutants have only two chambers in the heart tube. Labeling
with Hand1 and Tbx5 probes show that the left ventricle is present; however, markers of
the right ventricle and outflow tract are not detected[100]. Chick embryo studies have
shown that fibroblast growth factor signaling, including Fgf8 and Fgf10,

may be

necessary for the proliferation of cells in the secondary heart field[123].

The

transcription factor Pitx2 is expressed during the primitive heart tube stage and is
responsible for the left/right specification of the chambers and the outflow tracts. It is coexpressed in the secondary, or anterior, heart field with Tbx1, which acts as an enhancer
for Pitx2 and affects asymmetric cardiac morphogenesis[232, 233]. While each of these
genes has been identified as playing a role in the development of the heart, there has not
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been, to our knowledge, a global study of the gene expression differences between the
normal LV and the normal RV.

In addition to considering differences in embryological development between the
ventricles, it is also necessary to consider the differences in physiology. The normal
pulmonary artery and right ventricular systolic pressure is 1/5 that of the systemic
pressure. Additionally, the thickness of the RV free wall is approximately 1/5 less than
that of the LV free wall – 2 to 5 mm in the RV compared to 7 – 11mm in the LV[146,
234]. The mass of the RV is 1/6 that of the LV[148]. While the LV has an ellipsoidal
shape, the RV has a crescent shape in cross-section and appears triangular from the
side[146, 234]. It has been reported that there are regional differences in the size of
cardiomyocytes in adult rat hearts[235], and that cardiomyocytes respond differently to
changes in hemodynamic load depending on the ventricle in which they are located[236].
During the development of severe pulmonary hypertension (PH), the RV systolic
pressure undergoes a 4-5 fold increase above normal[8, 237], whereas the LV systolic
pressure in a widely studied model of chronic left ventricular failure, aortic stenosis,
increases in pressure by only a few percent[202, 238, 239].

It is also known that α1-

adrenergic receptor agonists decrease the contractile force in the normal RV, whereas
they increase the force in the corresponding LV[240]. Similarly, long-term infusion of
norepinephrine led to LV hypertrophy, but the RV did not respond with
hypertrophy[241]. Based on these physiological differences, we postulate that there is a
difference in gene expression between the two ventricles.
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Rationale: Based on the differences in embryology and physiology, there is sufficient
reason to postulate that the normal RV and the normal LV have different gene expression
profiles. While many studies have examined the gene expression profile of the LV or the
use the nonspecific term “ventricle”, none have looked at the differences between the RV
and the LV. In fact, many studies do not make the distinction between LV and RV and
treat the ventricles as one muscle. However, as explained above, the RV and LV neither
respond in the same manner, nor do they arise from the same embryological background.
It stands to reason that there is a difference in the normal gene expression patterns in the
adult rat that ultimately lead to the differences in the ventricles during right ventricular
failure.

3.2

Microarray Analysis

In order to more clearly determine the gene expression changes of the right ventricle
during failure caused by PAH, our first goal was search for postulated differences in gene
expression between the normal RV and the normal LV. To this end, we adopted DNA
microarray technology to elucidate the differences (Figure 6). We used the Agilent
Whole Rat Genome 4 x 44k chips, a commercially available microarray from Agilent
Technologies, Inc. Each array is comprised of probes that have been validated for
sequence orientation, accuracy, and clustering assembly classification using the rat
genome build m3[242]. In order to obtain an overview of the normal ventricle gene
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Figure 6: Clustergram of normal RV and normal LV
Normal RVs and LVs were isolated from the same animal and snap frozen on liquid
nitrogen. RNA was isolated from each ventricle and labeled with Cyanine-5 (red).
Universal rat reference RNA from Stratagene was labeled with Cyanine-3 (green). Genes
were selected using the procedure in the text. The left column shows expression in the
LV and the middle column the RV. Genes colored red indicate higher expression than
reference RNA, green indicates lower expression, and black indicates equal expression.
The column to the right of the grey line is the difference between the RV and LV; in this
case, red represents higher expression in the RV, and green represents higher expression
in the LV.
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expression, we performed a microarray analysis using paired samples, that is, the LV and
the RV from six biological replicates (six rats).
Our experimental design utilized a so-called “Type II” approach: each condition was
hybridized against a pool of reference RNA from Strategene designed to provide a
hybridization signal at each spot and to provide a consistent pool of RNA for each
experiment. As such, the expression of the RV and LV as shown is relative to the
reference RNA pool and can be considered arbitrary; the important difference comes in
the comparison between the two ventricles. All data from the scanned arrays were
uploaded to the Ramhorn Array Database, a VCU-specific installation of the Longhorn
Array Database[218], for archiving and analysis. To produce the clustergram shown in
Figure 6, the basic analysis is as follows. Microarray data were retrieved from the
Ramhorn Array Database after filtering the data using a set of spot-quality metrics. Spots
were included in the dataset if they have a signal greater than or equal to 1.5 fold above
background in both the red and green channels and greater than 50% good data across the
set of arrays. Technical replicates were averaged together. To determine which genes
had a statistically significant difference in their expression between the normal RV and
normal LV, we used the Significance Analysis of Microarrays (SAM) algorithm[219] to
perform a two-class paired analysis between the data from the normal RV and the normal
LV. The SAM analysis was conducted using 64 permutations of the replicate data, the
maximum number of permutations given a two-class paired analysis and six biological
replicates. Our approach to determining significance was to control the False Discovery
Rate (FDR) of the analysis by choosing the lowest delta value resulting in a median FDR
of 5% or less; for this analysis, a delta value of 0.92 was chosen giving a median FDR of
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4.64%.

This results in reporting of genes with q-values (the multiple-comparison

adjusted analog of the p-value used by SAM) < 0.05. Of the 20,556 genes that passed
filtering conditions, 335 were called significant.

The Stanford Unique Intentifiers

(SUIDs) representing each significantly regulated gene were retrieved. The expression of
biological replicates was averaged for both the RV and LV arrays. The Cluster 3.0
program[220] was used to perform average-linkage hierarchical clustering and exported
to the Java TreeView program[221] for visualization. The resulting cluster shown in
Figure 6 is comprised of the 355 genes passing the criteria listed above. The major
columns from left to right are: left ventricle average, right ventricle average, and the
relative difference between the right ventricle average and the left ventricle average (red
means higher expression in the RV than the LV and green means higher expression in the
LV than the RV).

Overall, the cluster shows a small number of genes that were differentially expressed. Of
the 355 genes with differential expression between the RV and LV, 332 had higher
relative expression in the RV than the LV, while only 23 had higher relative expression in
the LV than the RV. The clustergram shows the expression in the LV in the first column
and the RV expression in the middle column. The third column represents the difference
in expression between the RV and LV. In focusing on the third column, smaller clusters
become apparent, each with a different pattern of expression that corresponds to different
biological functions and pathways. The list of all biological processes associated with
these genes that differ in expression was identified using the PANTHER classification
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system and is given in Table 7[222, 223]. PANTHER was also used to assign the
molecular functions of genes in each sub-cluster.

Cluster I

This cluster has genes with higher relative expression in the RV

than in the LV. Genes in this cluster are involved in binding, catalytic activity, enzyme
regulator activity, ion channel activity, receptor activity, structural molecule activity,
transcription regulator activity, and transporter activity.

In this cluster are several genes that control the Wnt signaling pathway, a signaling
pathway that is active during the heart’s development in the secondary heart field to
promote growth and diversification of precursor cells into the right ventricle and
interventricular myocardium[243]. These genes include: FAT tumor suppressor homolog
3 (Fat3), SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily d, member 2 (Smarcd2), and transducer-like enhancer of split 3 (Tle3). Thus,
having higher expression of Wnt signaling pathways in the RV than the LV is consistent
with the different embryological backgrounds of the two ventricles.

In addition, genes involved in the IGF1/insulin signaling pathway can be found in this
cluster: insulin-like growth factor 1 (Igf1) and insulin-like growth factor binding protein 3
(Igfbp). IGF1 signaling has been shown to cause cardiomyocyte growth[244] and control
cell differentiation and apoptosis[245].

81

Table 7: List of biological processes that are differentially expressed between the
normal RV and normal LV.
The biological processes were assigned by PANTHER for each gene and summarized
here.
Biological Process
Apoptosis
Blood circulation and gas exchange
Cell adhesion
Cell cycle
Cell proliferation and differentiation
Developmental processes
Homeostasis
Immunity and defense
Neuronal activities
Oncogenesis
Carbohydrate metabolism
Lipid, fatty acid, and steroid metabolism
Nucleoside, nucleotide, and nucleic acid metabolism
Other metabolism
Protein metabolism and modification
Protein targeting and localization
Cell structure and motility
Intracellular protein traffic
Transport
Sensory perception
Signal transduction
Miscellaneous
Unclassified or unknown
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# of Genes
5
1
3
8
10
25
4
15
5
9
3
11
30
11
22
1
7
5
16
3
46
2
212

Cluster II

This cluster is composed of a single gene, heme binding protein 1

(Hebp1), which has higher relative expression in the LV than in the RV. Hebp1 is
thought to play a role in heme utilization for hemoprotein synthesis[246]. In addition, it
may play a role in the sequestration and extraction of porphyrins from cells[247].

Cluster III

Genes in this cluster have higher relative expression in the RV than

in the LV. These genes are involved in binding, catalytic activity, and encode structural
molecules. Of particular interest, protein phosphatase 3, catalytic subunit, alpha isoform
(Ppp3ca), also known as calcineurin, is involved in several pathways, including the
previously discussed Wnt signaling pathway and T-cell activation. Activation of the
Ca2+/calcineurin pathway increases Th2 cell development[248]. Additionally, inhibition
of calcineurin was shown to be cardioprotective.

A decrease in calcineurin was

associated with decreased cardiac hypertrophy and improved vascularization[249].

Cluster IV

In this cluster there are genes that have lower relative expression in

the RV than in the LV. These genes participate in cellular activities such as binding,
catalysis, enzyme regulation, and transcription regulation. Both cyclin D2 (Ccnd2) and
growth arrest and DNA-damage inducible, alpha (Gadd45a) are involved in cell cycle
regulation. Gadd45a acts to repair damaged DNA, while Ccnd2 induces the transition
from G1 to S in the cell cycle. It has been shown that sirtuin (silent mating type
information regulation 2 homolog) 1 (Sirt1) regulates both genes in the heart. Increased
levels of Sirt1 are associated with oxidative stress and cause induction of Gadd45a and
repression of Ccnd2[250].
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Cluster V

Genes in this cluster have a higher relative expression in the RV

than in the LV. They have functions including: antioxidant activity, binding, catalytic
activity, enzyme regulator activity, receptor activity, structural molecule activity, and
transcription regulator activity.

In addition, two genes play roles in the endothelin

signaling pathways: endothelin converting enzyme 1 (Ece1) and protein kinase N1
(Pkn1).

Endothelin signaling is known to stimulate myocyte grown and affect the

contractile properties of the heart. It may also increases resistance to apoptosis[251].
Rho-associated coil-coil containing protein kinase 1 (Rock1) and von Willebrand factor
(Vwf ) are members of the inflammation by chemokine and cytokine signaling pathway.

Cluster VI

In this cluster, the genes have lower relative expression in the RV

than the LV. These genes participate in activities of catalysis, structural molecules, and
transport.. While there are no significant pathways representative of these genes, several
do act as signaling molecules, including homer homolog 2 (Homer2), regulator of
calcineurin 1 (Rcan1), and natriuretic peptide precursor B (Nppb).

3.3
Comparison of the gene expression pattern between the normal RV and LV
by qRT-PCR

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate the
microarray expression results of several genes from several different clusters: nuclear
receptor subfamily 2, group F, member 2 (Nr2f2), Igf1, Iroquois homeobox 2 (Irx2), and
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Nppb. Igf1 and Nr2f2 were found in Cluster I, Irx2 in Cluster IV, and Nppb in Cluster
VI. The qRT-PCR results (Figure 7) were all consistent with the trends seen in the
microarray data, giving us confidence in the technique and analysis of those data. Nr2f2,
also known as COUP-TFII (chicken ovalbumin upstream promoter-transcription factor
2), is required for angiogenesis during heart development[252]. Nr2f2 is expressed twofold higher in the normal RV than the LV.

Igf1 was selected for its roles in

cardiomyocyte growth and control of cell differentiation and apoptosis[244, 245]. Igf1
was found to have levels in the normal RV 2.5 fold higher than those in the normal. Irx2
is a transcription factor expressed in the interventricular septum during heart
development where it is thought to play a role in septum specification[253]. Irx2 was
only found to be expressed in the normal LV and was expressed at high levels. Nppb is
the precursor to the protein BNP (brain natriuretic peptide), which is used clinically as a
marker of heart failure. Levels of Nppb were 7 fold higher in the LV than the RV.

3.4

Discussion

In this chapter, we identify the differences in gene expression between the normal RV
and the normal LV.

These results are consistent with our understanding of the

development and the normal physiology of the heart. While it has been shown previously
that chamber-specific gene expression occurs during formation of the LV and the
RV[115, 117, 254], it is our understanding that these data represent the first systematic
study of the differences in gene expression between the RV and the LV in the adult rat.
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Figure 7: Comparison of expression levels of selected genes between the normal RV
and normal LV by qRT-PCR
Quantitative real-time PCR analysis of a) Nr2f2 (a, p<0.05 vs. LV), b) IGF1 (a, p<0.01 vs
LV), c) Irx2 (a, p<0.05 vs RV), and d) BNP (a, p<0.005 vs RV) mRNA in rat normal left
and right ventricles. Data were normalized to expression of 18S rRNA and are shown as
mean ± s.e.m. (n=3)
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While the majority of the genes expressed in the normal rat heart shared gene expression
profiles, a relatively small number of genes showed a significant difference in gene
expression (Table 8). While the set of differentially expressed genes between the normal
LV and normal RV is small, they are enriched for genes and pathways that are known to
play a role in the heart. In the case of the transcription factor Irx2, the difference was
categorical in that there was no expression in the normal RV. Because Irx2 determines
interventricular septum specification, absent free wall of the RV tissue expression of Irx2
and high expression in the LV wall may serve as evidence that the interventricular
septum is indeed part of the LV rather than the RV as is normally held. For the majority
of differentially expressed genes, the difference in expression was a matter of degree,
exemplified by Nr2f2, Nppb, and Igf1.
While previous studies investigating right ventricular failure have operated with concepts
that were derived from the failing LV, these data make it clear that the RV and LV should
be evaluated independently because of differences in gene expression patterns. This
notion is supported by the divergent response of the RV and LV to therapeutic agents in
particular prostaglandin, which worsens left ventricular failure but improves right
ventricular failure[240, 241].

We postulate that a set of gene expression changes

associated with right ventricular failure can be identified and this study of the normal RV
and the normal LV will serve as the basis for that work.
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Table 8: Summary of genes with differential expression in the normal RV and
normal LV

Right Ventricle
Nr2f2
Igf1
calcineurin
Ece1
Vwf
Rock1

Left Ventricle
Irx2
Nppb
Hebp1
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Chapter 4: Changes in Gene Expression in the RV during Hypertrophy and Failure

4.1

Introduction

Right ventricular failure (RVF) is increasingly recognized as an important clinical
problem[255] and most patients with severe and progressive pulmonary arterial
hypertension (PAH) die from right-heart failure. Additionally, right ventricular failure is
the worst prognostic indicator in patients with left ventricular failure[256, 257]. Acute
right ventricular failure in PAH patients can arise due to the progression of the lung
vascular disease or neurohormonal activation[154].

During the progression of PAH, the mean pulmonary artery pressure (mPAP) increases
progressively as the pulmonary vascular resistance (PVR) increases while the cardiac
output (CO) remains the same (Figure 8). The right ventricle (RV) usually adapts to the
high pressure in the pulmonary artery with an increase in right ventricular wall thickness
achieved through muscle hypertrophy[180]. This adaptation is also associated with an
increased myocardial oxygen demand[48]. The increase in afterload, defined as the
amount of pressure the RV must generated to move blood from the heart to the lungs, is

90

Figure 8: Progression of PAH
As the pulmonary vascular resistance (PVR, purple line) increases, mean pulmonary
artery pressure (PAP, green line) also increases. Cardiac output (CO, blue line) remains
constant initially. As resting cardiac output decreases, patients begin to decline.
Pulmonary artery pressure eventually decreases.

Reprinted from Clinics in Chest Medicine, vol. 28(1), D.B. Taichman and J. Mandel,
“Epidemiology of Pulmonary Hypertension,” 1-22, Copyright 2007, with permission
from Elsevier
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sensed by integrins and stretch-activated ion channels in cardiac cells to initiate protein
synthesis for the adaptive hypertrophy[156]. Myocardial blood supply must keep up with
the hypertrophy. Angiogenesis, the growth of new vessels from existing vessels, is
known to be initiated by vascular endothelial growth factor (VEGF), angiopoietin 1
(Ang1), and other growth factors[48].

As the RV begins to fail and is no longer able to overcome the increased pulmonary
vascular resistance, the mean pulmonary artery pressure and cardiac output fall [258]
(Figure 8). As RV end-diastolic volume and pressure increase, RV wall stress also
increases, which leads to a reduction in RV stroke volume[154]. While it is often
assumed that elevated mean pulmonary artery pressure and increased RV afterload is a
sufficient cause of right ventricular failure associated with PAH, it has been shown in
animal models of pulmonary hypertension that increased afterload alone does not cause
the RV to fail[180].

In animal studies comparing models of elevated pulmonary

afterload, achieved through pulmonary artery banding (PAB), with models of failure, the
RV hypertrophies but does not fail after PAB[180].

While an increase in afterload is the first trigger for adaptation in the RV, development of
RVF in PAH also arises from neurohormonal signaling, oxidative stress, inflammation,
ischemia, and cell death[48]. Associated with the changes in pathology are a set of
known changes in protein levels. Levels of uric acid increase in hypoxic states and are
correlated with functional decline in patients with PAH.[259] Serum levels of BNP are
also increased in PAH patients versus control and were inversely correlated with
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functional status and survival rates[260]. Troponin levels are often elevated in patients
with RVF due to myocardial stretch and ischemia[154]. Reactive oxygen species (ROS),
reactive nitrogen species (RNS), and inflammatory responses further the development of
right heart failure in PAH[48]. Excessive production of reactive oxygen and reactive
nitrogen species induce contractile dysfunction and favor cardiac remodeling through
induction of cell damage, apoptosis, and inflammation[48]. Patients with chronic heart
failure have increased serum levels of tumor necrosis factor alpha (TNF-α), interleukin 1
(IL-1), and interleukin 6 (IL-6)[210]. The switch from the α- to β-isotype of major thick
filament protein myosin heavy chain (MHC) [MHC-α to MHC-β switch] in
cardiomyocytes is a known hallmark of maladaptive cardiac growth and is known to be
associated with right heart failure in PAH[181]. In addition, contractile dysfunction can
be associated with mitochondrial defects, depletion of myocardial ATP, and
modifications of myocardial energy metabolism and utilization[48].

Rationale: We have previously shown that the normal RV and normal LV have different
gene expression profiles.

As such, we hypothesize that the failing RV cannot be

examined in terms of known failing LV gene expression profiles. We also hypothesize
that the transition from adaptive hypertrophy to right ventricular failure in PAH is
associated with a change in gene expression. Using microarray techniology, we will
characterize the gene expression of the failing RV and the RV with adaptive hypertrophy.
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4.2

Animal models of hypertrophy and failure

Pulmonary hypertension research began in Colorado in the 1950s and 1960s with studies
of “brisket disease”, now known as pulmonary hypertension and heart failure, in cattle.
In pioneering early PH studies, some cattle were kept at an altitude of 5,000 feet while
others were kept at 10,000 feet and hemodynamic measurements were made of both
groups. Those cattle kept at the higher altitude developed pulmonary hypertension, while
those kept at the lower altitude did not[261]. Later studeies comparing the response in
sheep and cattle showed that sheep did not respond to the same extent as cattle to chronic
high altitude hypoxia and that the hypoxic pulmonary vascular reponse is species
dependent[262].

Roughly at the same time, the monocrotaline model of pulmonary hypertension was
being developed. Monocrotaline is a purified pyrollizidine alkaloid found in plants of the
genus Crotalaria [263] that has been shown to cause hepatotoxicity, pneumotoxicity, and
chronic pulmonary hypertension in humans[264-266].

Pathologically, injection of

monocrotaline has been shown to cause endothelial cell damage [267, 268];
microvascular leak [269, 270]; arterial thickening; muscularization of small, normally
nonvascular arteries; and thickening of the pulmonary artery trunk [271]. A progressive
rise in pulmonary artery pressure and development of RVF also result from
monocrotaline administration[272]. While the monocrotaline model produces a set of
predictable pathological changes in the rat, it has come under criticism in recent years
because it also causes myocarditis and pulmonary fibrosis making it difficult for
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pulmonary hypertension researchers to correlate the data from this model with human
idiopathic pulmonary arterial hypertension [273-276].

As such, it is likely not an

appropriate model to for the study of RVF caused by PAH.

A newer model of pulmonary hypertension is the SU5416/hypoxia model[277-279]. It
requires administration of the selective vascular endothelial growth factor receptor 2
(VEGFR2) tyrosine kinase inhibitor SU5416 (3-[2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one) [280] and exposure to chronic hypoxia (10% FiO2). This model rests on
two components: stress and death of lung vessel endothelial cells and chronic hypoxia.
The

SU5416/hypoxia

model

simulates

human

idiopathic

PAH

by

inducing

angioproliferative pulmonary lesions similar to those seen in human patients, severe
pulmonary hypertension, and, ultimately, right ventricular failure [281]. The hearts show
dilation and hypertrophy of the RV and paradoxical movement of the interventricular
septum (Figure 9). When SU5416 is given alone, it causes mild pulmonary hypertension
and pulmonary vascular remodeling, but neither irreversible PAH nor RVF[282].
Exposure to chronic hypoxia alone for 4 weeks generates moderate pulmonary
hypertension and RV hypertrophy, but not right ventricular failure[283]. While the
Fulton index (RV/LV+S) increases with both chronic hypoxia and SU5416, the body
weight of the animals does not change significantly with treatment (Figure 10). SU5416
given alone does not cause a change in the body weight or in the Fulton index. Because
of the similarity to human disease, the SU5416/hypoxia model will be used for our
studies
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Figure 9: Maladaptive remodeling in rat models of right heart failure.
a) The normal RV imaged by echocardiography has a crescent shape (arrow), an
interventricular septum that is crescent shaped (dashed line) and a free wall that is
difficult to identify by routine echocardiography. b) in the RV failure model (SuHx),
echocardiography shows RV hypertrophy (arrow), dilation, and paradoxical movement
(towards the LV rather than the RV) of the interventricular septum (dashed line) c)
freshly excised normal rat heart d) freshly excised failing (SuHx) rat heart. Arrow points
to hypertrophied RV.
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Figure 10: Body weight and Fulton index of animal models used in failure study
a) Body weight in grams and b) RV hypertrophy expressed as Fulton index (RV/LV+S)
of normal (control), SU5416 (SU5416) treated, hypoxia (hypoxia) treated, and
SU5416/hypoxia (SuHx) treated rats (a, p<0.05 vs control).
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4.3

Microarray analysis

In order to identify differences in gene expression that occur during right ventricular
failure associated with PAH, we used a microarray analysis similar to that employed in
the comparison between the normal RV and normal LV. Again, this was a “Type II”
approach in which each hybridization was a combination of RNA from an animal model
and a pool of commercially available reference RNA. Total RNA was isolated from RV
tissue from animals treated with SU5416 alone, chronic hypoxia alone, and SU5416 in
combination with chronic hypoxia. Because the normal RV was hybridized against the
same pool of reference RNA, it can be used again in this analysis. The expression of
each RV treatment as shown is relative to the normal RV.

Total RNA was isolated from the free wall of the RV from rats treated with SU5416
(SU5416) only, rats exposed to chronic hypoxia for 4 weeks, and rats given a
combination of SU5416 and chronic hypoxia.

RNA was converted to cDNA and

fluorescently labeled with either Cyanine-3 (green) or Cyanine-5 (red) dye. The two
labeled cDNA samples were mixed together and hybridized to an Agilent Whole Rat
Genome 4x44k microarray chip overnight. Six biological replicates and three technical
replicates per condition were hybridized. Microarrays were washed and then scanned
with an Axon GenePix 4200A scanner and GenePix Pro 5.0 software. All data were
uploaded into the Ramhorn Array Database (http://ramhorn.csbc.vcu.edu). Microarray
data were retrieved from the Ramhorn Array Database if they had a signal greater than or
equal to 1.5 fold above background for both the red and green. A gene was called “good”
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and used for analysis if greater than 50% of all arrays for each condition used in the
analysis passed the filtering conditions of expression greater than or equal to 1.5 fold
above background expression. Technical replicates were averaged together.

To determine which genes had a stastically significant difference in their expression
between conditions, we used the Significance Analysis of Microarrays (SAM)
algorithm[219] to perform a two-class unpaired analysis with 1,000 permutations of
replicate data.

To control the False Discovery Rate (FDR), the lowest delta value

resulting in a median FDR of 5% or less was chosen to give genes with a q-value < 0.05.
First, a pairwise comparison of each condition compared to normal was made. In the
comparison between the normal RV and the SU5416-only treated RV, 18,137 genes
passed the filtering conditions. Of these, 6,611 were called significant at a delta value of
0.70 and a FDR of 4.83%. When comparing the normal RV and the hypoxia-only RV,
10,967 genes passed filtering conditions and 5,855 of these were significant using a delta
value of 0.73 and a FDR of 4.79%. Finally, in a comparison between the normal RV and
the SU5416/hypoxia RV, 13,050 genes passed filtering conditions. 3,595 were called
significant at a delta value of 0.80 corresponding to a FDR of 4.3%. A venn diagram of
the number of genes called significant between each condition and the overlap of those
significant genes is shown in Figure 11. 493 genes were called significant in all of the
pairwise conditions and there was also overlap in the genes called significant between
sets of comparisons. However, the majority of genes in each comparison were not shared
in another condition and these differences most likely represent the genes causing
changes in phenotype by the treatments.
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Figure 11: Venn Diagram of Genes Called Significant in Pairwise Comparisons
Pairwise comparisons were made between the normal RV and each condition, SU5416
RV, hypoxia RV, and SU5416/hypoxia RV, using the Significance Analysis of
Microarrays two-class unpaired comparison algorithm. For each analysis a delta value
was chosen such that the False Discovery Rate was 5% or less. The number of genes
called significant in each comparison is shown here as well as the number of significant
genes shared between each pairwise comparison. 493 genes were called significant in all
pairwise comparisons.
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To determine which genes had statistically significant difference in their expression
between the normal RV, the failing (SU5416/hypoxia) RV, and the hypoxic RV, a series
of two-class unpaired comparisons were made. First, a two-class comparison between
the normal RV and the SU5416/hypoxia RV was done to identify 3,595 called significant
using the parameters listed previously. Next, a two-class unpaired comparison was made
between the SU5416/hypoxia RV and the hypoxia RV for those 3,595 genes called
significant between the normal and failing RV. Of the 3,595 genes, 1,980 were called
significant between the SU5416/hypoxia RV and hypoxia RV at a delta value 0.74, which
gives a FDR of 4.96%. The Stanford Unique Indentifiers representing genes called
signficant between both comparisons were compiled and data for all conditions – normal
RV, SU5416 RV, Hypoxia RV, and SU5416/hypoxia RV – were retrieved from the
Ramhorn Array Database and transformed by subtracting the average expression of the
normal RV from each condition.

This gives the expression in each experimental

condition relative to the normal RV and allows us to visualize the change in expression
resulting from the treatment.

The Cluster 3.0 program[220] was used to perform

average-linkage hierarchichal clustering of the whole dataset and exported to the Java
TreeView program[221] for visualization. The resulting cluster shown in Figure 12 is
comprised of the 1,980 genes passing the filtering conditions above. The major columns
from left to right are: normal RV, SU5416 RV, Hypoxia RV, and SU5416/hypoxia RV.

Overall, the cluster shows that an approximately equal number of genes were upregulated and down-regulated in the RV with SU5416/hypoxia treatment as compared to
the normal RV. Treatment with SU5416 had a clear pattern of expression in the; this
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Figure 12: Clustergram of differentially expressed genes between the normal RV,
hypertrophied RV, and failing RV
Six biological replicates per condition were hybridized to Agilent Whole Rat Genome
microarrays. RV hypertrophy is generated by treating rats with SU5416 (samples labeled
“SU5416”) or exposure to chronic hypoxia (samples labeled “Hypoxia”). RV failure
(samples labeled “SuHx”) is due to the treatment of rats with a combination of SU5416
and chronic hypoxia. Green indicates lower expression in a given condition than in the
normal RV, red indicates higher expression in a condition than in the normal RV. Black
indicates that the expression in the condition is equal to expression in the normal RV.
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pattern was not shared with the chronic hypoxia or SU5416/hypoxia treatment. When
contrasting RV hypertrophy caused by chronic hypoxia exposure and RV failure caused
by SU5416/hypoxia treatment, there are distinct patterns of expression not shared by the
two treatments. Of particular interest are clusters where overexpressed genes in chronic
hypoxia are decreased in the failing RV. These genes could indicate a pattern of adaptive
hypertrophy gene expression. Ingenuity Pathway Analysis (http://www.ingenuity.com)
was used to identify the biological process associated with the genes that differ in
expression between the normal RV and the failing RV and is shown in Table 9. In
focusing on cluster diagram, smaller clusters become apparent, each with a different
pattern of expression that corresponds to different biological functions and pathways as
determined by Ingenuity Pathway Analysis and the PANTHER Classification
System[222, 223].

Subcluster I consists of genes that represent a “frank failure-activated” cluster;
they have higher expression in the SU5416/hypoxia RV than the chronically hypoxic RV.
The top five canonical pathways as defined by Ingenuity Pathway Analysis for genes in
this cluster are listed in Table 10. Integrin signaling is known to play a role in the heart’s
adaptation to pressure overload by increasing synthesis of contractile proteins[157, 158].
Expression of integrin-like kinase (ILK) is highest in the heart and is an essential for
regulating cardiac growth, contractility, and repair[284]. Cardiac-specific expression of
ILK induces hypertrophy suggesting that ILK is a regulator of hypertrophic signaling
pathways[285]. Additionally, levels of α-skeletal mRNA have been shown to increase
10-fold in a calf model of pulmonary hypertension induced by chronic hypoxia[286]. In
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Table 9: Biological processes of genes differentially expressed between normal RV
and SU5416/hypoxia RV

Biological Process
Apoptosis
Blood circulation and gas exchange
Muscle contraction
Cell adhesion
Cell cycle
Cell proliferation and differentiation
Developmental processes
Homeostasis
Immunity and defense
Neuronal activities
Non-vertebrate process
Oncogenesis
Amino acid metabolism
Carbohydrate metabolism
Coenzyme and prosthetic group metabolism
Lipid, fatty acid and steroid metabolism
Nitrogen metabolism
Nucleoside, nucleotide and nucleic acid metabolism
Other metabolism
Phosphate metabolism
Protein metabolism and modification
Sulfur metabolism
Protein targeting and localization
Cell structure and motility
Intracellular protein traffic
Transport
Electron transport
Sensory perception
Signal transduction
Miscellaneous
Unclassified or unknown
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# of Genes
261
61
142
270
424
518
935
119
731
256
8
253
116
280
97
417
12
1173
206
33
1240
33
105
505
400
613
149
149
1522
19
1369

Table 10: Top Five Canonical Pathways of Genes in Subcluster I

Pathway Name
Integrin Signaling
Actin Cytoskeleton Signaling
ILK Signaling
Nrf2-mediated Oxidative Stress Response
IGF-1 Signaling

p-value
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1.56 x 10-6
4.11 x 10-6
6.40 x 10-6
8.35 x 10-6
2.27 x 10-5

the microarray dataset, expression of several actin genes were increased: actin alpha 1
(Acta1) and actin gamma 1 (Actg1) were increased 3.5-fold in the SU5416/hypoxia RV
over the hypoxic RV while actin beta (Actb) was increased 2-fold in the SU5416/hypoxia
RV over the hypoxic RV. Rho-kinase (Rock), a downstream effector of RhoA, plays a
role in regulating rearrangement of the actin cytoskeleton[287] and has previously been
shown to be increased in expression during pressure overload-induced cardiac
hypertrophy[288]. Deletion of Rock1 was associated with reduced remodeling, including
fibrosis, apoptosis, and chamber dilation[287].

RhoA was increased 2-fold in the

SU5416/hypoxia RV compared to the hypoxic RV in the microarray dataset. Based on
these pathways and their involvement in heart disease and hypertrophy, it can be
hypothesized that this cluster represents the damaged hearts’s attempt to compensate for
the increased stress.

However, because these genes have higher expression in the

SU5416/hypoxic RV than in the hypoxic RV, it is possible that this subcluster represents
a maladaptive hypertrophy pattern reflecting damage.

Subcluster II is comprised of genes that reflect a “hypoxia activation cluster”
and have increased expression in both the SU5416/hypoxia RV and the hypoxic RV. The
top five canonical pathways for genes in this subcluster as defined by Ingenuity Pathway
Analysis are listed in Table 11. There are several genes in this cluster that are members
of the transforming growth factor beta (Tgf-β) signaling pathway: inhibin beta B (Inhba);
mitogen-activated protein kinase 3 (Mapk3); and s100 calcium-binding protein A4. Tgf-β
has been shown to be induced by pressure overload[289] and injury[290] in the heart and
increased Tgf-β1 expression has been identified in the myocardium during cardiac
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Table 11: Top Five Canonical Pathways in Subluster II
Pathway Name
IL-8 Signaling
Hepatic Fibrosis/Hepatic Stellate Cell Activation
Ovarian Cancer Signaling
Pancreatic Adenocarcinoma Signaling
Role of Tissue Factor in Cancer
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p-value

5.73 x 10-7
2.24 x 10-5
6.30 x 10-5
9.05 x 10-5
9.71 x 10-5

hypertrophy and failure[291-293].

Inhbb was increased by 3-fold in both the

SU5416/hypoxia RV and hypoxic RV relative to normal. Mapk3 was increased 2-fold in
the hypoxic RV and 1-fold in the SU5416/hypoxia RV compared to normal. S100a4 was
increased 1-fold in the hypoxic RV and 3-fold in the SU5416/hypoxia RV compared to
the normal RV. Expression of interleukin-8 (IL-8) was increased in the serum of patients
with PAH and patients with higher serum levels of IL-8 had lower 1-year and 5-year
survival rates than patients with low IL-8 serum levels[294]. While IL-8 is a modulator
of immune responses, IL-8 also plays a role in vascular remodeling and modulate smooth
muscle and endothelial cell function[295-298]. This expression pattern is most likely an
attempt to compensate for stress rather than a failure-specific pattern because genes are
expressed almost equally in the hypoxic and SU5416/hypoxia RVs.

Subcluster III consists of genes that make up a “repression cluster” because they
have decreased expression in both the hypoxic RV and the SU5416/hypoxia RV. The top
five canonical pathways as defined by Ingenuity Pathway Analysis for genes in this
subcluster are listed in Table 12. The entire mitochondrial biogenesis pathway has been
reported to be downregulated in heart failure[299] and the generation of reactive oxygen
species (ROS) increases[300-303]. Mitochondria are the source of ROS and they are also
damaged by the generated ROS[304].

This ROS damage is associated with

mitochondrial dysfunction in failing hearts characterized by increased lipid peroxidation,
decreased mitochondrial DNA (mtDNA) copy number, a decrease in mtDNA transcripts,
and reduced oxidative capacity[305]. The decrease in oxidative capacity in the heart is
caused by defects in the major electron transport chain (ETC) complexes[306]; this is
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Table 12: Top Five Canonical Pathways in Subluster III
Pathway Name
Oxidative Phosphorylation
Ubiquinone Biosynthesis
Mitochondrial Dysfunction
Purine Metabolism
Valie, Leucine, and Isoleucine Degradation
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p-value

3.25 x 10-9
1.83 x 10-6
1.96 x 10-6
2.06 x 10-5
8.81 x 10-4

reflected in our data in Figure 13. Additionally, heart failure is characterized by a shift
from fatty acid oxidation to glucose oxidation in both clinical[307-309] and
experimental[310-312] studies. Furthermore, the ubiquitin proteasome system is involved
in cell proliferation and adaptation to stress[313] and increased levels of ubiquitinated
proteins are associated with depressed protseasomal activities. Under normal conditions,
the ubiquitin proteasome system protects cardiomyocytes by removing pro-apoptotic
signaling molecules, but decreased ubiquiting-proteasome system activity allows proapoptotic proteins to accumulate and trigger apoptosis[314].

Subcluster IV represents a “loss of hypoxic adaptation cluster;” genes in this
cluster have increased expression in the hypoxic RV, but decreased expression in the
SU5416/hypoxia RV. Although the top five canonical pathways for genes in this cluster
are listed in Table 13, none of the pathways has a p-value greater than 0.05. As a result,
we looked at specific genes within this subcluster. Of particular interest are the genes
caspase 4 (Casp4) and transcription factor T-box 3 (Tbx3), both of which induce
apoptosis signaling. Casp4 induces apoptosis in response to ER-mediated stress[315,
316] and is expressed 1.6-fold higher in the hypoxic RV than in the SU5416/hypoxia RV.
Tbx3 causes inhibition of cell proliferation and induction of apoptosis[317] and has 2-fold
higher expression in the hypoxic RV than the SU5416/hypoxia RV. Patients with PAH
have a decrease in proapoptic gene expression and an increase in antiapoptotic gene
expression[318]. Additionally, treatment with dichloroacetate in a monocrotaline model
of PAH results in induction of mitochondria-dependent aptoptosis and reversal of
PAH[319]. This expression pattern could be interpreted as a failure of the
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Figure 13: Mitochondrial dysfunction pathway in the failing RV
Canonical pathway analysis indentified the pathways from the Ingenuity Pathway
Analysis® library of canonical pathways that were most significant to the dataset. The pvalue for the mitochondrial dysfunction canonical pathway is 6.51 x 10-9. Genes are
colored based on fold-change comparison between SU5416/hypoxia (failing) RV and
hypoxia (hypertrophy) RV. Red correlates to relatively higher expression in the failing
RV than the hypertrophied RV, and green correlates to relatively higher expression in the
hypertrophied RV than the failing RV.
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Table 13: Top Five Canonical Pathways in Subcluster IV
Pathway Name
Purine Metabolism
Oxidative Phosphorylation
Relaxin Signaling
Aldosterone Signaling in Epithelial Cells
Endothelin-1 Signaling

p-value
0.0585
0.0729
0.0826
0.0961
0.1150
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SU5416/hypoxia heart to sustain stress to the same degree as the hypoxic heart, thus
leading to failure.

4.4

Prediction analysis

In order to identify the postulated gene signature that could predict between the three
conditions (normal, adaptive hypertrophy, and failing), prediction analyses were
performed by applying a leave one-out cross-validation (LOOCV) approach on a dataset
comprising six biological replicates in each class (normal RV, chronic hypoxia RV, and
SU5416/hypoxia RV), including several technical replicates per class. The LOOCV
method takes into account the sample size and is suitable for small sample numbers[227,
229]. Averaging the technical replicates in each class, four prediction algorithms were
used: 1-nearest neighbor, 3-nearest neighbors, nearest centroid, and diagonal linear
discriminant analysis[228]. We performed 2,000 permutations, which resulted in p <
0.0005 for all prediction algorithms. Thus, we found that 499 probes the provided a
prediction accuracy of 100% on all four algorithms. In addition, 450 of the 499 probes
showed a 100% support of the LOOCV method. These probes were clustered together
(Figure 14) and are listed in Appendix A. These 450 probes, corresponding to 405
different genes, can now be used to predict to which class a new sample belongs and
show a gene expression pattern that differentiates RV hypertrophy from right ventricular
failure.
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Figure 14: Prediction analysis cluster.
Dendogram for clustering experiments using centered correlation and average linkage of
the 450 probes that showed 100% agreement across LOOCV. Red represents greater
relative expression than reference RNA and green represents less relative expression than
reference RNA.
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A number of genes that demonstrated a fold-change difference in expression based on
microarray analysis between RV hypertrophy and RV failure (Figure 12, Figure 14)
were selected for qRT-PCR and their corresponding proteins selected for Western Blot
(Figures 15 - 18). These genes and proteins fell into one of five categories: signals
shared between hypertrophy and failure, glycolytic enzymes, cell-growth promoting
genes, angiogenesis, and cytoskeletal rearrangement.

4.5

Shared signals between hypertrophy and failure

As expected from previous reports, several genes, including natriuretic peptide prescursor
a (Nppa), natriuretic peptide prescuror b (Nppb), and myosin heavy chain β (MHC-β),
shared a gene expression pattern between hypoxia (hypertrophy) and SU5416/hypoxia
(failure). Nppa is the mRNA sequence precursor for atrial natriuretic peptide (ANP) and
Nppb is the mRNA sequence encoding the precursor for brain natriuretic peptide, both of
which are biomarkers of heart failure and increased plasma levels have been reported in
patients with PAH[260]. Likewise, an increase in the expression of MHC-β is associated
with hypertrophy and PAH-associated RV failure[48, 181]. Both NppA and NppB show
increased expression in both hypoxia and SU5416/hypoxia and are not significantly
different between hypoxia and SU5416/hypoxia[320]. Hypoxia-inducible factor 2, alpha
(HIF-2α) is a transcription factor that, like hypoxia-inducible factor 1, alpha (HIF-1α), is
activated in response to hypoxia. HIF-2α recognizes the same DNA consensus sequence
in the hypoxia response element (HRE) in promoters of target genes as HIF-1α[321].
While both transcription factors recognize the same consensus sequence, they do not
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Figure 15: Expression of genes shared between hypertrophy and failure.
Quantitative real time PCR analysis of HIF-2α (a, p<0.01 vs SuHx; b, p<0.01 vs normal)
mRNA in normal (normal), pulmonary artery banding (PAB), hypoxic (hypoxia), and
SU5416/Hypoxia (SuHx) rat right ventricles. Data were normalized to expression of 18S
rRNA and are shown as mean ± s.d. (n=3).
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transactivate the same genes nor can they compensate for each other[322, 323]. HIF-2α
is mainly expressed in endothelial cells, where it enhances transcription of endothelialspecific genes related to angiogenesis and vessel maturation, such as vascular endothelial
growth factor receptors 1 and 2 (Vegfr1 and Vegfr2), endothelium-specific receptor
tyrosine kinase 2 (Tie2), and angiopoietin-1 (Ang1)[324-326].

In addition, HIF-2α

maintains mitochondrial homeostasis by regulating the production of cellular factors to
alleviate oxidative stress[327, 328].

The HIF-2α null phenotype shows increased

oxidative stress because of decreased expression of genes encoding antioxidant enzymes,
including Sod2[328]. HIF-2α can promote VEGF expression in some tumors that lack
HIF-1α expression[329] and an activation mutant of HIF-2α dysregulates erythropoietin
production in humans leading to PAH.[330] As shown in Figure 15, HIF-2α expression
increases 3.5 fold over normal in both the hypoxia and SU5416/hypoxia RVs, suggesting
that HIF-2α may be important for adaptive hypertrophy.

While these data do not

distinguish between hypertrophy and failure, they do show that the models produce the
expected markers of hypertrophy and failure.

4.6

Loss of cell-growth promoting genes

Expression of growth factors, including insulin-like growth factor 1 (IGF-1), has been
shown to increase in response to exercise[168-173] and overexpression of IGF-1 receptor
or activated Akt leads to myocardial hypertrophy[170, 174]. In the hypoxic RV tissues,
mRNA expression of Igf1 was increased 3-fold compared to normal; however, Igf1 was
not increased in the SU5416/hypoxia RV compared to normal (Figure 16).
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Figure 16: Expression of cell-growth promoting genes
Quantitative real time PCR analysis of a) IGF-1 (a, p<0.05 vs normal; b, p<0.01 vs
SuHx) and b) KLF-5 (a, p<0.01 vs normal; b, p<0.01 vs SuHx; c, p<0.05 vs SuHx)
mRNA in normal (normal), pulmonary artery banding (PAB), hypoxic (hypoxia), and
SU5416/Hypoxia (SuHx) rat right ventricles. Data were normalized to expression of 18S
rRNA and are shown as mean ± s.d. (n=3). c) Western blot for expression of IGF-1 from
these normal, hypoxia, and SU5416/hypoxia. d) Densitometry was performed using Quantity One
1-D Analysis software (Bio-Rad) for normalized IGF-1 (a, p<0.001 vs Hx)
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SuHx

Importantly, the expression of IGF-1 protein was decreased in the SU5416/hypoxia RV
in comparison to the normal and hypoxic RV. Kruppel-like factor 5 (Klf5) has been
identified as a factor that transactivates IGF-1 in cardiac fibroblasts; the secreted protein
stimulates

cardiomyocyte

growth[244]

and

controls

cell

differentiation

and

apoptosis[245]. Klf5 expression also increased in the hypoxic RV (2 fold increase over
normal), but not in the failing (SuHx) RV. Together, these results suggest that in the
failing RV cell growth is impaired.

4.7

Impairment of angiogenic capillary maintenance

HIF-1α also plays a role in the development of cardiac hypertrophy[331]. In addition,
capillary rarefaction, the loss of capillaries, occurs in the failing RV[180]. While the
expression of HIF-1α mRNA did not differ between RV hypertrophy and RV
failure[180], downstream signaling molecules transcribed by HIF-1α were affected in the
failing RV in comparison to the hypertrophied RV.

VEGF[320], Ang1, and apelin

expression were reduced in the SU5416/hypoxia RV compared to the hypoxic RV tissue
(Figure 17). Similarly, apelin protein levels were also decreased in the SU5416/hypoxia
RV when compared to the hypoxia RV (Figure 17). Reduced apelin expression can
impair capillary growth and maintenance[332], which is consistent with the results seen
in the failing RV. The combined effect of reduced expression of VEGF, Ang1, and apelin
is that of a loss of capillary vessels and reduced angiogenesis. Whereas HIF-1α gene
expression cannot explain the decreased angiogenesis factor gene and protein expression,
HIF-1α protein stability may account for the impaired angiogenesis profile.

130

Figure 17: Expression of angiogenic capillary maintenance genes
Quantitative real time PCR analysis of a) Angiopoietin-1 (a, p<0.05 vs normal; b, p<0.05
vs SuHx) and b) apelin (a, p<0.01 vs normal; b, p<0.01 vs SuHx) mRNA in normal
(normal), hypoxic (hypoxia), pulmonary artery banded (PAB), and SU5416/hypoxia
(SuHx) rat right ventricles. Data were normalized to expression of 18S rRNA and are
shown as mean ± s.d. (n=3). c) Representative Western blots for expression of
angiopoietin-1, apelin and α-actinin from these groups. Densitometry was performed using
Quantity One 1-D Analysis software (Bio-Rad) for normalized d) Ang1 (no significant
difference) and e) apelin (a, p<0.005 vs control; b, p<0.001 vs Hx).
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4.8

Cytoskeletal rearrangement

CTGF is an extracellular matrix-secreted protein that is induced by TGF-β[333, 334].
Increased levels of CTGF are associated with cardiac fibrosis in a mouse model of
cardiomyopathy[335].

CTGF can cause hypertrophy in cardiomyocytes and induce

apoptosis via an activated caspase-3 pathway[336].

Induction of CTGF may be

important in an initial beneficial adaptive response to cardiac stress; however, long-term
activation of CTGF leads to dilation of ventricles and loss of cardiomyocytes[337]. As
shown in Figure 18, expression of Ctgf increases 19-fold over normal in the hypoxic RV
and then further increases in the SU5416/hypoxia RV – 46 fold over normal – consistent
with the theory that CTGF can have both a beneficial and detrimental role in the RV.
Adducin 3 (Add3) encodes the γ subunit of the adducin protein, a heterodimeric
cytoskeletal protein[338, 339]. Mutations in Adducin 1, encoding the α subunit of
adducin, and Add3 have been associated with the development of hypertension[340].
Adducin has been reported to positively regulate the intercellular junction of epithelial
cells[341]. Overexpression of Add3 in cardiomyocytes blocks cell elongation and results
in a more rounded structure[342]. While Add3 is expressed in the fetal heart, it is not
typically expressed in the adult heart; microRNA (miR)-143 supresses expression of
Add3[342].

Add3 is re-activated in the RV during development of pulmonary

hypertension associated with RVF. In hypoxic RV tissues, Add3 was increased by 8-fold
over normal and increased 13-fold over normal in the SU5416/hypoxia tissues. PAB, a
model of increased afterload alone, did not increase levels of Add3 suggesting that this is
an important adaptation to a hypoxic response.

Expression of miR-143 in the

SU5416/hypoxia RV was approximately one-half that of the normal RV (Figure 19).
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Figure 18: Expression of cytoskeletal rearrangement genes
Quantitative real time PCR analysis of a) CTGF (a, p<0.05 vs normal; b, p<0.05 vs
SuHx; c, p<0.01 vs normal) and b) Add3 (a, p<0.01 vs SuHx; b, p<0.001 vs normal; c,
p<0.05 vs SuHx) mRNA in normal (normal), pulmonary artery banding (PAB), hypoxic
(hypoxia), and SU5416/Hypoxia (SuHx) rat right ventricles. Data were normalized to
expression of 18S rRNA and are shown as mean ± s.d. (n=3).
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Figure 19: Expression of miR-143 expression in the RV

Quantitative real-time PCR analysis of miR-143 (a, p<0.01 vs control) in normal
(control), hypoxic (Hx), and Sugen/hypoxia (SuHx) rat right ventricle. Data were
normalized to expression of SNORA73A and are shown as mean ± s.d. (n=3).
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4.9

Elevated expression of glycolytic enzymes

We used the Ingenuity Pathway Analysis program (http://www.ingenuity.com) to further
explore the microarray gene expression data with respect to the pathways involved in the
different response to hypertrophy and failure. Canonical pathways analysis identified the
pathways from the Ingenuity Pathways Analysis library of canonical pathways that were
most significant to the data set. Molecules from the dataset that had a fold-change greater
than 2 between failing and hypertrophied RV were included in the analysis. The
significance of the association between the data set and the canonical pathway was
measured in 2 ways: 1) A ratio of the number of molecules from the data set that map to
the pathway divided by the total number of molecules that map to the canonical pathway
is displayed. 2) Fisher’s exact test was used to calculate a p-value determining the
probability that the association between the genes in the dataset and the canonical
pathway

is

explained

by

chance

alone.

The

expression

pattern

of

the

glycolysis/gluconeogensis canonical pathway had a p-value of 0.009 (Figure 20) and
seven different genes encoding glycolytic enzymes were found to be differentially
expressed (Table 14). Of particular interest, hexokinase 1 (Hk1) gene expression was
five-fold greater in the SU5416/hypoxia RV compared to the hypertrophied RV, and
phosphofructokinase (Pfkb) was increased 3-fold in expression between SU5416/hypoxia
and hypoxia. In contrast, alcohol dehydrogenase 7 (Adh7) was decreased two-fold in the
SU5416/hypoxia RV compared to hypoxia RV.

Additionally, Ucp2, a marker of

mitochondrial function, was increased 3-fold in SU5416/hypoxia RV compared to
hypoxia RV supporting the concept of impaired metabolism and energy utilization.
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Figure 20: Glycolysis and gluconeogenesis pathway in the failing RV
Canonical pathway analysis indentified the pathways from the Ingenuity Pathway
Analysis® library of canonical pathways that were most significant to the dataset. The pvalue for the glycolysis and gluconeogenesis canonical pathway is 0.00923. Genes are
colored based on fold-change comparison between SU5416/hypoxia (failing) RV and
hypoxia (hypertrophy) RV. Red correlates to relatively higher expression in the failing
RV than the hypertrophied RV, and green correlates to relatively higher expression in the
hypertrophied RV than the failing RV. Enzyme classification (EC) numbers reported by
Ingenuity were converted to recommended names using the BRENDA enzyme
database[343]; these names were then incorporated into the Ingenuity canonical pathway
using the MyPathway® feature
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Table 14: Expression of genes encoding glycolytic enzymes
Hypertrophy fold change is given relative to the normal RV and failure fold change is
given relative to the hypertrophied RV. Hexokinase 1 (Hk1) mRNA is clearly
overexpressed in the failing RV when compared to the hypertrophied RV of the
chronically hypoxic rats (Hx); likewise, phosphofructokinase (Pfkm) is overexpressed in
the failing RV.

GENES
Adh7
HK1
PfkB
Ucp2

FOLD CHANGE
HYPERTROPHY
FAILURE
3.45
1.59
-3.73
1.33
-1.48
2.31
-1.25
1.86
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These results are consistent with the observations that in tissues and cells from patients
with PAH there is a shift from oxidative phosphorylation to glucose metabolism and
glycolysis[195, 196].

4.10

Cytokine production in plasma samples

The levels of inflammatory cytokines were measured in rat serum using a multiplex
ELISA kit. Patients with chronic heart failure have increased serum levels of IL-1, IL-6,
and TNF-α[210]. Similarly, patients with PAH have increased serum levels of IL8[294], IL-1β, IL-6, and TNF-α[344] in comparison to healthy controls. Treatment with
an IL-1 receptor agonist reduced right ventricular hypertrophy and PH in a rat
monocrotaline model of PH[345].

Mice overexpressing IL-6 develop spontaneous

pulmonary vascular remodeling and PH[346], while mice overexpressing TNF-α develop
right ventricular hypertrophy and severe PH[347]. Additionally, levels of VEGF are
significantly higher in the serum of patients with PAH than in control patients[348].
These studies suggest that serum levels of these cytokines may be increased in the rat
models of PH studied here.

In fact, levels of IL-1β, IL-10, IL-13, IL-17, TNF-α, and VEGF were increased
significantly in serum samples from the SU5416/hypoxia rats when compared with
normal (Figure 21), whereas only VEGF and IL-13 were also significantly increased in
the samples from hypoxia-only rats. Levels of IL-6 were out-of-range for this assay (data
not shown). The increased levels of IL-1β, TNF-α, and VEGF are consistent with
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Figure 21: Expression of cytokines in rat serum from normal, hypertrophy, and
failing models
Multiplex ELISA analysis of a) IL-1α, b) IL-1β, c) IL-2, d) IL-4, e) IL-5, f) IL-10, g) IL13, h) IL-17, i) IL-18, j) TNF-α, and k) VEGF protein in normal (normal), pulmonary
artery banded (PAB), hypoxic (hypoxia), and SU5416/hypoxia (SuHx) rat serum samples
(a, p<0.05 vs normal; b, p<0.01 vs normal). Data are shown as mean ± s.d. (n=3).
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reported increases in serum levels of these cytokines in PAH patients. Although levels of
IL-13 and IL-17 have not been investigated in the serum of patients with PH or animal
models of PH, they do have previously characterized roles. IL-13 is upregulated in
schistosomiasis-induced PH[349] and dysregulation of IL-13 signaling in PAH may play
a role in vascular remodeling[350]. IL-17 is increased in lung samples from PAH
patients[351]. Given these results, increased levels of IL-1β, IL-13, IL-17, TNF-α, and
VEGF are to be expected in serum from SU5416/hypoxia rats. However, IL-10 is an antiinflammatory cytokine and is typically decreased in animal models of PH[349]. IL-10
expression may be a compensatory mechanism and levels in the SU5416/hypoxia serum
may not be high enough to exert and anti-inflammatory effect.

4.11

Discussion

Here, we identify changes in gene expression between the normal, hypertrophied, and
failing RV in an attempt to understand the mechanisms leading to RV failure associated
with PAH. A major assumption underlying our experimental strategry has been that
adaptive hypertrophy without failure exists. The rat PAB and chronic hypoxia models
both support this concept. We induced hypertrophy in rats by exposing the animals to
chronic hypoxia, and we induced right heart failure by combining chronic VEGF receptor
blockade (SU5416) with chronic hypoxia[180, 283]. RV hypertrophy without failure was
characterized by a normal cardiac output, while RV failure was characterized by a
decrease in cardiac output and by RV dilation[180]. The gene expression pattern was
analyzed by microarray analysis (Figure 12) and prediction analysis (Figure 14) to
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identify genes that can distinguish between RV hypertrophy and RVF. While some
signals, such as ANP, BNP, and HIF-2α, are shared between hypertrophy and failure
(Figure 15), it is also clear from Figure 12 that there are large differences in the overall
gene expression patterns between hypertrophy and RV failure. Through use of pathway
analysis tools, we can characterize these changes in terms of several categories: loss of
cell-growth promoting genes, changes in energy metabolism, impairment of
angiogenesis, and cytoskeletal rearrangement.

Several genes associated with cell growth are increased in expression in the hypoxic RV,
but are decreased in the failing RV. Although Igf1 has been reported to increase in
cardiomyopathy[352] and in myocardial biopsies from patients with LV failure[353], Igf1
and its transcription factor Klf5[244] are both decreased in the failing rat RV. Klf5
transactivates Igf1 in cardiac fibroblasts to activate cardiomyocte growth[244] and Igf1
controls cell differentiation and apoptosis[245]. That Klf5 and Igf1 are increased in the
hypertrophied RV (chronic hypoxia model), but not in the failing RV, suggests an
important loss of cell-growth promoting genes, which may be maladaptive.

The changes in energy metabolism as the RV progresses from hypertrophy to failure are
associated with a shift from fatty acid oxidation to glycolysis and downregulated
expression of mitochondrial electron transport chain complexes. A switch from fatty acid
oxidation to glycolysis has been reported in left ventricular failure (LVF) [354] and has
been hypothesized to occur in the transition from RV hypertrophy to RVF[198]. The
increased expression of glycolytic enzymes and the mitochondrial uncoupling protein
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Ucp2[355] in the failing RV suggests energy limitation and impaired energy utilization as
described in LVF[356]. An increase in glycolytic enzymes and natriuretic peptides
(including ANP and BNP)[357, 358] may be “attempts of the RV” to survive and
maintain contractile function.

Furthermore, impairment of mitochondrial respiratory

chain complexes is characteristic of damaged and dysfunctional mitochondria in failing
hearts[305], mostly likely caused by increased generation of reactive oxygen
species[300-303].

Figure 13 shows the decreased expression of genes encoding

mitochondrial electron transport chain complexes; this combined with an increase in the
expression of genes encoding glycolytic enzymes (Figure 20) indicates that there are
indeed drastic changes in the energy generation and ultilization in the failing RV.

Like the failing LV, the failing RV is characterized by capillary rarefaction[180], and
here we show that the loss of expression of a number of angiogenic capillary
maintenance.

VEGF signaling is important for the maintenance of normal cardiac

function[359]. VEGF also induces expression of anti-hypertrophy signals, including
regulator of calcineurin 1 (Rcan1) [360]. Apelin is induced by Ang1 and controls blood
vessel diameter during angiogenesis[332]. Increases in apelin expression due to hypoxic
stimuli have been linked to endothelial cell proliferation and angiogenesis[361, 362].
Additionally, increased apelin expression has been shown in the hypoxic RV[363]
consistent with the results seen here. Similarly, Ang1 promotes both cardiac myocyte
survival[364] and endothelial cell survival[365]. Without expression of these genes,
there is most likely an impairment of capillary growth and maintenance in the failing RV.
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In addition to changes in capillary maintenance, the switch from RV hypertrophy to RVF
is associated with changes in the cytoskeletal arrangement. Integrins are activated to
compensate from the pressure overload in the RV and induce expression of contractile
proteins[157, 158]. ILK regulates cell hypertrophy signaling[285] and RhoA, via ROCK,
regulates rearrangement of the cytoskeleton[287].

In addition, Add3, normally only

expressed in the fetal tissue, is re-expressed in the failing RV and miR-143, expressed in
the normal heart to suppress expression of Add3[342], is turned off (Figures 18 and 19).
With increased expression of Add3, cardiomyocytes have a less elongated phenotype and
hypertrophy[342], as is seen in the failing RV. Finally, CTGF is typically seen as a
hypertrophy signal, but long-term signaling leads to dilation of the ventricle and loss of
cardiomyocytes[338]. These changes may be initially beneficial in the hypertrophied
RV, but with long-term expression of these signals, the heart undergoes changes that are
maladaptive and lead to RVF.

Taken together, the data define a gene expression pattern that can robustly distinguish
between adaptive RV hypertrophy and RV failure in a rat model of PAH. To thoroughly
assess the clinical importance of the gene expression set, it will be necessary to confirm
the expression of these genes in human heart tissue. However, this expression set also
provides a basis for understanding the reversal of gene expression changes in the
SU5416/hypoxia model of severe PAH using various therapeutic strategies.
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Chapter 5: Reversibility of Right Ventricular Failure

5.1

Introduction

Although pulmonary arterial hypertension (PAH) is a disease originating in the lungs,
most patients with PAH die from right-heart failure. The three-year mortality rate for
patients with PAH ranges from 20% for patients with heart disease to 80% for patients
with PAH associated with scleroderma[366]. The response of the right ventricle (RV)
typically determines the outcome of the disease[8, 367]. Current treatment for PAH
includes the use of vasodilators, endothelin receptor blockers, and phosphodiesterase-5
inhibitors[47, 48], but these do not specifically focus on reversing right ventricular failure
(RVF).

It is known from studies of post-lung transplant PAH patients that the RV is not
irreversibly damaged by enlargement and hypertrophy[368]. In the 1980s, heart-lung
transplant was the surgical treatment for PAH patients[369]. However, in the early
1990s, this shifted towards lung transplant only[370]. A significant improvement in right
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ventricular function occurs soon after lung transplantation – either single or double lung
transplant[371-374]. Additionally, patients receiving living-donor lobar lung transplant
have similar improvements within two months after transplantation[368]. After lung
transplantation, the 1-, 3-, and 5-year survival rates for PAH patients have been reported
as 77%, 62.6%, and 53.6%[375], with slightly higher rates for patients receiving a
double-lung transplant than a single-lung transplant.[376] Three years after transplant,
89.6% of patients report no activity limitations[377]. These findings show that the right
ventricular failure (RVF) associated with PAH is reversible and motivates the search for
a non-surgical intervention that can reverse RVF.

β-adrenergic receptor blockers are often used in the treatment of patients with left
ventricular failure[378]. The β-adrenergic receptors are G-protein coupled receptors that
activate c-AMP mediated protein kinase A[379, 380].

Long-term activation of the

receptor leads to maladaptive cardiac remodeling and receptor down-regulation[381,
382]. However, β-adrenergic receptors can also recruit β-arrestins to initiate a second
wave of signaling that is independent of the G-protein signaling pathway[383, 384] and
promote mitogenic and anti-apoptotic effects[385, 386]. Signaling through β-arrestins
also transactivates epidermal growth factor receptor (EGFR) to promote cardioprotective
signals in response to mechanical stress[387].

The effects of β-blockers in left heart failure include: improved ventricular remodeling,
preserved cardiac contractility, reduced oxidative stress, and reduced cardiac expression
of proinflammatory cytokines[388, 389]. However, β-adrenergic receptor blockers are
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not currently used as a treatment for PAH. Reasons for this could be the potentially
detrimental effects on hemodynamics and exercise capacity.

PAH patients increase

cardiac output through increased heart rate because they have a decreased stroke volume
and contractility problems prevent its increase[390]. A small group of patients with PAH
due to portopulmonary hypertension was treated with propanalol, a non-specific βadrenergic receptor blocker, or atenolol, a β1-adrenergic receptor agonist.

Upon

withdrawal of the adrenergic receptor blockers, patients had an improved exercise
capacity[391] leading researchers to conclude that the adrenergic receptor blockers were
not beneficial to the patients. However, this study was limited due to small size – 10
patients – and propanalol or atenalol are presently not used to treat left ventricular failure.

Carvedilol, an α1/β1/β2-adrenergic receptor blocker that also has anti-oxidant
properties[392], has been used to treat left-heart failure and to treat an animal model of
PAH[360]. In post-myocardial infarction (MI) studies of the left ventricle, carvedilol
treatment is associated with improved ventricular function, reduced left ventricular
dilation, and there is improved survival in post-MI patients[393, 394].

Similarly,

treatment with carvedilol of patients with chronic heart failure caused by ischemia has
also improved survival when given in combination with conventional heart failure
treatments[393, 395].

In animal studies of carvedilol treatment in the Su5416/hypoxia model of pulmonary
hypertension, carvedilol had no effect on pulmonary vascular remodeling[360] and did
not change the number of occluded small pulmonary vessels[277], but did have effects in
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the heart. While the amount of pressure overload was the same in both Su5416/hypoxia
rats and Su5416/hypoxia rats treated with carvedilol, those that were given carvedilol
treatment had decreased cardiac hypertrophy[360]. In addition, carvedilol treatment was
associated with increased cardiac output, decreased RV dilation, increased stroke volume,
decreased cardiomyocyte death, and decreased fibrosis[360].

Clinically, the

SU5416/hypoxia + carvedilol rats have increased exercise capactity and increased
survival when compared with the SU5416/hypoxia animals[360], suggesting that
carvedilol treatment benefits the heart and reduces PAH symptoms.

A decrease in

fibrosis was also reported with carvedilol treatment of pressure overload in the LV[396,
397]. While some changes in gene expression have been reported in carvedilol-treated
rats[360], a systematic study of the gene expression changes in the heart as a
consequence of carvedilol treatment does not exist.

Rationale: We have previously demonstrated the changes in gene expression associated
with the development of right ventricular failure caused by PAH. We hypothesize that
right heart failure is reversible and that treatment of the failing RV with carvedilol will
show a different gene expression profile than a non-treated failing RV. Using microarray
technology, quantitative real-time polymerase chain reaction (qRT-PCR), and multiplex
enzyme-linked immunosorbent assays (ELISAs), we characterized the changes in gene
expression due to the carvedilol treatment and reversal of RVF.
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5.2

Physiological and gene expression changes with carvedilol treatment

We first investigated the effects of carvedilol treatment on normal (control) rats. There
was no change in body weight in the carvedilol-treatment animals, and there was no
significant difference in the Fulton index (RV/LV + S) between normal and carvediloltreated animals (Figure 22).

As previously reported by Bogaard et al., carvedilol

treatment of normal rats had no effect on the resting hemodynamics of the heart, with the
exception of a small change in heart rate[360].

We then examined the changes in gene expression in the RV of the carvedilol-treated
animals in comparison to normal animals using quantitative real-time polymerase chain
reaction (qRT-PCR). Genes were selected based on their inclusion in previous analyses
in Chapter 4 (Figure 23). Although there was no significant difference in expression
between normal and carvedilol-treated animals for the genes natriuretic peptide precursor
A (Nppa, mRNA for the atrial natriuretic peptide [ANP]); natriuretic peptide precursor B
(Nppb, mRNA for brain natriuretic peptide [BNP]); and connective tissue growth factor
(Ctgf), there was a significant difference (p<0.05) for the remaining genes analyzed. As
previously discussed, insulin-like growth factor 1 (Igf1) and kruppel like factor 5 (Klf5)
serve to promote cell growth in the heart; Igf1 expression was increased 2.8-fold and Klf5
was increased almost 9-fold in the carvedilol treated control RV compared to the
untreated normal RV. Hypoxia-inducible factor 1α (HIF-1α), hypoxia-inducible factor
2α (HIF-2α), vascular endothelial growth factor (VEGF), angiopoietin 1 (Ang1) and
apelin are angiogenic and can increase capillary density in the heart. Both
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Figure 22: Body Weight and Fulton Index of Animal Models Used in Study
a) Body weight in grams and b) Fulton index (RV/LV+S) (a, p<0.05 vs normal) of
normal (control), SU5416 (SU5416) treated, hypoxia (hypoxia) treated, SU5416/hypoxia
(SuHx) treated, carvedilol (carvedilol) treated, and SU5416/hypoxia + carvedilol (SuHx
+ carv) treated rats. Data are shown as mean mean ± s.d. (n=6).
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Figure 23: Effects of Carvedilol on Gene Expression in the Normal Right Ventricle
Quantitative real-time PCR analysis of Add3, Ang1, ANP, Apelin, BNP, CTGF, HIF-1α,
HIF-2α, IGF-1, KLF5, MHC-α, MHC-β, and VEGF mRNA in normal and carvedilol rat
right ventricles (a, p<0.05 vs normal; b, p<0.01 vs normal; c, p<0.005 vs normal). Data
were normalized to expression of 18S rRNA and are shown as mean ± s.d. (n=3).

159

160

HIF-1α and HIF-2α were increased by over 4-fold in the carvedilol-treated RV
compared to the normal RV, VEGF and apelin increased by approximately 3.5-fold, and
Ang1 increased by 6-fold. Adducin 3 (Add3), myosin heavy chain alpha (MHC-α), and
myosin heavy chain beta (MHC-β) all function in cytoskeletal rearrangement. Add3,
MHC-α, and MHC-β were increased by 3.3-, 2.5-, and 4-fold respectively in the
carvedilol-treated RV compared to the normal RV.

5.3

Microarray analysis

In order to identify differences in gene expression that occur during right ventricular
failure associated with PAH, we used a microarray analysis similar to that employed in
the comparison between the normal RV and normal LV and the models of adaptive
hypertrophy and RVF. Again, this was a “Type II” approach in which each hybridization
was between RNA from an animal model and a pool of commercially available reference
RNA.

Total RNA was isolated from RV tissue from animals subjected to the

SU5416/hypoxia protocol for four weeks, then treated with carvedilol for four weeks.
Because the SU5416/hypoxia RVs from previous studies in Chapter 4 were hybridized
against the same pool of reference RNA, they can be used again in this analysis.

Total RNA was isolated from the free wall of the RV from rats treated with a
combination of SU5416 and chronic hypoxia for four weeks to establish RVF. The
animals were then treated with carvedilol for four weeks[360]. RNA was first converted
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to cDNA and fluorescently labeled with either Cyanine-3 (green) or Cyanine-5 (red) dye
and then the two samples were mixed together for overnight hybridization. Six biological
replicates per condition were hybridized to an Agilent Rat Whole Genome 4 x 44k
microarray chip. Microarrays were washed and scanned with an Axon GenePix 4200A
Scanner and GenePix Pro 5.0 Software. All data were uploaded into the Ramhorn Array
Database (http://ramhorn.csbc.vcu.edu).

Microarray data were retrieved from the

Ramhorn Array Database if they had a signal greater than or equal to 1.5 fold above
background for both the red and green channels. A gene was called “good” if greater
than 50% of arrays for each condition (SU5416/hypoxia and SU5416/hypoxia +
carvedilol) passed the filtering conditions of expression greater than or equal to 1.5 fold
above the background expression. Technical replicates were averaged together.

To determine which genes had a statistically significant difference in their expression
between the SU5416/hypoxia (failing) RV and the SU5416/hypoxia treated for four
weeks with carvedilol (treated) RV, we used the Significance Analysis of Microarrays
(SAM) algorithm[219] to perform a two-class unpaired analysis with 1,000 permutations
of replicate data. To control for the False Discovery Rate (FDR), the lowest delta value
resulting in a median FDR of 5% or less was chosen. For this analysis, a delta value of
0.645 was selected corresponding to an FDR of 4.59%. This results in reporting of genes
with q-values < 0.05.

Of the genes passing initial filtering conditions, 4,714 were

identified as significantly different in expression.

The Stanford Unique Indentifiers

representing significantly regulated genes were compiled and data for the following
conditions: normal RV, SU5416/Hypoxia RV, and SU5416/hypoxia + carvedilol RV
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were retrieved from the Ramhorn Array Database. The replicates for each condition were
averaged and transformed by subtracting the average expression of the normal RV from
each condition. This gives the expression in each experimental condition relative to the
normal RV and allows us to visualize the change in expression resulting from the
treatment.

The Cluster 3.0 program[220] was used to perform average-linkage

hierarchichal clustering by gene of the whole dataset, and clustered data was exported to
the Java TreeView program[221] for visualization.

The resulting cluster shown in Figure 24 is comprised of the 4,714 genes called
significant by SAM between the SU5416/hypoxia RV and the SU5416/hypoxia +
carvedilol RV. The major columns from left to right are: normal RV, SU5416/Hypoxia
RV, SU5416/hypoxia + carvedilol RV and the difference in SU5416/Hypoxia RV +
carvedilol and SU5416/hypoxia RV (shown to the right of the grey line). This final
column allows us to focus in on the genes that are changing in the attempt to reverse right
heart failure due to carvedilol treatment. The subclusters seen in the figure are based on
the Pearson correlation coefficient for similarity of genes in that cluster.

Using a

threshold correlation value of 0.8 generates the four smaller clusters seen in Figure 24.

Subcluster 1 is comprised of genes that have increased expression in the
SU5416/hypoxia and the SU5416/hypoxia + carvedilol RV and could represent a pattern
of expression associated with increased hypertrophy in the heart. The top five canonical
pathways for genes in this cluster are listed in Table 15. Of these, the hepatic fibrosis and
hepatic stellate cell activation pathway stood out because fibrosis is known to increase in
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Figure 24: Microarray Cluster
Six biological replicates per condition were hybridized to Agilent Whole Rat Genome
microarrays. Failing RV (samples labeled “SuHx”) is obtained by treating rats with a
combination of SU5416 and chronic hypoxia.

Carvedilol treatment given after a

combination of SU5416 and chronic hypoxia (samples labeled “SuHx + Carv) is an
attempt to reverse right heart failure. Genes to the right of the grey line (column labeled
“-“) show the difference in expression between the average SuHx + carvedilol RV and
the average SuHx RV. The small columns represent different animals treated with the
same condition. Each row represents a gene called significant by the SAM algorithm.
Green indicates lower expression in a given condition than in the normal RV, red
indicates higher expression in a condition than in the normal RV. Black indicates that the
expression in the condition is equal to expression in the normal RV.
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Table 15: Top Five Canonical Pathways of Genes in Subcluster 1
Pathway Name
Hepatic Fibrosis/Hepatic Stellate Cell Activation
Calcium Signaling
ILK Signaling
VEGF Signaling
Actin Cytoskeleton Signaling
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p-value
6.01 x 10-8
1.09 x 10-5
2.40 x 10-5
1.13 x 10-4
1.13 x 10-4

PAH and in the SU5416/hypoxia model of PAH[291-293]. In the microarray data set,
expression of transforming growth factor alpha (TGF-α) was increased 1.5-fold in the
SU5416/hypoxia RV compared to the normal RV and 3-fold in the SU5416/hypoxia +
carvedilol RV compared to the normal RV. Similarly, transforming growth factor beta 2
(TGF-β2) was increased 3-fold and 2.5-fold, respectively, in the SU5416/hypoxia RV
and SU5416/hypoxia + carvedilol RV compared to the normal RV. In addition, another
of the pathways – Integrin-like kinase (ILK) signaling – has been implicated as a
regulator of hypertrophic signaling pathways because cardiac-specific expression of ILK
has been shown to induce hypertrophy[285]. ILK expression is highest in the heart and is
essential for mediating repair, growth, and contractility in the heart[284].

Actin

cytoskeleton rearrangement is mediated by rho-kinase (ROCK), a downstream mediator
of RhoA[286]. Levels of ROCK have been reported to increase in expression during
pressure overload-induced hypertrophy[288].

Deletion of Rock1 is assocated with

reduced fibrosis, apoptosis, and chamber dilation in the heart[287]. RhoA was increased
1.02-fold in the SU5416/hypoxia RV and 1.25-fold in the SU5416/hypoxia + carvedilol
RV compared to normal.

Additionally, two actin molecules also showed increased

expression: cardiac alpha actin 1 (Actc1) was increased 1.1-fold in the SU5416/hypoxia
RV and 2-fold in the SU5416/hypoxia + carvedilol RV compared to normal and alpha
actinin 2 (Actn2) was increased 1.8-fold in the SU5416/hypoxia RV and 2.1-fold in the
SU5416/hypoxia + carvedilol RV compared to normal. Overall, genes in this cluster have
increased levels of expression in the SU5416/hypoxia and SU5416/hypoxia + carvedilol
RVs (Figure 24, subcluster 2) suggesting that these pathways are a mechanism of
compensation for stress in the right ventricle.
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Subcluster 2 is made up of genes that might be characterized as having a
“reversal of failure” expression pattern; these genes have increased expression in the
carvedilol-treated SU5416/hypoxia RV when compared with the SU5416/hypoxia RV.
The top five canonical pathways for these genes are listed in Table 16. Of particular
interest are the oxidative phosphorylation and mitochondrial dysfunction pathways. The
failing RV is known to be associated with a shift in energy metabolism towards glucose
oxidation and away from fatty acid oxidation in clinical and experimental studies[307312]. In addition, mitochondrial biogenesis is downregulated in the failing heart[299]
along with an increase in the generation of reactive oxygen species[300-303]. A decrease
in the genes encoding proteins of the electron transport chain complexes is associated
with a decrease in oxidative capacity[306]. These changes in metabolism were reflected
in the failing RV in the SU5416/hypoxia RV (Chapter 4, Figure 13). With carvedilol
treatment after SU5416/hypoxia, there is an increase in expression of genes encoding
mitochondrial enzymes (Figures 25 and 26). Cytochrome c oxidase (Complex IV of the
electron transport chain) is the last enzyme in the electron transport chain and catalyzes
the oxidation of cytochrome c and reduction of oxygen to water.

Four subunits of

cytochrome c oxidase are increased in the microarray dataset: cytochrome c oxidase
subunit I (Cox1), cytochrome c oxidase subunit II (Cox2), cytochrome c oxidase subunit
VIa polypeptide 2 (Cox6a2), and cytochrome c oxidase subunit VIIIb (Cox8b). Cox1 is
increased 1.5-fold, Cox2 is increased 1.7-fold, Cox6a2 is increased 1.2-fold, and Cox8b is
increased 1.6-fold in the SU5416/hypoxia + carvedilol RV compared to SU5416/hypoxia
RV. We can conclude that these alterations in metabolism are beneficial to the heart and
reflect the beginning of a return towards normal metabolism in the heart.
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Table 16: Top Five Canonical Pathways of Genes in Subcluster 2
Pathway Name
Oxidative Phosphorylation
Mitochondrial Dysfunction
Phospholipase C Signaling
G Protein Signaling Mediated by Tubby
Non-Small Cell Lung Cancer Signaling

p-value
1.86 x 10-3
5.16 x 10-3
1.07 x 10-3
1.46 x 10-2
1.88 x 10-2
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Figure 25: Mitochondrial Dysfunction Genes in Subcluster 2
Microarray gene expression of genes encoding proteins involved in mitochondrial
dysfunction in subcluster 2. The first three major columns on the left labeled “normal,”
“SuHx”, and “SuHxCarv” denote expression in the normal, SU5416/hypoxia, and
SU5416/hypoxia + carvedilol RVs.

Red coloration indicates increased expression

compared to the average normal RV expression level while green indicates reduced
expression.

The small columns represent different animals treated with the same

condition. The last major column on the right of the grey line labeled “-“ denotes the
difference in expression between the SU5416/hypoxia + carvedilol and SU5416/hypoxia
RVs. Red coloration indicates increased expression in the SU5416/hypoxia RV with
carvedilol treatment compared to an untreated SU5416/hypoxia RV, and green indicates
reduced expression in the SU5416/hypoxia + carvedilol RV compared to the
SU5416/hypoxia RV.
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Figure 26: Mitochondrial Dysfunction Canonical Pathway
Canonical pathway analysis indentified the pathways from the Ingenuity Pathway
Analysis® library of canonical pathways that were most significant to the dataset. The pvalue for the mitochondrial dysfunction canonical pathway is 5.16 x 10-3. Genes are
colored based on fold-change comparison between the SU5416/hypoxia + carvedilol
(treated) RV and the SU5416/Hypoxia (failing) RV. Red correlates to relatively higher
expression in the treated RV than the failing RV, and green correlates to relatively higher
expression in the failing RV than the treated RV.
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Subcluster 3 contains genes that could represent a “reversal of failure”
expression pattern; these genes have increased expression in the SU5416/hypoxia RV and
decreased expression in the SU5416/hypoxia + carvedilol RV.

The top canonical

pathways for genes in this cluster are shown in Table 17. Two pathways, Regulation of
eIF4 and p70S6k and eIF2 Signaling, will be discussed in more detail in section 5 of this
chapter, while the protein ubiquitination pathway will be discussed further as part of
subcluster 4. One of the main biological functions of genes in this pathway is cardiac
hypertrophy (Figure 27); a reduction in genes encoding cardiac hypertrophy functions is
consistent with studies reporting that carvedilol reduces hypertrophy in the
SU5416/hypoxia RV[360]. Of particular importance to pulmonary hypertension are the
genes HIF-1α and angiopoietin-2 (Ang2). Hypoxia-driven activation of HIFs plays a role
in the pathogenesis of experimental PH[398, 399] by increasing angiogenesis[400] and
the metabolic switch towards glycolysis[401]. HIF-1α, along with HIF-2α and VEGF, is
found in plexiform lesions[10] and pulmonary artery smooth muscle cells[196]
suggesting that HIF-dependent signaling contributes to proliferative activities in PAH. In
a HIF-1α heterozygous mouse there was impaired vascular remodeling, decreased RV
hypertrophy, and decreased pulmonary artery pressure[399].

HIF-1α expression is

decreased 2.1-fold in the SU5416/hypoxia + carvedilol RV in comparison to the
SU5416/hypoxia RV. Ang2 is also known to play a role in PAH. Ang2 has proangiogenic properties when expressed in high concentrations[402] or in combination with
VEGF[403, 404]. Patients with idiopathic PAH had increased plasma levels of Ang2, and
these levels correlated with cardiac index and pulmonary vascular resistance; increased
Ang2 was an independent risk factor for mortality[405]. Ang2 expression is decreased
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Table 17: Top Five Canonical Pathways in Subcluster 3
Pathway Name
Protein Ubiquitination Pathway
Estrogen Receptor Signaling
Androgen Signaling
Regulation of eIF4 and p70S6k Signaling
eIF2 Signaling

p-value
1.13 x 10-9
6.59 x 10-8
3.54 x 10-6
4.06 x 10-6
5.61 x 10-6
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Figure 27: Cardiac Hypertrophy Genes
Microarray gene expression of genes involved in cardiac hypertrophy functions in
subcluster 3. The first three major columns on the left labeled “normal,” “SuHx”, and
“SuHxCarv” denote expression in the normal, SU5416/hypoxia, and SU5416/hypoxia +
carvedilol RVs. Red coloration indicates increased expression compared to the average
normal RV expression level while green indicates reduced expression.

The small

columns represent different animals treated with the same condition. The last major
column on the right of the grey line labeled “-“ denotes the difference in expression
between the SU5416/hypoxia + carvedilol and SU5416/hypoxia RVs. Red coloration
indicates increased expression in the SU5416/hypoxia RV with carvedilol treatment
compared to an untreated SU5416/hypoxia RV, and green indicates reduced expression in
the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia RV.
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2.3-fold in the SU5416/hypoxia + carvedilol RV in comparison to the SU5416/hypoxia
RV. A reduction in these genes, as seen in the SU5416/hypoxia + carvedilol RV, could
lead to reduced cardiac hypertrophy and improved myocardial function.

Subcluster 4 is composed of genes that have a “repression” expression pattern
and have reduced expression in the SU5416/hypoxia RV and in the SU5416/hypoxia +
carvedilol RV. The top five canonical pathways for these genes are listed in Table 18, of
which 2 are related: ubiquinone biosynthesis and the protein ubiquitination pathway. As
previously discussed, the protein ubiquination system is cardioprotective because it
removes pro-apoptotic signaling molecules from the cell[314]. Decreased expression of
ubiquitination proteins leads to reduced proteasomal activities[313] and allows
accumulation of pro-apoptotic proteins[314].

While carvedilol treatment of the

SU5416/hypoxia RV does not change expression of these pathway genes compared to
SU5416/hypoxia RV, they may not be essential for reversal of RV failure.

5.4

Prediction analysis

The prediction set generated in Chapter 4 was used to evaluate the SU5416/hypoxia +
carvedilol data set. The prediction set is made up of those 450 genes that had expression
patterns that were most discriminatory between normal, hypertrophy, and failure in the
RV. By comparing the expression of carvedilol-treated failing RVs to the prediction set,
we can determine which expression pattern carvedilol most resembles and see the effects
that carvedilol had on this small subset of genes.
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Table 18: Top Five Canonical Pathways in Subcluster 4
Pathway Name
Ubiquinone Biosynthesis
Pyruvate Metabolism
Protein Ubiquitination Pathway
Citrate Cycle
AMPK Signaling

p-value
4.03 x 10-11
2.49 x 10-06
1.62 x 10-05
1.19 x 10-04
8.65 x 10-04
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This is a supervised learning method; the initial data set applies the knowledge
represented by data label to create a class predictor that can classify samples in a new
data set. The previous data set, composed of the normal, hypoxia, and SU5416/hypoxia
microarrays, acts as a training data set against which the SU5416/hypoxia + carvedilol
data set – the prediction data set – is compared. Using the 1-nearest neighbor, 3-nearest
neighbors, nearest centroid, and linear discriminant analysis algorithms[228], each of the
arrays in the SU5416/hypoxia + carvedilol data set was assigned a label of either
“normal,” “hypertrophy,” or “failure” based on the similarity of the 450 genes in the
training data set to the 450 genes in the prediction data set.

As seen in Table 19, each of the SU5416/hypoxia + carvedilol arrays was classified as
“failure” by all of the algorithms. It is evident from Figure 28, that the expression of the
genes in the SU5416/hypoxia + carvedilol set has a great deal of similarity to the failure
gene set, but that there are also some genes with distinct expression patterns. Although
the SU5416/hypoxia + carvedilol data were classified as being most similar to failure
(SU5416/hypoxia), it is important to remember that this is based on a small set of genes
rather than the data set as a whole.

However, there are some genes with a distinct gene expression pattern between the
SU5416/hypoxia and SU5416/hypoxia + carvedilol RVs which may represent the genes
that are responsible for reversal of failure. Cox1, as previously discussed, was increased
1.5-fold in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia RV
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Table 19: Summary of Prediction Analysis Results
Description of how the SU5416/hypoxia + carvedilol microarrays were classified by the
prediction analysis set generated in Chapter 4.
Array ID

237
238
239
526
527
604

Number of
genes in
classifier
435
435
435
435
435
435

1-Nearest
Neighbor

3-Nearest
Neighbors

Nearest
Centroid

Linear
Discriminant
Analysis

Failure
Failure
Failure
Failure
Failure
Failure

Failure
Failure
Failure
Failure
Failure
Failure

Failure
Failure
Failure
Failure
Failure
Failure

Failure
Failure
Failure
Failure
Failure
Failure
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Figure 28: Prediction Analysis Results
Dendogram for clustering experiments using centered correlation and average linkage of
the 450 probes that showed 100% agreement across LOOCV. The first three major
columns on the left labeled “normal,” “SuHx”, and “SuHxCarv” denote expression in the
normal, SU5416/hypoxia, and SU5416/hypoxia + carvedilol RVs.

Red coloration

indicates increased expression compared to the average normal RV expression level
while green indicates reduced expression. The small columns represent different animals
treated with the same condition. Each row represents a gene from the prediction set. The
last major column on the right of the grey line labeled “-“ denotes the difference in
expression between the SU5416/hypoxia + carvedilol and SU5416/hypoxia RVs. Red
coloration indicates increased expression in the SU5416/hypoxia RV with carvedilol
treatment compared to an untreated SU5416/hypoxia RV, and green indicates reduced
expression in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia
RV.
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demonstrating that there are effects of carvedilol on the complexes of the electron
transport chain.

In addition, endothelin 2 (Edn2) was decreased 2.6-fold in the

SU5416/hypoxia + carvedilol RV when compared to the SU5416/hypoxia RV; in several
cancer cell lines, hypoxia triggers production of Edn2[406-408].

Edn2 has strong

vasoconstricting activity[409] similar to endothelin 1, which has been implicated as a
mediator of vascular tone and vascular remodeling in pulmonary hypertension[410].
Similarly, expression of beta 5 tubulin (Tubb5) were decreased 2.9-fold in the
SU5416/hypoxia + carvedilol RV in comparison to the SU5416/hypoxia RV. Levels of
β-tubulin increase in rat models of cardiac hypertrophy and pulmonary hypertension
induced by monocrotaline[411], which has been associated with contractile
dysfunction[412]. It may be that only a few differences in gene expression such as these
can have a positive outcome on the function of the RV.

5.5

Class comparison analysis

Although the class prediction set classified all of the SU5416/hypoxia + carvedilol
microarrays as “failure” because of similarities to the SU5416/hypoxia data set, there are
a few significant changes in gene expression in that dataset. In addition, the microarray
analysis showed a large number of genes that were differentially expressed between the
SU5416/hypoxia + carvedilol and SU5416/hypoxia microarrays. As such, there is reason
to believe that we can identify the genes that had the greatest difference in expression
between the two data sets. To do so, we employed a class comparison algorithm, which
uses a T-test to compare the expression of each gene between the two classes in the data
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set[413].

Those genes with a p-value below a given threshold value are called

significant. In addition, multivariate permutation testing can be used to control the false
discovery rate[226, 414]. For each permutation in the multivariate permutation testing
algorithm, the data labels are changed and the p-value is re-calculated for each gene. The
genes are then ordered by their p-value and the number of genes with a p-value below the
threshold is recorded. The process is repeated for all permutations. For a given p-value,
the number of genes selected via permutation testing is known and is the false discovery
rate. A threshold p-value is chosen to minimize the false discovery rate.

When comparing the SU5416/hypoxia (failing) and SU5416/hypoxia + carvedilol
(treatment) microarrays, a two-sample T-test was used to compare the two classes. The
p-value threshold was set at 0.001 to allow no more than 10 false-positive genes and a
proportion of false-positive genes less than 5%. Of the 43,379 probes in the data set, 489
were selected as significant given the chosen test conditions. The probability of selecting
at least 489 probes by chance at the threshold p-value of 0.001 if there was no difference
between the classes is 0.216%. The list of these genes is given in Appendix 2 and the
cluster showing their expression is shown in Figure 29. Two clear subclusters are
apparent in the cluster diagram and will be explained in more detail.

Subcluster 1 is composed of 282 probes that correspond to 275 different genes.
The top five canonical pathways for genes in this cluster are given in Table 20. Two of
these pathways, regulation of eIF4 and p70S6k signaling and eIF2 signaling, are involved
in common biological processes. Eukaryotic initiation factor (eIF)-2 and 4 are both
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Figure 29: Class Comparison between SU5416/hypoxia and SU5416/hypoxia +
carvedilol
Cluster for class comparison analysis between SU5416/hypoxia RV (failure) and
SU5416/hypoxia + carvedilol RV (Tx = treatment) microarray data sets. 489 probes
were called significant at an α<0.001 level and multivariate permutation testing gives a
false discover rate less than 5%. Red represents greater relative expression than reference
RNA and green represents less relative expression than reference RNA.
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Table 20: Top Five Canonical Pathways of Genes in Subcluster 1 of Multivariate
Analysis
Pathway Name
Regulation of eIF4 and p70S6k Signaling
Glucocorticoid Receptor Signaling
Ceramide Signaling
EGF Signaling
eIF2 Signaling

p-value
1.98 x 10-4
2.61 x 10-4
4.04 x 10-4
4.94 x 10-4
5.68 x 10-4
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required for the initiation of translation. eIF2 forms a complex with GTP and methionyl
tRNA, which binds to the 40S ribosomal subunit to form the 43S preinitiation complex.
The 43S preinitiation complex binds to mRNA.

Mammalian target of rapamycin

(mTOR) phosphorylates eIF4e binding protein allowing eIF4e to separate from its
binding protein and to bind to the mRNA and begin translation[415]. It is known that
cardiac hypertrophy requires an increase in protein synthesis by individual
cardiomyocytes[416], thus would require greater activity of the eIFs. In a model of
cardiac hypertrophy caused by chronic alcohol intake, eIF2 levels were increased[417].
eIF4b has been shown to regulate translation of proliferative and pro-survival
mRNAs[418]. Similarly, decreased expression of eIF4e leads to reduced rates of cell
growth[419]. In the microarray dataset, several of the eIF genes were decreased in
expression in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia
RV: eIF2B3 was decreased 1.51-fold, eIF3F was decreased 2.19-fold, and eIF4G2 was
decreased 2.46-fold, which should lead to decreased protein synthesis in the
SU5416/hypoxia + carvedilol RV. Another pathway, EGF Signaling, also plays a known
role in the heart.

Transactivation of the epidermal growth-factor receptor (EGF-R)

activates G protein-coupled receptors to mediate proliferation and mitogenic effects,
including hypertension, vascular inflammation, tissue remodeling, and left ventricular
hypertophy[380, 420-422].

Activation of EGF-R induces expression of interferon

regulatory factor (IRF1) via phosphorylation of signal transducer and activator of
transcription 1 and 3 (STAT1 and STAT3)[423]; in the microarray dataset, expression of
Stat1 is decreased by 3.36-fold in the SU5416/hypoxia + carvedilol RV compared to the
SU5416/hypoxia RV.

Another member of the EGF-R signaling pathway, mitogen-

189

activated protein kinase 4 (Mapk4), was also decreased by 1.96-fold in the
SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia RV in the microarray
dataset. Disruption of EGF signaling has been shown to be protective against cardiac
hypertrophy[424, 425]. In addition, EGF-R signaling mediated the development of PAH
in mice overexpressing transforming growth factor alpha (TGF-α)[426]. As shown in
Figure 29, the eIF2-, eIF4-, and EGF signaling pathways are increased in the
SU5416/hypoxia model when compared with the SU5416/hypoxia + carvedilol model.
This suggests that these pathways have been affected by carvedilol to decrease
hypertrophy and return the heart to a more normal state.

Subcluster 2 is made up of 207 probes that represent 192 different genes. The
top five canonical pathways for genes in this cluster are listed in Table 21. Of these
pathways, three – PPAR signaling, PPARα/RXRα activation, and Nrf2-mediated
oxidative stress response – have common functions in the heart. Peroxisome proliferatoractivator receptor (PPAR) alpha and gamma are both activated by PPAR coactivator-1
alpha (PGC-1α) and signal through nuclear factor-like 2 (Nrf2). Both PGC-1α and
PPAR-α are preferentially expressed in tissues with high oxidative capacity, including
the heart[427]. Through co-activation of PPAR-α and estrogen-related receptor alpha
(ERRα), PGC-1α activates genes involved in the cellular uptake and mitochondrial
activation of fatty acids[428]. As shown in gene knock-out studies, both ERRα and
PPARα have been shown to play an important role in the functional adaptation of the
heart to pressure overload[427, 429]. In PGC-1α knockout mice, there is a reduction of
fatty acid oxidation and a reduction in expression of mitochondrial genes in the
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Table 21: Top Five Canonical Pathways of Genes in Subcluster 2 of Multivariate
Analysis
Pathway Name
PPAR Signaling
PPARα/RXRα Activation
Agrin Interactions at Neuromuscular Junction
NRF2-mediated Oxidative Stress Response
Prostate Cancer Signaling
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p-value
2.59 x 10-5
5.75 x 10-4
8.10 x 10-4
8.76 x 10-4
1.56 x 10-3

heart[430, 431]. It has been shown that levels of PGC-1α, PPAR-α, and ERR-α genes
and protein are decreased in the SU5416/hypoxia RV and that this reduction in mRNA
expression is correlated with RV function[432]. The reactive oxygen species created
during oxidative stress increase levels of nuclear factor kappa B (NF-κB), which
subsequently increases levels of pro-inflammatory cytokines such as IL-1, IL-6, and
TNF-α[433]. Increased expression of NF-κB inhibitor alpha (NF-κBIA) suppresses the
transcriptional activity of NF-κB; in the microarray data set, expression of NF-κBIA is
increased 2.1-fold in the SU5416/hypoxia RV compared to the SU5416/hypoxia RV.
Additionally, NF-κB activation prevents changes in expression of ATP-binding cassette
subfamily C member 1 (Abcc1, also called multidrug-resistance associated protein 1
(Mrp1)), which protects against oxidative stress[434, 435].

Further confirming this

protective role, patients with COPD have decreased expression of Abcc1 compared with
healthy patients[436]. In the SU5416/hypoxia + carvedilol RV, Abcc1 is expressed 1.4fold higher than that of the Su5416/hypoxia RV. As shown in Figure 29, genes in these
pathways are returning towards normal expression levels in the RV with carvedilol
treatment, indicating that a change in energy metabolism and mitochondrial function is
associated with the reversal of RVF.

5.6

qRT-PCR and additional pathway analysis

We next examined the changes in gene expression in RV tissue samples in rats treated
with SU5416/hypoxia and carvedilol for genes previously examined by quantitative realtime polymerase chain reaction (qRT-PCR) (Figure 30). Treatment of the
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Figure 30: RT-PCR Results
Quantitative real-time PCR analysis of a) Add3 (a, p<0.01 vs SuHx; b, p<0.01 vs normal;
c, p<0.05 vs SuHx), b) Ang1 (a, p<0.05 vs normal; b, p<0.05 vs SuHx; c, p<0.01 vs
normal), c) apelin (a, p<0.01 vs normal; b, p<0.01 vs SuHx; c, p<0.05 vs normal; d,
p<0.05 vs SuHx), d) HIF-2α (a, p<0.01 vs SuHx; b, p<0.01 vs normal; c, p<0.05 vs
normal; d, p<0.05 vs SuHx), e) IGF-1 (a, p<0.05 vs normal; b, p<0.05 vs SuHx; c,
p<0.01 vs SuHx), and f) KLF5 (a, p<0.01 vs normal; b, p<0.01 vs SuHx; c, p<0.05 vs
SuHx; d, p<0.05 vs normal) mRNA in normal and carvedilol rat right ventricles. Data
were normalized to expression of 18S rRNA and are shown as mean ± s.d. (n=3).
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SU5416/hypoxia RV with carvedilol was associated with a decrease in the expression of
Add3 and HIF-2α; both genes returned towards normal levels of expression. Similarly,
expression of Ang1 and apelin also both returned towards normal RV expression levels
and were increased in comparison to SU5416/hypoxia RV levels. In contrast, levels of
Aqp1, Nppb, and Klf5 increased above the SU5416/hypoxia RV levels, which were also
increased in comparison to normal RV levels. There was no significant effect on the
expression of IGF-1 in the SU5416/hypoxia + carvedilol RV tissue.

In addition, we examined the glycolysis/gluconeogenesis pathways (Figure 31) with
respect to carvedilol treatment on the failing RV. Genes that were up-regulated by
SU5416/hypoxia treatment (Chapter 4, Figure 20) are now down regulated by carvedilol
treatment. In patients with PAH, there is a shift from oxidative phosphorylation to
glycolysis in the heart[195, 196], which is associated with reduced RV contractility and
impairment of cardiac function[198].

A reduction in expression of genes encoding

glycolytic enzymes in the carvedilol-treated failing RV may be an indication that the
heart is switching from glycolysis back to oxidative phosphorylation and may be
consistent with some degree of myocardial metabolic recovery.

5.7

Inflammatory genes

On a molecular level, carvedilol treatment has been shown to affect inflammatory
cytokines and apoptosis. In post-MI rats that were treated with carvedilol, there was:
preservation of myocardial contractility, reduced cardiac expression of IL-1β, and
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Figure 31: Glycolysis and Gluconeogenesis Canonical Pathway
Canonical pathway analysis identified the pathways from the Ingenuity Pathway
Analysis® library of canonical pathways that were most significant to the dataset. The pvalue for the glycolysis and gluconeogenesis canonical pathway is 0.00929. Genes are
colored based on fold-change comparison between Sugen/Hypoxia (failing) RV and
Sugen/Hypoxia with carvedilol treatment (treated) RV. Carvedilol was given to rats for
four weeks at a dose of 15 mg/kg. Red correlattes to relatively higher expression in the
treated RV than the failing RV, and green correlates to relatively higher expression in the
failing RV than the treated RV.

Enzyme classification (EC) numbers reported by

Ingenuity were converted to recommended names using the BRENDA enzyme database
(32); these names were then incorporated into the Ingenuity canonical pathway using the
MyPathway® feature.
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beneficial effects on ventricular remodeling; however, no effect on cardiac oxidative
stress was seen[437]. Additionally, four weeks of treatment with carvedilol after MI
reduced expression of the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and TGF-β
while increasing levels of the anti-inflammatory cytokine IL-10[438].

Similarly,

carvedilol as a treatment for myocarditis reduced expression of IL-1β and TNF-α and
increased expression of IL-10[439]. Furthermore, carvedilol suppressed the activation of
caspase3 via downregulation of TNF-α and inhibition of mitochondrial cytochrome c
release, resulting in reduced endothelial cell apoptosis induced by congestive heart
failure[440]. Because neither prazosin, an α1-adrenergic receptor blocker, or propanolol,
a non-specific β-blocker, were able to induce the same effect but an antioxidant did, it is
speculated that this effect is due to the antioxidant properties of carvedilol[440]. Finally,
carvedilol has been shown to inhibit proliferation of pulmonary artery smooth muscle
cells isolated from patients with idiopathic pulmonary arterial hypertension (PAH)[441].

We examined the effect of carvedilol on the production of cytokines using a multiplex
ELISA. As shown in Figure 32, there was no significant difference in the expression of
cytokines between the normal rat and carvedilol-only treated normal rat serum samples.
These signals activated by carvedilol may play a cardioprotective role and contribute to
the beneficial effects seen with carvedilol treatment in the right ventricular failure animal
models. Whether carvedilol also affects the expression of the above-mentioned genes in
the normal and carvedilol-treated LV will be investigated.
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Figure 32: Effects of carvedilol on cytokine production in serum samples
Multiplex ELISA analysis of IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, IL-18,
TNF-α, and VEGF protein in normal and carvedilol rat serum samples (no significant
difference). Data are shown as mean ± s.d. (n=3).
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In addition, we analyzed the expression of cytokines in the serum taken from different rat
models (Figure 33). Of the previously analyzed cytokines (Chapter 4, Figure 21), only
IL-1β and VEGF had increased expression in the SU5416/hypoxia + carvedilol samples
when compared to normal rat serum samples. Additionally, there was no significant
difference in cytokine expression in serum samples between the SU5416/hypoxia
samples and the SU5416/hypoxia + carvedilol samples. It is possible that there is a
change in cytokine levels in the tissues of the heart that is not reflected in the serum
samples.

To determine if there were effects on the expression of cytokines in the RV, the
microarray data were analyzed with respect to inflammatory genes (Figure 34). Several
genes were affected by carvedilol in the manner expected based on previously published
literature results.

VEGF forms B and C were decreased by 1.5-fold and 1.3-fold

respectively in the SU5416/hypoxia + carvedilol RV compared to the SU5416/hypoxia
RV. IL-18 also decreased by 1.4-fold and IL-10 increased 1.2-fold, consistent with
previously published literature that shows IL-10 decreases with carvedilol treatment[438,
439]. VEGF-A did have a different expression in the two conditions. However, other
pro-inflammatory cytokines were increased in expression with carvedilol treatment in the
SU5416/hypoxia RV compared to the SU5416/hypoxia RV, including IL-1α (1.6-fold
increase), IL-1β (1.3-fold increase), IL-2 (6.5-fold increase), IL-4 (1.8-fold increase), IL5 (1.4-fold increase), IL-6 (1.6-fold increase), IL-13 (2-fold increase), and TNF-α (1.5fold increase). However, unlike the cytokine assay that measures protein levels, the
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Figure 33: Expression of cytokines in rat serum from normal, failing, and
carvedilol-treated models
Multiplex ELISA analysis of a) IL-1α, b) IL-1β, c) IL-2, d) IL-4, e) IL-5, f) IL-10, g) IL13, h) IL-17, i) IL-18, j) TNF-α, and k) VEGF protein in normal (normal), pulmonary
artery banded (PAB), hypoxic (hypoxia), SU5416/hypoxia (SuHx), carvedilol (Carv), and
SU5416/hypoxia + carvedilol (SuHx + Carv) rat serum samples (a, p<0.05 vs normal; b,
p<0.01 vs normal). Data are shown as mean ± s.d. (n=3).
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Figure 34: Clustergram of inflammatory genes
Microarray gene expression of inflammatory genes in microarray dataset. The first three
major columns on the left labeled “normal,” “SuHx”, and “SuHxC” denote expression in
the normal, SU5416/hypoxia, and SU5416/hypoxia + carvedilol RVs. Red coloration
indicates increased expression compared to the average normal RV expression level
while green indicates reduced expression. The small columns represent different animals
treated with the same condition. The last major column on the right of the grey line
labeled “-“ denotes the difference in expression between the SU5416/hypoxia +
carvedilol and SU5416/hypoxia RVs. Red coloration indicates increased expression in
the SU5416/hypoxia RV with carvedilol treatment compared to an untreated
SU5416/hypoxia RV, and green indicates reduced expression in the SU5416/hypoxia +
carvedilol RV compared to the SU5416/hypoxia RV.
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microarray only measures mRNA expression and the actual protein levels of these
cytokines in the RV may be different due to post-translational mRNA modifications.

5.8

Discussion

Carvedilol, an α1/β1/β2-specific adrenergic receptor blocker, has been shown to improve
the hemodynamics in the failing RV of the SU5416/hypoxia model, as well as reduce RV
hypertrophy and dilation, myocardial fibrosis, and increase RV capillarization. Animals
given carvedilol treatment after development of PAH from SU5416/hypoxia had an
increased exercise capacity and survival rate. Here, we test whether the partial reversal of
the RV failure in the SU5416/hypoxia model by carvedilol was also associated with a
change of the RV-associated gene expression pattern. The gene expression pattern was
analyzed by microarray analysis (Figure 24), prediction analysis (Figure 28), and class
comparison analysis (Figure 29) to identify those signals that reverse failure.

Although the prediction analysis classified the SU5416/hypoxia + carvedilol predictor set
as being most similar to the expression of the failing RV, it is clear from the class
comparison analysis in Figure 28 that there are distinct changes in gene expression
between the failing and treated RVs, including genes involved in endothelin signaling
and genes encoding mitochondrial electron transport chain complexes.

Carvedilol

treatment is associated with a reduction in translation initiation and epidermal growth
factor receptor signaling, both of which are involved in the cardiac response to
hypertrophy. A reduction in EGF signaling leads to reduced cardiac hypertrophy[424,
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425]; similarly, a reduction in translation will also lead to a decrease in hypertrophy[416].
Treatment with carvedilol also increased expression of genes involved in PPAR and
Nrf2-mediated signaling.

These signaling pathways are activated while the heart

compensates for increased pressure afterload[427, 429]. Additionally, the mitochondrial
dysfunction pathway (Figure 26) and glycolysis/gluconeogenesis pathway (Figure 31)
have been affected by carvedilol treatment. In both, there is a higher expression of genes
in the failing (SU5416/hypoxia) RV than in the treated (SU5416/hypoxia + carvedilol)
RV. As it is known that PAH causes a shift from oxidative phosphorylation to glucose
metabolism and glycolysis[195, 196], this may be a return towards normal metabolism in
the RV.

Treatment of the failing RV with carvedilol also changed the expression of the genes that
were previously examined. While some, including Ang1, Add3, apelin, and HIF-2a,
returned towards normal RV expression levels with carvedilol treatment, others,
including Aqp1, BNP, and Klf5, increased further above normal RV and SU5416/hypoxia
RV levels with carvedilol treatment. There was no change in Igf1 expression in the
SU5416/hypoxia + carvedilol RV. Although there is a change in some of the genes
analyzed, it is unclear whether they are responsible for the functional improvement seen
in the heart or whether they are a consequence of the RV functional improvement.

Carvedilol has been reported to decrease expression of pro-inflammatory cytokines and
increase expression of anti-inflammatory cytokines[438, 439].

Microarray analysis

(Figure 13) reflected these results in the expression of IL-18, which decreased with
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carvedilol treatment, and increased expression of IL-10. However, an increase in mRNA
expression of IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, and TNF-α was also found and
is not consistent with literature results. There may be differences in protein levels in the
RV that are not reflected in the mRNA results. In the serum, there were no significant
differences in the expression of cytokines between the SU5416/hypoxia and
SU5416/hypoxia + carvedilol samples. As such, the reported anti-inflammatory effects
of carvedilol may not play a role in the reversal of RVF.

In the SU5416/hypoxia model of PAH, carvedilol treatment has improved RV function
and reversed maladaptive RV remodeling.

On a gene expression level, carvedilol

affected key signaling pathways, including mitochondrial dysfunction, oxidative stress,
and glycolysis. These changes in energy utilization should be studied further to examine
the extent of metabolic remodeling caused by carvedilol treatment. In addition, further
characterization of the signaling pathway activated by carvedilol in the heart to change
gene expression should be undertaken. Silencing RNA (siRNA) has been used against βarrestin to characterize the signaling pathway[442]; such a strategy could be employed to
effectively knock-out β-arrestin in the carvedilol-treated rat model and compare the
resulting RVF in the normal and knock-out rats. Finally, these results indicate the
promise in using carvedilol to treat PAH in human patients. A Phase I/Phase II clinical
trial on the safety and efficacy of carvedilol in PAH was started at Virginia
Commonwealth University in 2011 (NCT00964678). Based on the results of these and
additional trials, carvedilol may become a standard treatment for PAH patients.

209

Chapter 6: Discussion and Future Directions

6.1

Introduction

Pulmonary arterial hypertension (PAH) is associated with changes in gene expression in
the right ventricle (RV) of the heart corresponding to physiological changes such as
hypertrophy, capillary rarefaction, and reduced contractility. Identifying a therapeutic
intervention that targets these changes in the RV has been a challenge for researchers.
We show that carvedilol, a β-adrenergic receptor blocker, reduces hypertrophy, induces
angiogenesis, and increases contractility; these physiological changes are associated with
a change in gene expression. Here, we provide a brief overview of PAH before focusing
more in-depth on the three aims of this study and its implications on future research
directions.

PAH is a disease of the lung vessels in which vascular changes increase the pulmonary
vascular resistance (PVR) which, in turn, leads to increase afterload in the right ventricle
(RV) of the heart. Patients are diagnosed with PH if they have a mean pulmonary artery
pressure of greater than 25 mmHg at rest or greater than 30 mmHg during exercise; a
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normal mean pulmonary artery pressure is 8 – 20 mmHg at rest[1]. The mean pulmonary
artery pressure increases in PAH patients as the PVR increases. The RV can adapt to the
increase in pressure by hypertrophying – an increase in RV wall thickness through
increased muscle mass and a more rounded shape[180]. The RV begins to fail as PH
progresses, which is usually associated with RV dilation, a decrease in cardiac
output[258], and a reduction in RV stroke volume[154]. Right ventricular failure (RVF)
is the leading cause of death in patients with PH[255]. The estimated mean life span after
diagnosis of PAH prior to the period of drug treatment is 2.8 years[8] with a 1-, 2-, and 3year survival rate of 77%, 69%, and 35%[9].

Three classes of drugs are current standards of treatment for PH: prostanoids
(prostacyclin and analogues like iloprost), endothelin receptor blocks (bosentan or
ambristentan), and phosphodiesterase-5 inhibitors (sildenafil)[47, 48]. These drugs act as
pulmonary vasodilators and there had been the hope that they would also reverse
pulmonary vascular remodeling[47, 48]. However, they can have negative effects on the
heart by increasing RV contractility, which causes an increase in oxygen[48]. While
these treatments for PH focus on controlling symptoms and inducing pulmonary
vasodilation, they do not address the aspect of RVF associated with PH. RVF is known
to be reversible from studies of patients that have undergone lung transplant[368]. After
lung transplant, a significant improvement in both pulmonary artery pressure and right
ventricular function occur[374]. In addition, the 1-, 3-, and 5-year survival rates for PH
patients after lung transplant increase to 77%, 62.6%, and 53.6%[375]. These studies
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demonstrate that PH-associated RVF is reversible and motivate the search for
pharmacological interventions that can reverse RVF.

In order to investigate the effectiveness of drugs on reversing right ventricular failure, it
was necessary to first understand the changes in the RV that occur with hypertrophy and
failure associated with PAH. The studies here aimed to address these questions in the
following ways: 1) identifying the differences in gene expression between the normal
right ventricle and normal left ventricle, 2) identifying changes in gene expression
between the normal, hypertrophied, and failing right ventricle in animal models of
pulmonary hypertension, and 3) identifying changes in gene expression in the failing
right ventricle after treatment with carvedilol, an α1/β1/β2-adrenergic receptor blocker.

6.2

Identifying differences in gene expression between the normal LV and RV

Given that there are differences in embryology and physiology between the normal RV
and normal LV, we identified a small, but significant, number of genes that were
differentially expressed between the normal RV and normal LV using DNA microarray
technology. These genes were indentified using the Significance Analysis of Micorarrays
(SAM) two-class paired analysis[219]; 335 genes with identified as having significantly
different patterns of expression between the normal RV and normal LV from the total
20,556 genes. These genes were clustered together using average-linkage hierarchical
clustering[220] and pathway analysis using the PANTHER classification system[222,
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223] and Ingenuity Pathway Analysis (http://www.ingenuity.com) identified molecular
functions and differentially expressed pathways.

Differentially expressed genes are associated with known cardiac functions. The Wnt
signaling pathway is active during development in the secondary heart field and helps
promote growth and diversification of precursor cells in the RV[243]. Genes in this
pathway had higher expression in the normal RV than the normal LV. Additionally,
genes in the IGF-1/insulin signaling pathway are more highly expressed in the normal
RV than the normal LV. Activation of this pathway leads to cardiomyocyte growth[244]
and can control cell differentiation and apoptosis[245]. In contrast, genes involved in
cell-cycle regulation and DNA damage repair were more highly expressed in the normal
LV than the normal RV.

From cluster and pathway analysis, several genes were selected for follow-up by
quantitative real-time polymerase chain reaction (qRT-PCR): Nr2f2, Igf1, Irx2, and Nppb.
Nr2f2, also known as COUP-TFII (chicken ovalbumin upstream promoter-transcription
factor 2) is required during development for angiogenesis[252]. Igf1, as previously
mentioned, controls cardiomyocyte growth, differentiation, and apoptosis[244, 245].
Irx2 is expressed during development in the interventricular septum and is thought to
play a role in septum specification[253].

Nppb is the precursor to BNP, which is

commonly used as a clinical marker of heart failure. These genes may provide insight
into gene expression changes that occur during heart failure.
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This study sought to identify differences in gene expression between the normal RV and
normal LV. These data support the concept that the RV and LV should be evaluated
independently rather than using the LV as the basis for studies of the RV. This study also
serves as the basis for studies of changes in gene expression in the RV caused by
hypertrophy and right ventricular failure associated with PH.

Another unanswered

question is whether the interventricular septum is part of the right or left ventricle.
Microarray studies similar to those used above can answer this question both for the
normal, unstressed heart and for the heart in PAH where the interventricular septum is
shifted into the LV cavity impairing LV filling.

6.3
Identifying changes in gene expression between the normal, hypertrophied,
and failing RV in animal models of PAH
Given that the normal RV and normal LV have different gene expression profiles, it can
be hypothesized that RVF cannot a priori be described by known patterns of gene
expression in the failing LV.

In addition, we hypothesize that the transition from

adaptive hypertrophy to RVF associated with the development of PAH will be associated
with a change in gene expression.

Using DNA microarray technology, the gene

expression patterns associated with the normal RV, hypertrophied RV, and failing RV
were examined in a rat model.

Hypertrophy was induced by exposure to chronic

hypoxia[283] while failure was induced by a combination of chronic hypoxia and
administration of a vascular endothelial growth factor receptor (VEGFR) blocker
SU5416[281]. Echocardiography and hemodynamic studies showed that the RV was
fully functional in the chronically hypoxic and pulmonary hypertension rats, but that the
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RV failed (had decreased cardiac output) in the SU5416/hypoxia rats. The SAM twoclass unpaired analysis[219] was used to identify 3,595 genes with significantly different
expression between the normal RV and the failing RV. In addition, a prediction set of
450 probes corresponding to 405 different genes that distinguish between the normal RV,
hypertrophied RV, and failing RV was developed using four algorithms and leave oneout cross-validation[226-229]. These genes were analyzed with cluster analysis[220], the
PANTHER classification system[222, 223], and Ingenuity Pathway Analysis
(http://www.ingenuity.com) to identify biological functions and pathways associated with
the differences in gene expression as the RV transitions from hypertrophy to failure.

There were several genes with shared expression patterns between the failing RV and the
hypertrophied RV, including ANP, BNP, and hypoxia-inducible factor 2, alpha (HIF-2α).
Increased expression of ANP and BNP can be expected from previously described
reports[48, 181] as they are markers of heart stress and failure. HIF-2α expression is
increased in response to hypoxia signaling[321] and enhances transcription of
endothelial-specific genes related to angiogenesis and vessel maturation[324, 325].
Because these genes have increased expression in both the hypertrophied and failing
RVs, it suggests that they are important to the adaptation to hypertrophy, but may not
play a role in the transition to RVF. Several themes with different expression patterns
between the failing RV and the hypertrophied RV became apparent in the analysis steps:
elevated expression of glycolytic enzymes, loss of cell-growth promoting genes, impaired
angiogenic capillary maintenance, and cytoskeletal rearrangement.
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A switch from fatty acid oxidation to glycolysis has been reported in studies of left
ventricular failure[354] and has been hypothesized to occur in the failing RV associated
with PAH[198]. The increased expression of genes encoding glycolytic enzymes in the
failing RV in this study suggests a shift in energy metabolism that has been described in
left ventricular failure. In addition, the data show a downregulation of genes encoding
mitochondrial electron transport chain complexes, which is known to be a characteristic
of damaged and dysfunctional mitochondria in the failing heart[305]. These findings
indicated that there are drastic changes in energy utilization as the RV transitions from
hypertrophy to failure.

The studies described here as well as previous studies suggest that there is a shift from
fatty acid oxidation to glycolysis in the failing RV.

However, these are based on

expression of mRNA of genes involved in the glycolytic and mitochondrial dysfunction
pathways rather than studies of respiration in intact cardiac mitochondria.

Single

populations of cardiac mitochondria can be isolated from the normal and failing
RVs[443].

Oxygen consumption by these intact mitochondria can be measured to

determine the ADP/O ratio[444-446]. A lower ADP/O ratio indicates more oxygen used
per unit of ADP provided in the assay and is an indication of impaired mitochondrial
efficiency. We would expect to find that the failing RV from the SU5416/hypoxia rat has
a lower ADP/O2 ratio than the normal rat based on our microarray results showing
increased mitochondrial dysfunction and decreased expression of genes encoding
mitochondrial electron transport chain subunits in the SU5416/hypoxia RV on the mRNA
level.
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Several genes, including Igf1 and Kruppel-like factor 5 (Klf5), had an increased
expression in the hypertrophied RV, but a decrease in expression in the failing RV. Igf1
is transactivated by Klf5 in cardiac fibroblasts and secreted to activated cardiomyocyte
growth[244] and control cell differentiation and apoptosis[245]. Although increased
expression of Igf1 has been reported in cardiomyopathy[352] and in myocardial biopsies
from failing hearts[353], we did not find an increase in Igf1 expression in the failing rat
RV.

This suggests that cell-growth promoting genes are important in triggering a

response to hypertrophy, and that a reduction in the expression of cell-growth promoting
genes may characterize RV failure.

Based on these results, increasing expression of IGF-1 may prove to be beneficial to the
failing heart. Mecasermin is a recombinant human insulin-like growth factor I (rhIGF-1)
approved by the United States Food and Drug Administration in the fall of 2005 for use
in treating severe primary IGF-1 deficiency[447]. Patients with growth hormone and
IGF-1 deficiency have increased cardiac mortality[448], and studies are ongoing to see
whether rhIGF-1 has a beneficial effect on heart failure in humans[449]. rhIGF-1 may
also prove beneficial in the treatment of pulmonary hypertension because of the role of
IGF-1 in adaptive, or beneficial, hypertrophy that is lost in the failing heart. We could
induce PAH using the SU5416/hypoxia model as described in our studies here and then
treat with mecasermin. After mecasermin treatment, hemodynamic measurements would
be taken and the gene expression profile analyzed using microarrays and analysis
techniques similar to those described here. We would expect to see a gene expression
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profile more closely resembling the hypertrophied RV. However, mecasermin may need
to be administered in combination with an existing therapy for PAH, such as sildenafil, to
improve the hemodynamic performance in the heart. Future studies may also address the
aspects of combination therapy of rhIGF-1 and another treatment.

This study sought to identify differences in RV gene expression between normal,
hypertrophy, and failure. A set of genes that were descriptive of those changes and a set
of genes that could predict those differences was identified and analyzed for common
themes among the differences in gene expression.

Our data show that there is a

difference in expression between the hypertrophied and failing RV and the key pathways
that may govern the transition from hypertrophy to failure associated with PAH. This
data set also provides a basis for evaluating any changes in gene expression in the RV as
a result of a pharmacological intervention, a treatment goal for PAH.

One possible pharmacological intervention for PAH is dexamethasone, an antiinflammatory and immunosuppressive glucocorticoid used to treat inflammatory and
autoimmune disorders[450]. Dexamethasone inhibits secretion of T-helper 1 (Th1) cells
and enhances production of T-helper 2 (Th2) cytokines both in vitro and in vivo[451453]. Small groups of patients with PAH due to connective tissue disorders including
scleroderma, systemic lupus erythematosus (SLE), and mixed connective tissue diseases
have been treated with a combination of immunosuppressant drugs and glucocorticoids
resulting in an improvement of PAH symptoms[454]. Additionally, dexamethasone was
used to prevent development of PAH in a rat monocrotaline model; these rats had
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significantly decreased pulmonary artery pressure and RV hypertrophy compared to the
monocrotaline-induced PAH rats[455]. While the prevention of PAH shows promising
results, treatment with dexamethasone after development of PAH would be the most
clinically relevant study. PAH could be induced using the SU5416/hypoxia model as
described in our studies here followed by treatment with dexamethasone. Following
several weeks of dexamethasone treatment, hemodynamic measurements would be taken
and the gene expression profile analyzed using microarrays and analysis techniques
similar to those described here. We would expect to see a decrease in RV hypertrophy
compared to the untreated SU5416/hypoxia RV and a gene expression profile more
closely resembling the normal or hypertrophied RV.

6.4
Identifying changes in gene expression in the failing RV after treatment with
carvedilol
Treatment for PAH is currently focused on the use of vasodilators, endothelin-receptor
blockers, and phosphodiesterase-5 inhibitors[47, 48], but none of these drugs have effects
on reversing RVF. One possible pharmacological intervention is the use of β-adrenergic
receptor blockers, which are often used in treatment of patients with left ventricular
failure[378].

In recent animal studies, carvedilol, an α1/β1/β2-adrenergic receptor

blocker[360], was tested as a treatment for PAH.

Carvedilol had no effect on the

pulmonary vascular remodeling in these animals, but did reduce RV hypertrophy and
reverse the capillary rarefaction; increase cardiac output and stroke volume; and decrease
fibrosis and cardiomyocyte apoptosis[360].
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Although some changes in gene expression due to carvedilol treatment have been
reported[360], a systematic study of the gene expression changes in the RV as a result of
carvedilol treatment of a failing RV had not been done. Carvedilol was given to rats for
four weeks after SU5416/chronic hypoxia treatment and the carvedilol-treated RV was
compared to the untreated failing RV using DNA microarrays. Although the previously
described prediction set classified the carvedilol-treated data set as being similar to the
failing RV, other methods were used to identify genes that were different between the
failing and carvedilol treated RV. A two-class unpaired SAM analysis[219] identified
4,714 genes that were differentially expressed between the failing RV and the carvediloltreated RV. Additionally, a class comparison analysis[226, 413, 414] identified 489
genes that were significantly different between the failing and carvedilol-treated RV at a
p-value < 0.001. The genes from these two analyses were analyzed with clustering
algorithms[220], the PANTHER classification system[222, 223], and Ingenuity Pathway
Analysis (http://www.ingenuity.com).

Previously discussed results demonstrate that the failing RV was characterized by a shift
from fatty acid oxidation to glycolysis[197] and a decrease in expression of genes
encoding mitochondrial electron transport chain complexes[198, 305]. With carvedilol
treatment, there was an increase in the expression of mitochondrial electron transport
chain genes and a decrease in expression of glycolytic enzymes, suggesting that there was
a return towards normal myocardial metabolism in the heart after treatment with
carvedilol. In addition, there was an increase in expression in genes in the peroxisome
proliferator-acitvator receptor (PPAR) and nuclear factor-like 2 (Nrf2) signaling
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pathways. PPAR-α is activated by PPAR coactivator-1, alpha (PGC-1α) and signals via
Nrf2. PGC-1α and PPAR-α are preferentially expressed in the heart[427] and activate
genes involved in the cellular uptake and mitochondrial activation of fatty acids[428].
PPAR-α plays an important role in the functional adaptation in the heart to pressure
overload[427, 429]. An increase in the expression of genes in these signaling pathways
in the carvedilol-treated RV suggests that a change in energy metabolism and
mitochondrial function is important in reversing RVF. Targeting mitochondrial function
pharmacologically may be an important aspect of clinical treatment for PAH.

In addition, signaling for fibrosis and integrin-like kinase (ILK) were increased in both
the SU5416/hypoxia RV and the SU5416/hypoxia + carvedilol RV. TGF-β-mediated
cardiac fibrosis can be induced by increased pressure afterload[289] and injury[214].
Similarly, increased pressure or afterload induces expression of rho-kinase (ROCK),
which induces cardiac hypertrophy[288].
mechanisms of cardiac compensation.

These pathways may be involved in

Conversely, the SU5416/hypoxia RV and

SU5416/hypoxia + carvedilol RV also show the same expression pattern for
downregulated pathways, including protein ubiquitination and ERK/MAPK signaling.
Without protein ubquitination pathway, pro-apoptotic proteins accumulate in the
RV[314].

ERK signaling induces adaptive hypertrophic responses, such as

cardiomyocyte growth and cytoskeletal rearrangement[456-458]. ERK signaling can also
prevent myocardial damage, as is evident from studies of pre-ischemic conditioning[459].
Although these pathways may be maladaptive, changes in expression may or may not be
required for “beneficial effects” of carvedilol on the overall function of the RV.
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Carvedilol treatment of the failing RV also affected the expression of genes that were
previously examined. mRNA expression of Ang1, Add3, apelin, and HIF-2α returned
towards normal expression levels in the carvedilol-treated RV. However, Aqp1, BNP,
and Klf5 increased in expression further above normal RV and failing RV levels with
carvedilol treatment. However, carvedilol had no apparent effect on changing serum
cytokine levels from those observed in the SU5416/hypoxia animals, although there was
a significant increase in the expression of IL-1β and VEGF from normal serum levels.

Although our data demonstrate that carvedilol changes gene expression in the failing RV,
they are not descriptive of the mechanism by which carvedilol acts. Carvedilol acts as an
α1/β1/β2-adrenergic receptor blocker, but also has antioxidant properties.

Whether

carvedilol-induced gene expression changes occur mainly via adrenergic receptor activity
or via antioxidant activity in the failing heart has yet to be examined. In addition, the
adrenergic receptors may signal either through G protein-coupled receptors to promote
anti-apoptotic

and

mitogenic

effects[383-386]

or

via

β-arrestin

to

promote

cardioprotective signals in response to mechanical stress[387]. The role of these two
signaling pathways could be elucidated in future research by using siRNA to β-arrestin in
the rat or by using β-arrestin knockout mice. We have demonstrated here that carvedilol
treatment of normal rats is associated with increased mRNA expression of angiogeneic
and growth factor genes. If these are a consequence of β-arrestin signaling rather than
signaling through G-protein coupled receptors, there should be no increase in mRNA
expression of those genes in animals lacking β-arrestin.
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The data described here characterize a set of expressed genes that distinguishes between
the normal RV and failing RV and between a failing RV and a carvedilol-treated RV.
While changes in specific genes and pathways have been characterized, these changes are
by no means a complete list of all of the genes associated with failure and recovery from
RVF. In addition, it is unclear whether the genes and pathways described after carvedilol
treatment are directly responsible for the functional improvement seen in the RV or are a
consequence of functional RV improvement. Further examination of the present data set
as well as time course studies to characterize the transition phase from compensated
hypertrophy to RVF are necessary to more rigorously describe the mechanisms governing
failure and recovery.

Although these data describe differences in the gene expression pattern between the
normal, hypertrophies, failing, and treated RV, they are derived from an animal model of
pulmonary hypertension (PH). As such, the same changes may or may not be present in
other animal models of PH or in human heart tissue samples. These data may serve as
the basis and reference for comparison to other animal models and to heart tissue samples
from patients with PAH.

Correlating these data with human sample data will be

important for developing therapeutic strategies for human PAH.
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Appendix A: Probes identified by prediction analysis with 100% across LOOCV

# of
Probes
1
1
1
1
1
1
1
1
1
1
1
1

Gene Name
40060
A_44_P105213
A_44_P314231
A_44_P384688
A_44_P431358
A_44_P459484
A_44_P546267
A_44_P575763
A_44_P704947
A_44_P729183
A_44_P921710
A_44_P944159

1

AA900990

1

AA963280

1

Aars

1

Abtb2

2
1
1

Acaa1
Actn4
Add2

1

Afg3l1_predicted

1

AI010816

1

AI043579

1

AI045508

1

AI229412

1

Akap2

1
1

Akt1
Aldoa

1

Aldoal1

1
1
10

Anp32b
Anxa5
Aqp1

1

Arhgap21_predicted

Description
Rattus norvegicus septin 4 (Sept4), mRNA [NM_001011893]
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
AA900990 UI-R-E0-dj-f-04-0-UI.s1 UI-R-E0 Rattus norvegicus cDNA
clone UI-R-E0-dj-f-04-0-UI 3' similar to gi [AA900990]
AA963280 UI-R-E1-gh-h-04-0-UI.s1 UI-R-E1 Rattus norvegicus cDNA
clone UI-R-E1-gh-h-04-0-UI 3', mRNA sequence [AA963280]
PREDICTED: Rattus norvegicus alanyl-tRNA synthetase (Aars),
mRNA [XM_214690]
Rattus norvegicus ankyrin repeat and BTB (POZ) domain containing 2
(Abtb2), mRNA [NM_134403]
Rattus norvegicus acetyl-Coenzyme A acyltransferase 1 (Acaa1),
mRNA [NM_012489]
Rattus norvegicus actinin alpha 4 (Actn4), mRNA [NM_031675]
Rattus norvegicus adducin 2 (beta) (Add2), mRNA [NM_012491]
PREDICTED: Rattus norvegicus AFG3(ATPase family gene 3)-like 1
(yeast) (predicted) (Afg3l1_predicted), mRNA [XM_341714]
EST205267 Normalized rat muscle, Bento Soares Rattus sp. cDNA
clone RMUAS84 3' end, mRNA sequence [AI010816]
UI-R-C1-jt-e-10-0-UI.s1 UI-R-C1 Rattus norvegicus cDNA clone UI-RC1-jt-e-10-0-UI 3', mRNA sequence [AI043579]
AI045508 UI-R-C1-kj-g-08-0-UI.s1 UI-R-C1 Rattus norvegicus cDNA
clone UI-R-C1-kj-g-08-0-UI 3', mRNA sequence [AI045508]
AI229412 EST226107 Normalized rat embryo, Bento Soares Rattus sp.
cDNA clone REMCG02 3' end, mRNA sequence [AI229412]
Rattus norvegicus A kinase (PRKA) anchor protein 2 (Akap2), mRNA
[NM_001011974]
Rattus norvegicus thymoma viral proto-oncogene 1 (Akt1), mRNA
[NM_033230]
Rattus norvegicus aldolase A (Aldoa), mRNA [NM_012495]
Rattus norvegicus aldolase A-like 1 (Aldoal1), mRNA
[NM_001013943]
Rattus norvegicus acidic nuclear phosphoprotein 32 family, member B
(Anp32b), mRNA [NM_131911]
Rattus norvegicus annexin A5 (Anxa5), mRNA [NM_013132]
Rattus norvegicus aquaporin 1 (Aqp1), mRNA [NM_012778]
PREDICTED: Rattus norvegicus Rho GTPase activating protein 21
(predicted) (Arhgap21_predicted), mRNA [XM_225628]
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1

Arpc1b

1

Atox1

1

Atp2b2

1

AW141147

1

AW142959

1

AW143194

1

AW143900

1

AW144158

1

AW144236

1

AW253396

1

AW433572

1

AW529005

1

AW915016

1

AW915635

1

AW916021

1

AW917132

1

AW917894

1

AW918202

1

AW918729

1

AW919096

1

AW919109

Rattus norvegicus actin related protein 2/3 complex, subunit 1B
(Arpc1b), mRNA [NM_019289]
Rattus norvegicus ATX1 (antioxidant protein 1) homolog 1 (yeast)
(Atox1), mRNA [NM_053359]
Rattus norvegicus ATPase, Ca++ transporting, plasma membrane 2
(Atp2b2), mRNA [NM_012508]
AW141147 EST291183 Normalized rat brain, Bento Soares Rattus sp.
cDNA clone RGIBE08 5' end similar to C-1, putative transcription
factor, mRNA sequence [AW141147]
AW142959 EST293251 Normalized rat kidney, Bento Soares Rattus sp.
cDNA clone RGIBA46 5' end, mRNA sequence [AW142959]
AW143194 EST293490 Normalized rat brain, Bento Soares Rattus sp.
cDNA clone RGIBF39 5' end, mRNA sequence [AW143194]
AW143900 EST294196 Normalized rat embryo, Bento Soares Rattus
sp. cDNA clone RGICC51 5' end, mRNA sequence [AW143900]
AW144158 EST294454 Normalized rat ovary, Bento Soares Rattus sp.
cDNA clone RGICK08 5' end, mRNA sequence [AW144158]
AW144236 EST294532 Normalized rat ovary, Bento Soares Rattus sp.
cDNA clone RGICN59 5' end, mRNA sequence [AW144236]
AW253396 UI-R-BJ0-aen-d-08-0-UI.s1 UI-R-BJ0 Rattus norvegicus
cDNA clone UI-R-BJ0-aen-d-08-0-UI 3', mRNA sequence
[AW253396]
AW433572 UI-R-BJ0p-aez-g-10-0-UI.s1 UI-R-BJ0p Rattus norvegicus
cDNA clone UI-R-BJ0p-aez-g-10-0-UI 3', mRNA sequence
[AW433572]
AW529005 UI-R-BT1-aka-a-11-0-UI.s1 UI-R-BT1 Rattus norvegicus
cDNA clone UI-R-BT1-aka-a-11-0-UI 3', mRNA sequence
[AW529005]
AW915016 EST346320 Normalized rat ovary, Bento Soares Rattus sp.
cDNA clone RGIBN51 5' end, mRNA sequence [AW915016]
AW915635 EST346939 Normalized rat embryo, Bento Soares Rattus
sp. cDNA clone RGICY71 5' end, mRNA sequence [AW915635]
AW916021 EST347325 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIDF02 5' end, mRNA
sequence [AW916021]
EST348436 Rat gene index, normalized rat, norvegicus, Bento Soares
Rattus norvegicus cDNA clone RGIDZ63 5' end, mRNA sequence
[AW917132]
AW917894 EST349198 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIEJ82 5' end, mRNA
sequence [AW917894]
AW918202 EST349506 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIEN76 5' end, mRNA
sequence [AW918202]
AW918729 EST350033 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIEX24 5' end, mRNA
sequence [AW918729]
AW919096 EST350400 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIFC69 5' end, mRNA
sequence [AW919096]
AW919109 EST350413 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIFC89 5' end, mRNA
sequence [AW919109]
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1

AW920343

1

Bat1a

1

Bat3

1

Bcam

1

BF395647

1

BF404842

1

BF563221

1

BG376818

1

BI274747

1

BI294916

1

BM389289

1

BM986517

1
1

BQ210430
Bsg

2

Bst2

1

C1r

1

Casp4

1

CB606450

1

CB615257

1
1
1

CB759117
Ccnd2
Cd63

1

Cdc42ep2

4

Cdkn1a

1

Cebpd

AW920343 EST351647 Rat gene index, normalized rat, norvegicus,
Bento Soares Rattus norvegicus cDNA clone RGIGU32 5' end, mRNA
sequence [AW920343]
Rattus norvegicus HLA-B-associated transcript 1A (Bat1a), mRNA
[NM_133300]
Rattus norvegicus HLA-B-associated transcript 3 (Bat3), transcript
variant 2, mRNA [NM_053609]
Rattus norvegicus basal cell adhesion molecule (Bcam), mRNA
[NM_031752]
BF395647 UI-R-CM0-bjp-e-07-0-UI.s1 UI-R-CM0 Rattus norvegicus
cDNA clone UI-R-CM0-bjp-e-07-0-UI 3', mRNA sequence [BF395647]
BF404842 UI-R-CA1-bic-d-02-0-UI.s1 UI-R-CA1 Rattus norvegicus
cDNA clone UI-R-CA1-bic-d-02-0-UI 3', mRNA sequence [BF404842]
BF563221 UI-R-BO1-ajh-a-06-0-UI.r1 UI-R-BO1 Rattus norvegicus
cDNA clone UI-R-BO1-ajh-a-06-0-UI 5', mRNA sequence [BF563221]
UI-R-CA1-blh-e-03-0-UI.s1 UI-R-CA1 Rattus norvegicus cDNA clone
UI-R-CA1-blh-e-03-0-UI 3', mRNA sequence [BG376818]
BI274747 UI-R-CX0-bxd-e-07-0-UI.s1 UI-R-CX0 Rattus norvegicus
cDNA clone UI-R-CX0-bxd-e-07-0-UI 3', mRNA sequence [BI274747]
BI294916 UI-R-DK0-ced-f-05-0-UI.s1 UI-R-DK0 Rattus norvegicus
cDNA clone UI-R-DK0-ced-f-05-0-UI 3', mRNA sequence [BI294916]
BM389289 UI-R-DZ0-cko-f-18-0-UI.s1 NCI_CGAP_DZ0 Rattus
norvegicus cDNA clone IMAGE:7338356 3', mRNA sequence
[BM389289]
BM986517 EST594111 Rat gene index, normalized rat, norvegicus
Rattus norvegicus cDNA clone RGOAC85 3' end similar to
diphosphoinositol polyphosphate phosphohydrolase, mRNA sequence
[BM986517]
UI-R-DY1-coi-g-14-0-UI.s1 UI-R-DY1 Rattus norvegicus cDNA clone
UI-R-DY1-coi-g-14-0-UI 3', mRNA sequence [BQ210430]
Rattus norvegicus basigin (Bsg), mRNA [NM_012783]
Rattus norvegicus bone marrow stromal cell antigen 2 (Bst2), mRNA
[NM_198134]
C1r protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q4G030]
[ENSRNOT00000015897]
Rattus norvegicus caspase 4, apoptosis-related cysteine peptidase
(Casp4), mRNA [NM_053736]
CB606450 AMGNNUC:TRXP1-00001-B1-A trxp1 (10556) Rattus
norvegicus cDNA clone trxp1-00001-b1 5', mRNA sequence
[CB606450]
AMGNNUC:SRCS1-00113-G5-A srcs1 (10883) Rattus norvegicus
cDNA clone srcs1-00113-g5 5', mRNA sequence [CB615257]
AMGNNUC:SRPG2-00040-D8-A srpg2 (10238) Rattus norvegicus
cDNA clone srpg2-00040-d8 5', mRNA sequence [CB759117]
Rattus norvegicus cyclin D2 (Ccnd2), mRNA [NM_022267]
Rattus norvegicus CD63 antigen (Cd63), mRNA [NM_017125]
Rattus norvegicus CDC42 effector protein (Rho GTPase binding) 2
(Cdc42ep2), mRNA [NM_001009689]
Rattus norvegicus cyclin-dependent kinase inhibitor 1A (Cdkn1a),
mRNA [NM_080782]
Rattus norvegicus CCAAT/enhancer binding protein (C/EBP), delta
(Cebpd), mRNA [NM_013154]
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1

CF107866

1

CF111029

1

CF111207

1

Chrac1_predicted

1

Cilp_predicted

1

Ciz1_predicted

1

Col4a2_predicted

1

COX1

1

CR469283

1

Creld1

1
1
1

Crim1_predicted
Cst3
Cstb

10

Ctgf

1

CV102701

6

Cyp1a1

1
1
1

Cyp27a1
Dbnl
Dctn1

1

Dhrs4

1

Dlx1

1

Dnajb5_predicted

1

Dst_predicted

1

DV718416

1

DV722942

1

DV728620

Shultzomica01117 Rat lung airway and parenchyma cDNA libraries
Rattus norvegicus cDNA clone NA9257 5', mRNA sequence
[CF107866]
Shultzomica04280 Rat lung airway and parenchyma cDNA libraries
Rattus norvegicus cDNA clone Contig3797 5', mRNA sequence
[CF111029]
Shultzomica04458 Rat lung airway and parenchyma cDNA libraries
Rattus norvegicus cDNA clone Contig3944 5', mRNA sequence
[CF111207]
PREDICTED: Rattus norvegicus chromatin accessibility complex 1
(predicted) (Chrac1_predicted), mRNA [XM_235400]
PREDICTED: Rattus norvegicus cartilage intermediate layer protein,
nucleotide pyrophosphohydrolase (predicted) (Cilp_predicted), mRNA
[XM_236348]
PREDICTED: Rattus norvegicus CDKN1A interacting zinc finger
protein 1 (predicted) (Ciz1_predicted), mRNA [XM_216034]
PREDICTED: Rattus norvegicus procollagen, type IV, alpha 2
(predicted) (Col4a2_predicted), mRNA [XM_225043]
Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Cytochrome c oxidase
polypeptide I). [Source:Uniprot/SWISSPROT;Acc:P05503]
[ENSRNOT00000050156]
CR469283 Rat pBluescript Lion Rattus norvegicus cDNA clone
LIONp463E09157 3', mRNA sequence [CR469283]
Rattus norvegicus cysteine-rich with EGF-like domains 1 (Creld1),
mRNA [NM_001024783]
PREDICTED: Rattus norvegicus cysteine-rich motor neuron 1
(predicted) (Crim1_predicted), mRNA [XM_233798]
Rattus norvegicus cystatin C (Cst3), mRNA [NM_012837]
Rattus norvegicus cystatin B (Cstb), mRNA [NM_012838]
Rattus norvegicus connective tissue growth factor (Ctgf), mRNA
[NM_022266]
AGENCOURT_31523961 NIH_MGC_270 Rattus norvegicus cDNA
clone IMAGE:7446235 5', mRNA sequence [CV102701]
Rattus norvegicus cytochrome P450, family 1, subfamily a, polypeptide
1 (Cyp1a1), mRNA [NM_012540]
Rattus norvegicus cytochrome P450, family 27, subfamily a,
polypeptide 1 (Cyp27a1), mRNA [NM_178847]
Rattus norvegicus drebrin-like (Dbnl), mRNA [NM_031352]
Rattus norvegicus dynactin 1 (Dctn1), mRNA [NM_024130]
Rattus norvegicus dehydrogenase/reductase (SDR family) member 4
(Dhrs4), mRNA [NM_153315]
PREDICTED: Rattus norvegicus distal-less homeobox 1 (Dlx1), mRNA
[XM_230987]
BF558851 UI-R-A1-dv-f-06-0-UI.r1 UI-R-A1 Rattus norvegicus cDNA
clone UI-R-A1-dv-f-06-0-UI 5', mRNA sequence [BF558851]
PREDICTED: Rattus norvegicus dystonin (predicted) (Dst_predicted),
mRNA [XM_237042]
RVL9000 Wackym-Soares normalized rat vestibular cDNA library
Rattus norvegicus cDNA 5', mRNA sequence [DV718416]
RVL14623 Wackym-Soares normalized rat vestibular cDNA library
Rattus norvegicus cDNA 5', mRNA sequence [DV722942]
RVL21285 Wackym-Soares normalized rat vestibular cDNA library
Rattus norvegicus cDNA 5', mRNA sequence [DV728620]
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1

Dvl1

1
1

Edg2
Edn2

1

Eef2

1

Eef2k

1

Egln3

6

Eif4b

1

Eif4g3_predicted

1

Eml2

1
1

Enah
Eno1

1
1

ENSRNOT00000000707
ENSRNOT00000005432

1

ENSRNOT00000007351

1

ENSRNOT00000008057

1

ENSRNOT00000009344

1

ENSRNOT00000013672

1

ENSRNOT00000015113

1

ENSRNOT00000017043

2

ENSRNOT00000017422

1

ENSRNOT00000023601

1
1

ENSRNOT00000023696
ENSRNOT00000028121

1

ENSRNOT00000029141

Rattus norvegicus dishevelled, dsh homolog 1 (Drosophila) (Dvl1),
mRNA [NM_031820]
Rattus norvegicus endothelial differentiation, lysophosphatidic acid Gprotein-coupled receptor, 2 (Edg2), mRNA [NM_053936]
Rattus norvegicus endothelin 2 (Edn2), mRNA [NM_012549]
Rattus norvegicus eukaryotic translation elongation factor 2 (Eef2),
mRNA [NM_017245]
Rattus norvegicus eukaryotic elongation factor-2 kinase (Eef2k), mRNA
[NM_012947]
Rattus norvegicus EGL nine homolog 3 (C. elegans) (Egln3), mRNA
[NM_019371]
Rattus norvegicus eukaryotic translation initiation factor 4B (Eif4b),
mRNA [NM_001008324]
PREDICTED: Rattus norvegicus eukaryotic translation initiation factor
4 gamma, 3 (predicted) (Eif4g3_predicted), mRNA [XM_216563]
Rattus norvegicus echinoderm microtubule associated protein like 2
(Eml2), mRNA [NM_138921]
Rattus norvegicus enabled homolog (Drosophila) (Enah), mRNA
[NM_001012150]
Rattus norvegicus enolase 1, alpha (Eno1), mRNA [NM_012554]
Myristoylated alanine-rich C-kinase substrate (MARCKS) (Protein
kinase C substrate 80 kDa protein).
[Source:Uniprot/SWISSPROT;Acc:P30009] [ENSRNOT00000000707]
Unknown
PREDICTED: Rattus norvegicus similar to Small nuclear
ribonucleoprotein F (snRNP-F) (Sm protein F) (Sm-F) (SmF)
(LOC680737), mRNA [XM_001058626]
PREDICTED: Rattus norvegicus similar to small unique nuclear
receptor co-repressor (predicted) (RGD1560600_predicted), mRNA
[XM_214099]
PREDICTED: Rattus norvegicus similar to Calsequestrin-1 precursor
(Calsequestrin, skeletal muscle isoform) (LOC686019), mRNA
[XM_001063867]
PREDICTED: Rattus norvegicus similar to proline arginine rich coiled
coil 1, transcript variant 5 (LOC681287), mRNA [XM_001058826]
LOC501069 protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q5U4E6] [ENSRNOT00000015113]
PREDICTED: Rattus norvegicus similar to mKIAA1604 protein
(predicted) (RGD1565385_predicted), mRNA [XM_342453]
Mago-nashi-like proliferation-associated protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q27W02]
[ENSRNOT00000017422]
Memory related protein-1 (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q78E25] [ENSRNOT00000023601]
E3 ubiquitin-protein ligase MIB2 (EC 6.3.2.-) (Mind bomb homolog 2)
(RBSC-skeletrophin/dystrophin-like polypeptide).
[Source:Uniprot/SWISSPROT;Acc:Q68LP1]
[ENSRNOT00000023696]
Unknown
similar to Fructose-bisphosphate aldolase A (Muscle-type aldolase)
(Aldolase 1) (LOC290761), mRNA
[Source:RefSeq_dna;Acc:XR_007988] [ENSRNOT00000029141]
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1

ENSRNOT00000037887

1
1
1

ENSRNOT00000040029
ENSRNOT00000041388
ENSRNOT00000041594

1

ENSRNOT00000048684

1

ENSRNOT00000051257

1

ENSRNOT00000055469

1

ENSRNOT00000056257

1

ENSRNOT00000057386

1
1

ENSRNOT00000058206
Fads3

3

Fdps

2

Fhl1

1

Fkbp5

1

Fkrp

1

Fliih

1

Fln29

1
1
1
1

Flnc_predicted
Flot1
Ftl1
Fts

1

Gadd45a

2

Gas6

1

Gata4

1

Gcdh_predicted

1

Gchfr

1

Gdnf

Alpha-mannosidase 2 (EC 3.2.1.114) (Alpha-mannosidase II)
(Mannosyl- oligosaccharide 1,3-1,6-alpha-mannosidase) (MAN II)
(Golgi alpha- mannosidase II) (Mannosidase alpha class 2A member 1)
(Fragment). [Source:Uniprot/SWISSPROT;Acc:P28494]...
PREDICTED: Rattus norvegicus eukaryotic translation initiation factor
4 gamma, 1 (Eif4g1), mRNA [XM_213569]
Unknown
Unknown
similar to RIKEN cDNA 5031410I06 (LOC686886), mRNA
[Source:RefSeq_dna;Acc:XR_009064] [ENSRNOT00000048684]
PREDICTED: Rattus norvegicus dysferlin (predicted) (Dysf_predicted),
mRNA [XM_232123]
similar to nemo like kinase (LOC365949), mRNA
[Source:RefSeq_dna;Acc:XR_009210] [ENSRNOT00000055469]
LOC360570 protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q3B8R3] [ENSRNOT00000056257]
Col4a1 protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q5FWY9]
[ENSRNOT00000057386]
TSC22 domain family protein 1 (Transforming growth factor beta-1induced transcript 4 protein) (Regulatory protein TSC-22) (TGFBstimulated clone 22 homolog).
[Source:Uniprot/SWISSPROT;Acc:P62501] [ENSRNOT00000058206]
Rattus norvegicus fatty acid desaturase 3 (Fads3), mRNA [NM_173137]
Rattus norvegicus farensyl diphosphate synthase (Fdps), mRNA
[NM_031840]
Rattus norvegicus four and a half LIM domains 1 (Fhl1), transcript
variant 2, mRNA [NM_145669]
Rattus norvegicus FK506 binding protein 5 (Fkbp5), mRNA
[NM_001012174]
Rattus norvegicus fukutin related protein (Fkrp), mRNA
[NM_001025678]
Rattus norvegicus flightless I homolog (Drosophila) (Fliih), mRNA
[NM_001008279]
Fln29 protein. [Source:Uniprot/SPTREMBL;Acc:Q5M806]
[ENSRNOT00000033984]
PREDICTED: Rattus norvegicus filamin C, gamma (actin binding
protein 280) (predicted) (Flnc_predicted), mRNA [XM_342653]
Rattus norvegicus flotillin 1 (Flot1), mRNA [NM_022701]
Rattus norvegicus ferritin light chain 1 (Ftl1), mRNA [NM_022500]
Rattus norvegicus fused toes (Fts), mRNA [NM_001011926]
Rattus norvegicus growth arrest and DNA-damage-inducible 45 alpha
(Gadd45a), mRNA [NM_024127]
Rattus norvegicus growth arrest specific 6 (Gas6), mRNA
[NM_057100]
Rattus norvegicus GATA binding protein 4 (Gata4), mRNA
[NM_144730]
Rattus norvegicus similar to glutaryl-CoA dehydrogenase precursor
(LOC364975), mRNA [XM_344744]
Rattus norvegicus GTP cyclohydrolase I feedback regulator (Gchfr),
mRNA [NM_133595]
Rattus norvegicus glial cell line derived neurotrophic factor (Gdnf),
mRNA [NM_019139]
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Rattus norvegicus guanine nucleotide binding protein (G protein),
gamma 11 (Gng11), mRNA [NM_022396]
PREDICTED: Rattus norvegicus glucosamine-6-phosphate deaminase 2
(predicted) (Gnpda2_predicted), mRNA [XM_214029]
Rattus norvegicus golgi reassembly stacking protein 1 (Gorasp1),
mRNA [NM_019385]
Rattus norvegicus glypican 1 (Gpc1), mRNA [NM_030828]
Rattus norvegicus G-protein signalling modulator 1 (AGS3-like, C.
elegans) (Gpsm1), mRNA [NM_144745]
Rattus norvegicus glycogenin 1 (Gyg1), mRNA [NM_031043]
Rattus norvegicus granzyme C (Gzmc), mRNA [NM_134332]
Rattus norvegicus histocompatibility 2, T region locus 18 (H2-T18),
mRNA [NM_001002821]
Rattus norvegicus hypocretin (Hcrt), mRNA [NM_013179]
Rattus norvegicus histone deacetylase 5, mRNA (cDNA clone
IMAGE:7301599), partial cds. [BC086431]
HIP1 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q8VHU1]
[ENSRNOT00000001967]
Rattus norvegicus similar to nuclear body associated kinase 1a
(LOC362342), mRNA [XM_342662]
Rattus norvegicus hexokinase 1 (Hk1), mRNA [NM_012734]
Rattus norvegicus high mobility group box 1 (Hmgb1), mRNA
[NM_012963]
Rattus norvegicus Hermansky-Pudlak syndrome 6 (Hps6), mRNA
[NM_181432]
Rattus norvegicus heterogeneous nuclear ribonucleoproteins
methyltransferase-like 2 (S. cerevisiae) (Hrmt1l2), mRNA
[NM_024363]
PREDICTED: Rattus norvegicus heat shock protein 70kDa 12B
(predicted) (Hspa12b_predicted), mRNA [XM_230610]
Rattus norvegicus heat shock 70kDa protein 5 binding protein 1
(Hspa5bp1), mRNA [NM_178021]
Rattus norvegicus heat shock 27kDa protein 3 (Hspb3), mRNA
[NM_031750]
Rattus norvegicus heat shock protein 1, alpha (Hspca), mRNA
[NM_175761]
Rattus norvegicus heat shock 90kDa protein 1, beta (Hspcb), mRNA
[NM_001004082]
Rattus norvegicus heat shock protein 1 (chaperonin) (Hspd1), mRNA
[NM_022229]
Rattus norvegicus isocitrate dehydrogenase 3 (NAD+) beta (Idh3B),
mRNA [NM_053581]
PREDICTED: Rattus norvegicus ilvB (bacterial acetolactate synthase)like (predicted) (Ilvbl_predicted), mRNA [XM_343174]
Rattus norvegicus inhibin alpha (Inha), mRNA [NM_012590]
Rattus norvegicus similar to Type I inositol-1,4,5-trisphosphate 5phosphatase (5PTASE) (LOC365382), mRNA [XM_344971]
Rattus norvegicus importin 13 (Ipo13), mRNA [NM_053778]
Rattus norvegicus integrin beta 1 (fibronectin receptor beta) (Itgb1),
mRNA [NM_017022]
Rattus norvegicus Josephin domain containing 3 (Josd3), mRNA
[NM_001014207]
Rattus norvegicus type I keratin KA15 (Ka15), mRNA
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[NM_001004022]
Rattus norvegicus MHC class II region expressed gene KE2 (Ke2),
mRNA [NM_212506]
PREDICTED: Rattus norvegicus kinesin family member 3B (predicted)
(Kif3b_predicted), mRNA [XM_215883]
Rattus norvegicus Kruppel-like factor 9 (Klf9), mRNA [NM_057211]
Rattus norvegicus keratin complex 1, acidic, gene 18 (Krt1-18), mRNA
[NM_053976]
Rattus norvegicus laminin, beta 2 (Lamb2), mRNA [NM_012974]
Rattus norvegicus lactate dehydrogenase D (Ldhd), mRNA
[NM_001008893]
LOC288526 protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q496Y9] [ENSRNOT00000037829]
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phosphoD-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1)
(LOC289517), mRNA [XR_008796]
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phosphoD-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1)
(LOC290721), mRNA [XR_005691]
PREDICTED: Rattus norvegicus similar to 60 kDa heat shock protein,
mitochondrial precursor (Hsp60) (60 kDa chaperonin) (CPN60) (Heat
shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) (HSP-65)
(LOC291205), mRNA [XR_007380]
Rattus norvegicus similar to chromosome 6 open reading frame 106
isoform a (LOC294154), mRNA [NM_001039607]
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phosphoD-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1)
(LOC297826), mRNA [XM_001066983]
Rattus norvegicus similar to RIKEN cDNA 1810012H11 (LOC298606),
mRNA [NM_001013936]
PREDICTED: Rattus norvegicus similar to heat shock protein 1
(chaperonin) (LOC308950), mRNA [XR_009038]
Rattus norvegicus tangerin (LOC309169), mRNA [NM_001025117]
Rattus norvegicus similar to autoantigen (LOC361399), mRNA
[NM_001033068]
Rattus norvegicus Ab1-351 mRNA, complete cds. [AY325145]
PREDICTED: Rattus norvegicus similar to Alpha-enolase (2-phosphoD-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1)
(LOC365354), mRNA [XR_009200]
PREDICTED: Rattus norvegicus similar to zinc finger protein 296
(LOC365511), mRNA [XM_345065]
Quaking protein. [Source:Uniprot/SWISSPROT;Acc:Q91XU1]
[ENSRNOT00000023304]
PREDICTED: Rattus norvegicus similar to 60S ribosomal protein L7a
(LOC499778), mRNA [XR_006491]
Rattus norvegicus similar to RIKEN cDNA 2900010J23, mRNA
(cDNA clone MGC:105672 IMAGE:7304460), complete cds.
[BC082799]
Rattus norvegicus hypothetical protein LOC499856 (LOC499856),
mRNA [NM_001025042]
PREDICTED: Rattus norvegicus similar to voltage-dependent anion
channel 1 (LOC679923), mRNA [XM_001054981]
PREDICTED: Rattus norvegicus hypothetical protein LOC680319
(LOC680319), mRNA [XM_001056630]
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Muscleblind-like protein BLES04 (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q8CIQ0] [ENSRNOT00000014315]
PREDICTED: Rattus norvegicus similar to Smad ubiquitination
regulatory factor 1 isoform 2 (LOC690516), mRNA [XM_001074660]
Amine oxidase [flavin-containing] A (EC 1.4.3.4) (Monoamine oxidase
type A) (MAO-A). [Source:Uniprot/SWISSPROT;Acc:P21396]
[ENSRNOT00000003910]
Rattus norvegicus mitogen-activated protein kinase 12 (Mapk12),
mRNA [NM_021746]
Rattus norvegicus p38 mitogen activated protein kinase mRNA,
complete cds. [U73142]
PREDICTED: Rattus norvegicus methyl-CpG binding domain protein 3
(predicted) (Mbd3_predicted), mRNA [XM_343162]
Rattus norvegicus similar to 1110007F12Rik protein (MGC109491),
mRNA [NM_001009709]
Rattus norvegicus similar to RIKEN cDNA 1700001E04
(MGC116197), mRNA [NM_001025755]
Rattus norvegicus similar to hypothetical protein MGC35097
(MGC94736), mRNA [NM_001007685]
RVL633 Wackym-Soares normalized rat vestibular cDNA library
Rattus norvegicus cDNA 5', mRNA sequence [CX569607]
Rattus norvegicus mitochondrial carrier homolog 1 (C. elegans), mRNA
(cDNA clone IMAGE:7377090), partial cds. [BC098813]
Rattus norvegicus major vault protein (Mvp), mRNA [NM_022715]
Rattus norvegicus myeloid differentiation primary response gene 116
(Myd116), mRNA [NM_133546]
Putative myosin IIC (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q9EPH4] [ENSRNOT00000027132]
PREDICTED: Rattus norvegicus non-catalytic region of tyrosine kinase
adaptor protein 1 (predicted) (Nck1_predicted), mRNA [XM_217246]
Rattus norvegicus nucleolin (Ncl), mRNA [NM_012749]
Rattus norvegicus neuraminidase 1 (Neu1), mRNA [NM_031522]
Rattus norvegicus natriuretic peptide precursor type B (Nppb), mRNA
[NM_031545]
Rattus norvegicus neurexin 1 (Nrxn1), mRNA [NM_021767]
Rattus norvegicus O-linked N-acetylglucosamine (GlcNAc) transferase
(UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase) (Ogt), mRNA [NM_017107]
Rattus norvegicus olfactory receptor 1273 (predicted)
(Olr1273_predicted), mRNA [NM_001000458]
Rattus norvegicus olfactory receptor 1583 (predicted)
(Olr1583_predicted), mRNA [NM_001000080]
Rattus norvegicus olfactory receptor 3 (predicted) (Olr3_predicted),
mRNA [NM_001000110]
Rattus norvegicus olfactory receptor 53 (predicted) (Olr53_predicted),
mRNA [NM_001001008]
Rattus norvegicus olfactory receptor 778 (predicted)
(Olr778_predicted), mRNA [NM_001000607]
Rattus norvegicus osteoclast stimulating factor 1 (Ostf1), mRNA
[NM_148892]
PREDICTED: Rattus norvegicus oxidoreductase NAD-binding domain
containing 1 (predicted) (Oxnad1_predicted), mRNA [XM_224623]
Pabpc4 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q5I0G7]
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[ENSRNOT00000056592]
Rattus norvegicus Paf1, RNA polymerase II associated factor, homolog
(S. cerevisiae) (Paf1), mRNA [NM_001024898]
Rattus norvegicus PDZ binding kinase (predicted) (Pbk_predicted),
mRNA [NM_001079937]
Rattus norvegicus pre-B-cell leukemia transcription factor interacting
protein 1, mRNA (cDNA clone IMAGE:7097507) [BC085776]
Rattus norvegicus poly(rC) binding protein 2 (Pcbp2), mRNA
[NM_001013223]
Rattus norvegicus poly(rC) binding protein 3 (Pcbp3), mRNA
[NM_001011945]
Rattus norvegicus polycomb group ring finger 1 (Pcgf1), mRNA
[NM_001007000]
PDZ domain-containing RING finger protein 3 (Semaphorin
cytoplasmic domain-associated protein 3) (Protein SEMACAP3).
[Source:Uniprot/SWISSPROT;Acc:P68907] [ENSRNOT00000008032]
Rattus norvegicus peroxisomal biogenesis factor 14 (Pex14), mRNA
[NM_172063]
Rattus norvegicus phosphatidylinositol 3-kinase, regulatory subunit,
polypeptide 2 (Pik3r2), mRNA [NM_022185]
Rattus norvegicus plasminogen activator, tissue (Plat), mRNA
[NM_013151]
Rattus norvegicus pleckstrin homology domain-containing, family A
(phosphoinositide binding specific) member 3 (Plekha3), mRNA
[NM_001013077]
PREDICTED: Rattus norvegicus patatin-like phospholipase domain
containing 2 (predicted) (Pnpla2_predicted), mRNA [XM_341960]
PREDICTED: Rattus norvegicus processing of precursor 7,
ribonuclease P family, (S. cerevisiae) (predicted) (Pop7_predicted),
mRNA [XM_213733]
Rattus norvegicus P450 (cytochrome) oxidoreductase (Por), mRNA
[NM_031576]
PREDICTED: Rattus norvegicus periostin, osteoblast specific factor
(predicted) (Postn_predicted), mRNA [XM_342245]
POU domain, class 2, transcription factor 3 (Octamer-binding
transcription factor 11) (Oct-11) (Transcription factor Skn-1).
[Source:Uniprot/SWISSPROT;Acc:P42571] [ENSRNOT00000012170]
Rattus norvegicus peroxisome proliferative activated receptor, gamma,
coactivator 1 beta (Ppargc1b), mRNA [NM_176075]
PREDICTED: Rattus norvegicus protein tyrosine phosphatase, receptor
type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4
(Ppfia4), mRNA [XM_573454]
Rattus norvegicus protein phosphatase 1, regulatory subunit 9B
(Ppp1r9b), mRNA [NM_053474]
Rattus norvegicus protein kinase, AMP-activated, alpha 2 catalytic
subunit (Prkaa2), mRNA [NM_023991]
PREDICTED: Rattus norvegicus PRP38 pre-mRNA processing factor
38 (yeast) domain containing A (predicted) (Prpf38a_predicted), mRNA
[XM_216475]
Rattus norvegicus protease, serine, 15 (Prss15), mRNA [NM_133404]
Rattus norvegicus prosaposin (Psap), mRNA [NM_013013]
Rattus norvegicus proteasome (prosome, macropain) activator subunit 4,
mRNA (cDNA clone IMAGE:7128175), complete cds. [BC090326]
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RATRAB15X Sprague-Dawley (clone LRB9) RAB15 mRNA,
complete cds [M83679]
PREDICTED: Rattus norvegicus Rab6 interacting protein 1 (predicted)
(Rab6ip1_predicted), mRNA [XM_219270]
Rattus norvegicus RAD23b homolog (S. cerevisiae) (Rad23b), mRNA
[NM_001025275]
Rattus norvegicus hnRNP-associated with lethal yellow (Raly), mRNA
[NM_001011958]
PREDICTED: Rattus norvegicus RAS-like, family 10, member B
(predicted) (Rasl10b_predicted), mRNA [XM_220782]
PREDICTED: Rattus norvegicus RCSD domain containing 1
(predicted) (Rcsd1_predicted), mRNA [XM_341147]
Rattus norvegicus hypothetical LOC316091 (RGD1304827), mRNA
[NM_001009437]
PREDICTED: Rattus norvegicus similar to C11orf17 protein (predicted)
(RGD1306959_predicted), mRNA [XM_341902]
PREDICTED: Rattus norvegicus similar to SR rich protein
(RGD1307395), mRNA [XM_001060221]
Rattus norvegicus similar to RIKEN cDNA 2310005P05
(RGD1307401), mRNA [NM_001014088]
RGD1307772 protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q4FZU8] [ENSRNOT00000023710]
PREDICTED: Rattus norvegicus similar to 2900002H16Rik protein
(predicted) (RGD1307973_predicted), mRNA [XM_222150]
PREDICTED: Rattus norvegicus similar to FKSG26 protein (predicted)
(RGD1309054_predicted), mRNA [XM_214707]
PREDICTED: Rattus norvegicus LOC363020 (predicted)
(RGD1309410_predicted), mRNA [XM_347094]
Rattus norvegicus similar to hypothetical protein MGC6696
(RGD1309471), mRNA [NM_001034829]
Rattus norvegicus similar to RIKEN cDNA 2310004I24 gene
(RGD1309906), mRNA [NM_001009246]
PREDICTED: Rattus norvegicus similar to TBC1 domain family,
member 8; BUB2-like protein 1; vascular Rab-GAP [XM_340793]
RGD1310470 protein (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q5BJL1] [ENSRNOT00000003001]
Rattus norvegicus similar to RIKEN cDNA 4931426K16 gene
(RGD1311267), mRNA [NM_001039024]
Rattus norvegicus similar to 1300014I06Rik protein (RGD1311307),
mRNA [NM_001025719]
PREDICTED: Rattus norvegicus similar to mKIAA1797 protein
(predicted) (RGD1311849_predicted), mRNA [XM_233144]
PREDICTED: Rattus norvegicus similar to AI115348 protein
(predicted) (RGD1311939_predicted), mRNA [XM_233838]
Unknown
PREDICTED: Rattus norvegicus similar to Keratin, type II cytoskeletal
8 (Cytokeratin 8) (Cytokeratin endo A) (predicted)
(RGD1561232_predicted), mRNA [XM_001070211]
PREDICTED: Rattus norvegicus similar to cDNA sequence BC022133
(predicted) (RGD1561296_predicted), mRNA [XM_575607]
PREDICTED: Rattus norvegicus similar to RIKEN cDNA 1700009P17
(predicted) (RGD1562658_predicted), mRNA [XM_573504]
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PREDICTED: Rattus norvegicus similar to 60S ribosomal protein L23a
(predicted) (RGD1562755_predicted), mRNA [XM_223453]
Rattus norvegicus similar to tripartite motif protein 50 (predicted)
(RGD1562778_predicted), mRNA [NM_001077675]
PREDICTED: Rattus norvegicus similar to Heat shock protein HSP 90beta (HSP 84) (predicted) (RGD1562936_predicted), mRNA
[XR_007989]
PREDICTED: Rattus norvegicus similar to OTU domain containing 1
(predicted) (RGD1563344_predicted), mRNA [XM_574086]
PREDICTED: Rattus norvegicus similar to 60 kDa heat shock protein,
mitochondrial precursor (Hsp60) (predicted) (RGD1563524_predicted),
mRNA [XM_229115]
PREDICTED: Rattus norvegicus similar to ankyrin repeat domain 25
(predicted) (RGD1563532_predicted), mRNA [XM_001077488]
Rattus norvegicus similar to 8430411H09Rik protein (LOC300146),
mRNA [XM_217014]
PREDICTED: Rattus norvegicus similar to Nonspecific lipid-transfer
protein, mitochondrial precursor (NSL-TP) (predicted)
(RGD1564981_predicted), mRNA [XR_008599]
PREDICTED: Rattus norvegicus similar to calmodulin regulated
spectrin-associated protein 1 (predicted) (RGD1565022_predicted),
mRNA [XM_216007]
PREDICTED: Rattus norvegicus similar to Shb protein (predicted)
(RGD1565350_predicted), mRNA [XR_008772]
BG673264 DRNBRC09 Rat DRG Library Rattus norvegicus cDNA
clone DRNBRC09 5', mRNA sequence [BG673264]
PREDICTED: Rattus norvegicus similar to PLU1 (predicted)
(RGD1565602_predicted), mRNA [XM_239761]
PREDICTED: Rattus norvegicus similar to Factor VIII associated
protein (predicted) (RGD1566014_predicted), mRNA [XM_577058]
Rattus norvegicus ribonuclease H1 (Rnaseh1), mRNA
[NM_001013097]
Rattus norvegicus Rho family GTPase 1 (Rnd1), mRNA
[NM_001013222]
PREDICTED: Rattus norvegicus ring finger protein 3 (predicted)
(Rnf3_predicted), mRNA [XM_223729]
PREDICTED: Rattus norvegicus replication protein A3 (predicted)
(Rpa3_predicted), mRNA [XM_216097]
Rattus norvegicus ribosomal protein L4 (Rpl4), mRNA [NM_022510]
UI-R-FS0-cqo-a-09-0-UI.s1 UI-R-FS0 Rattus norvegicus cDNA clone
UI-R-FS0-cqo-a-09-0-UI 3', mRNA sequence [CA508544]
Rattus norvegicus Ras-related associated with diabetes (Rrad), mRNA
[NM_053338]
Rattus norvegicus restin (Reed-Steinberg cell-expressed intermediate
filament-associated protein) (Rsn), mRNA [NM_031745]
Rattus norvegicus RT1 class Ia, locus A2 (RT1-A2), mRNA
[NM_001008829]
Rattus norvegicus RT1 class I, CE1 (RT1-CE1), mRNA
[NM_001008832]
Rattus norvegicus RT1 class I, CE16 (RT1-CE16), mRNA
[NM_001008839]
Rattus norvegicus RT1 class I, CE2 (RT1-CE2), mRNA
[NM_001008840]

262

1

RT1-CE3

1

RT1-CE4

1

RT1-CE7

1

RT1-Cl

1

RT1-Db1

1

S63519

1

Scly

1

Serbp1

1

Serping1

1

Sfrs14_predicted

1

Sgcg

1

Slc12a7

1

Slc25a5

1

Spag7_predicted

1

Spg7

1
1

Spink5_predicted
Spsb4_predicted

1

Srp68_predicted

1

Stat3

1
1
1
1
1

Taf9
Tagln2
TC583295
TC584984
TC587305

1
1

TC588650
TC590435

1

TC595486

1
1

TC598739
TC599269

Rattus norvegicus RT1 class I, CE3 (RT1-CE3), mRNA
[NM_001008841]
Rattus norvegicus RT1 class I, CE4 (RT1-CE4), mRNA
[NM_001008842]
Rattus norvegicus RT1 class I, CE7 (RT1-CE7), mRNA
[NM_001008845]
Rattus norvegicus RT1 class Ib, locus Cl (RT1-Cl), mRNA
[NM_206848]
Rattus norvegicus RT1 class II, locus Db1 (RT1-Db1), mRNA
[NM_001008884]
S63519 Rattus sp. membrane protein-73 mRNA, partial cds;
mitochondrial gene for mitochondrial product [S63519]
Rattus norvegicus selenocysteine lyase (Scly), mRNA
[NM_001007755]
Rattus norvegicus Serpine1 mRNA binding protein 1 (Serbp1), mRNA
[NM_145086]
Rattus norvegicus serine (or cysteine) peptidase inhibitor, clade G,
member 1 (Serping1), mRNA [NM_199093]
Rattus norvegicus similar to arginine/serine-rich 14 splicing factor
(LOC361126), mRNA [XM_341413]
Rattus norvegicus sarcoglycan, gamma (dystrophin-associated
glycoprotein) (Sgcg), mRNA [NM_001006993]
PREDICTED: Rattus norvegicus solute carrier family 12 (potassium
[XM_001071999]
Rattus norvegicus solute carrier family 25 (mitochondrial carrier;
adenine nucleotide translocator), member 5 (Slc25a5), mRNA
[NM_057102]
PREDICTED: Rattus norvegicus sperm associated antigen 7 (predicted)
(Spag7_predicted), mRNA [XM_220574]
Rattus norvegicus spastic paraplegia 7 homolog (human) (Spg7),
mRNA [NM_181388]
PREDICTED: Rattus norvegicus serine protease inhibitor, Kazal type 5
(predicted) (Spink5_predicted), mRNA [XM_001056195]
PREDICTED: Rattus norvegicus splA [XM_236555]
Rattus norvegicus similar to signal recognition particle 68kDa
(LOC363707), mRNA [XM_343986]
Rattus norvegicus signal transducer and activator of transcription 3
(Stat3), mRNA [NM_012747]
Rattus norvegicus TAF9 RNA polymerase II, TATA box binding
protein (TBP)-associated factor (Taf9), transcript variant 2, mRNA
[NM_184048]
Rattus norvegicus transgelin 2 (Tagln2), mRNA [NM_001013127]
Unknown
Unknown
Unknown
Q3UE36_MOUSE (Q3UE36) Bone marrow macrophage cDNA,
RIKEN full-length enriched library, clone:G530015L18
product:TFIIIC2 subunit homolog, partial (3%) [TC588650]
Unknown
Q2KZQ6_BORA1 (Q2KZQ6) Mannose-6-phosphate isomerase ,
partial (6%) [TC595486]
Q8LP76_9SOLN (Q8LP76) HT-A protein (Fragment), partial (17%)
[TC598739]
Unknown
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1
1
1
1

TC599311
TC601277
TC601898
TC602662

1
1
1
1
1
1

TC603711
TC606685
TC607876
TC610053
TC611036
TC611785

1

TC613062

1

TC616203

1
1
1
1
1

TC634117
TC635003
TC637917
TC641622
TC642107

1

TC647139

1

Tcp11

1

Tex264

1

Tex9_predicted

1
1

Tgfb1i4
Thoc1

1

Thrap5_predicted

2

Tmed9

1

Tmem110

1

Tmf1

1

Tollip_predicted

1

Trak2

1

Trhde

1
1

Trim63
Ttr

Unknown
Unknown
Q7TQ12_RAT (Q7TQ12) Aa1114, partial (9%) [TC601898]
Unknown
Q9DEY1_CYPCA (Q9DEY1) Ovarian fibroin-like substance-1, partial
(5%) [TC603711]
Unknown
Unknown
Unknown
Unknown
Unknown
Q6PED9_MOUSE (Q6PED9) Rai16 protein (Fragment), partial (63%)
[TC613062]
Q33PR9_9GAMM (Q33PR9) Adenylyl cyclase CyaB, partial (10%)
[TC616203]
Q5NA53_ORYSA (Q5NA53) Glycogenin-like protein, partial (3%)
[TC634117]
Unknown
Q5SSP7_MOUSE (Q5SSP7) T-box 2, partial (8%) [TC637917]
Unknown
Q81D10_BACCR (Q81D10) Phage protein, partial (21%) [TC642107]
Q3C866_9CLOT (Q3C866) Helicase, C-terminal:DEAD/DEAH box
helicase, N-terminal, partial (4%) [TC647139]
Rattus norvegicus t-complex protein 11 (mouse) (Tcp11), mRNA
[NM_001007695]
Rattus norvegicus testis expressed gene 264 homolog (mouse)
(Tex264), mRNA [NM_001007665]
PREDICTED: Rattus norvegicus testis expressed gene 9 (predicted)
(Tex9_predicted), mRNA [XM_001054229]
Rattus norvegicus transforming growth factor beta 1 induced transcript
4, mRNA (cDNA clone IMAGE:6918096), complete cds. [BC059146]
Rattus norvegicus THO complex 1 (Thoc1), mRNA [NM_001047850]
PREDICTED: Rattus norvegicus thyroid hormone receptor associated
protein 5 (predicted) (Thrap5_predicted), mRNA [XM_216837]
Rattus norvegicus transmembrane emp24 protein transport domain
containing 9 (Tmed9), mRNA [NM_001009703]
Rattus norvegicus transmembrane protein 110 (Tmem110), mRNA
[NM_198774]
Rattus norvegicus TATA element modulatory factor 1 (Tmf1), mRNA
[NM_053671]
PREDICTED: Rattus norvegicus toll interacting protein (predicted)
(Tollip_predicted), mRNA [XM_341961]
Rattus norvegicus trafficking protein, kinesin binding 2 (Trak2), mRNA
[NM_133560]
Thyrotropin-releasing hormone-degrading ectoenzyme (EC 3.4.19.6)
(TRH- degrading ectoenzyme) (TRH-DE) (TRH-specific
aminopeptidase) (Thyroliberinase) (Pyroglutamyl-peptidase II) (PAPII). [Source:Uniprot/SWISSPROT;Acc:Q10836]
[ENSRNOT00000007461]
Rattus norvegicus tripartite motif protein 63 (Trim63), mRNA
[NM_080903]
Rattus norvegicus transthyretin (Ttr), mRNA [NM_012681]
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1
1
1
1

Tuba6
Tubb2b
Tubb2c
Tubb5

1

Ube2e2

2

Ube2q_predicted

5

Ucp2

1
1
1

Unc45b_predicted
Vil2
Vim

1

Wdr27_predicted

1

XM_215841

1

XM_222132

1

XM_229703

1

XM_230279

1

XM_230768

1

XM_236784

1

XM_340847

1

XM_342024

1

XM_343598

1

XM_345660

1

Zbtb17

1

Zdhhc2

Rattus norvegicus tubulin, alpha 6 (Tuba6), mRNA [NM_001011995]
Rattus norvegicus tubulin, beta 2b (Tubb2b), mRNA [NM_001013886]
Rattus norvegicus tubulin, beta 2c (Tubb2c), mRNA [NM_199094]
Rattus norvegicus tubulin, beta 5 (Tubb5), mRNA [NM_173102]
PREDICTED: Rattus norvegicus ubiquitin-conjugating enzyme E2E 2
(UBC4 [XM_341288]
PREDICTED: Rattus norvegicus ubiquitin-conjugating enzyme E2Q
(putative) (predicted) (Ube2q_predicted), mRNA [XM_215612]
Rattus norvegicus uncoupling protein 2 (mitochondrial, proton carrier)
(Ucp2), mRNA [NM_019354]
PREDICTED: Rattus norvegicus unc-45 homolog B (C. elegans)
(predicted) (Unc45b_predicted), mRNA [XM_220771]
Rattus norvegicus villin 2 (Vil2), mRNA [NM_019357]
Rattus norvegicus vimentin (Vim), mRNA [NM_031140]
PREDICTED: Rattus norvegicus WD repeat domain 27 (predicted)
(Wdr27_predicted), mRNA [XM_001055617]
Rattus norvegicus similar to hypothetical protein FLJ32800
(LOC296118), mRNA [XM_215841]
Rattus norvegicus similar to Spindlin-like protein 2 (SPIN-2)
(LOC288640), mRNA [XM_222132]
Rattus norvegicus similar to cDNA sequence BC003993 (LOC317034),
mRNA [XM_229703]
Rattus norvegicus similar to protein kinase C and casein kinase substrate
in neurons 3 (LOC311187), mRNA [XM_230279]
Rattus norvegicus similar to 60S ribosomal protein L7a (Surfeit locus
protein 3) (PLA-X polypeptide) (LOC311565), mRNA [XM_230768]
Rattus norvegicus similar to sex-determination protein homolog Fem1a
(LOC316131), mRNA [XM_236784]
Rattus norvegicus similar to myosin containing PDZ domain
(LOC360570), mRNA [XM_340847]
Rattus norvegicus similar to DNA damage binding protein 1 (Damagespecific DNA binding protein 1) (DDB p127 subunit) (DDBa) (UVdamaged DNA-binding protein 1) (UV-DDB 1) (Xeroderma
pigmentosum group E complementing protein) (XPCe) (X-associated...
Rattus norvegicus similar to titin isoform N2-A; connectin; CMH9,
included; cardiomyopathy, dilated 1G (autosomal dominant)
(LOC363258), mRNA [XM_343598]
Rattus norvegicus similar to RIKEN cDNA 1100001I23 (LOC366602),
mRNA [XM_345660]
Rattus norvegicus zinc finger and BTB domain containing 17 (Zbtb17),
mRNA [NM_001012105]
Rattus norvegicus zinc finger, DHHC domain containing 2 (Zdhhc2),
mRNA [NM_145096]
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Appendix B: Genes selected as significant by class comparison analysis

Parametric
p-value

Geom mean
of ratios in
class 1 :
Failure

1.00E-07
3.00E-07
4.00E-07
5.00E-07
5.00E-07
6.00E-07
7.00E-07
7.00E-07
1.10E-06
1.10E-06
1.10E-06
1.20E-06
1.40E-06
1.70E-06
2.30E-06
3.00E-06
3.30E-06
3.30E-06
3.70E-06
4.70E-06
4.70E-06
5.30E-06
5.70E-06
6.20E-06
7.20E-06
7.70E-06
7.90E-06
9.40E-06
9.70E-06
1.01E-05
1.02E-05
1.02E-05
1.03E-05
1.08E-05
1.09E-05
1.18E-05
1.18E-05
1.23E-05
1.24E-05
1.34E-05
1.37E-05
1.52E-05

0.648
1.108
0.545
0.744
0.636
1.372
0.629
0.597
0.893
2.174
1.098
0.59
0.296
1.11
0.587
0.595
0.344
2.135
0.85
0.71
0.675
0.84
0.958
0.937
0.748
0.578
0.383
0.927
0.617
24.293
2.828
1.829
1.059
1.211
0.938
0.06
0.946
1.507
0.171
0.11
0.92
0.258

Geom
mean of
ratios in
class 2 :
Unknown
0.367
0.594
0.298
1.278
0.383
0.888
0.333
0.363
1.819
5.398
2.404
0.355
0.117
2.063
0.351
0.35
0.631
0.973
0.515
0.4
1.019
0.415
0.518
1.78
0.304
0.361
1.049
1.72
0.39
101.384
9.214
4.532
0.565
0.773
1.708
0.218
1.812
2.463
0.82
0.63
1.763
0.139

Fold
difference
of geom
means
1.766
1.865
1.829
0.582
1.661
1.545
1.889
1.645
0.491
0.403
0.457
1.662
2.53
0.538
1.672
1.7
0.545
2.194
1.65
1.775
0.662
2.024
1.849
0.526
2.461
1.601
0.365
0.539
1.582
0.24
0.307
0.404
1.874
1.567
0.549
0.275
0.522
0.612
0.209
0.175
0.522
1.856
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Agilent ID

Gene Name

A_44_P490277
A_44_P998312
A_44_P234378
A_44_P250319
A_44_P232265
A_44_P196685
A_44_P222660
A_44_P447766
A_44_P992854
A_44_P210440
A_44_P929695
A_44_P351714
A_43_P14682
A_44_P131240
A_44_P342208
A_44_P203838
A_44_P860396
A_43_P10269
A_42_P496649
A_44_P651922
A_44_P348868
A_44_P511324
A_44_P1013385
A_44_P992854
A_43_P12806
A_44_P548455
A_44_P622201
A_44_P992854
A_42_P793008
A_44_P864923
A_44_P336664
A_44_P226208
A_42_P493785
A_44_P714524
A_44_P992854_2348
A_44_P594411
A_44_P992854
A_44_P1033739
A_44_P900646
A_44_P930730
A_44_P992854
A_44_P525250

ENSRNOT00000048403
NM_001037652
XR_006502
ENSRNOT00000031045
XM_346093
XM_341907
XM_226568
ENSRNOT00000050331
NM_057132
ENSRNOT00000014802
XM_228203
ENSRNOT00000043501
NM_022674
ENSRNOT00000050411
A_44_P342208
XM_225531
ENSRNOT00000047510
NM_001025712
DV727080
NM_017150
NM_019226
NM_053982
ENSRNOT00000022065
NM_057132
NM_053439
ENSRNOT00000032995
BC098778
NM_057132
NM_130432
AW916836
CF108444
AI170501
ENSRNOT00000001419
CX570178
NM_057132
CB804485
NM_057132
XM_573823
TC627022
TC585294
NM_057132
XM_227370

1.55E-05
1.56E-05
1.70E-05
1.74E-05
1.85E-05
1.89E-05
2.02E-05
2.20E-05
2.26E-05
2.28E-05
2.35E-05
2.36E-05
2.38E-05
2.43E-05
2.49E-05
2.59E-05
2.63E-05
2.65E-05
2.66E-05
3.07E-05
3.07E-05
3.10E-05
3.22E-05
3.26E-05
3.46E-05
3.59E-05
3.76E-05
3.81E-05
3.89E-05
4.14E-05
4.29E-05
4.41E-05
4.45E-05
4.46E-05
4.46E-05
4.58E-05
4.62E-05
4.92E-05
5.11E-05
5.18E-05
5.24E-05
5.61E-05
5.84E-05
5.87E-05
5.91E-05
5.96E-05
6.20E-05
6.29E-05

1.761
0.686
0.631
0.159
0.928
0.614
0.266
1.269
0.823
1.715
0.358
0.725
0.572
1.585
0.974
4.614
0.649
0.765
0.773
5.783
1.493
0.532
0.985
3.015
1.747
1.225
1.42
0.586
0.855
0.896
5.716
0.65
0.77
1.641
1.331
1.702
0.828
0.661
1.725
0.713
3.478
0.565
0.363
1.754
0.938
1.087
0.184
1.045

5.304
1.61
0.39
0.782
1.78
0.428
0.173
2.067
1.559
1.035
0.716
1.627
0.378
0.915
0.524
2.432
0.446
0.399
1.075
14.662
0.981
0.351
1.722
1.02
0.713
1.972
0.112
0.39
1.821
0.638
3.546
0.476
0.48
22.759
0.147
3.585
0.499
0.497
3.759
0.52
1.775
1.319
0.225
3.263
0.68
1.508
0.453
0.674

0.332
0.426
1.618
0.203
0.521
1.435
1.538
0.614
0.528
1.657
0.5
0.446
1.513
1.732
1.859
1.897
1.455
1.917
0.719
0.394
1.522
1.516
0.572
2.956
2.45
0.621
12.679
1.503
0.47
1.404
1.612
1.366
1.604
0.072
9.054
0.475
1.659
1.33
0.459
1.371
1.959
0.428
1.613
0.538
1.379
0.721
0.406
1.55
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A_43_P20704
A_44_P109998
A_44_P368365
A_44_P579214
A_44_P992854
A_44_P852623
A_44_P432965
A_44_P361380
A_43_P12215
A_44_P1042125
A_44_P142352
A_44_P868828
A_44_P302676
A_43_P10161
A_42_P632328
A_44_P387587
A_44_P391688
A_44_P360946
A_44_P446556
A_44_P550237
A_42_P547945
A_44_P215788
A_44_P992854
A_44_P118075
A_44_P214873
A_44_P288997
A_44_P264230
A_42_P728472
A_44_P165817
A_42_P709819
A_42_P793598
A_43_P14875
A_42_P777285
A_44_P435618_1878
A_44_P701240
A_44_P153979
A_44_P745027
A_43_P10034
A_44_P188729
A_43_P11181
A_42_P499282
A_44_P342075
A_44_P189065
A_44_P466111
A_44_P997815
A_44_P203421
A_44_P837560
A_44_P207907

ENSRNOT00000050411
XM_227287
XM_235395
TC633900
NM_057132
ENSRNOT00000060788
NM_031840
ENSRNOT00000038715
NM_022386
XM_001060585
ENSRNOT00000003707
TC628052
XM_221003
XM_213920
ENSRNOT00000003556
NM_022585
ENSRNOT00000034681
XR_008195
XM_342906
NM_017212
BC098813
NM_001005905
NM_057132
XM_575227
NM_024362
AW916759
XM_001062165
NM_001007600
NP798075
XM_001063185
NM_194354
NM_031324
AI013497
NM_017333
TC620596
NM_013164
XR_009438
NM_053928
ENSRNOT00000046108
XM_001077170
NM_001031660
ENSRNOT00000027314
ENSRNOT00000027123
AB012231
NM_001079698
U45479
TC583130
NM_022498

6.30E-05
6.30E-05
6.30E-05
6.44E-05
6.64E-05
6.80E-05
6.89E-05
6.92E-05
6.97E-05
7.07E-05
7.14E-05
7.30E-05
7.37E-05
7.43E-05
7.49E-05
7.71E-05
7.80E-05
7.83E-05
8.00E-05
8.67E-05
8.72E-05
8.75E-05
8.79E-05
9.06E-05
9.30E-05
9.37E-05
9.66E-05
9.70E-05
9.87E-05
9.93E-05
9.93E-05
9.94E-05
0.0001072
0.0001092
0.0001105
0.000112
0.0001123
0.0001133
0.0001135
0.0001136
0.0001146
0.0001147
0.0001157
0.0001168
0.0001195
0.0001215
0.0001224
0.0001245

0.522
0.337
0.484
0.508
1.887
1.28
0.523
1.178
0.653
1.148
0.538
0.453
0.543
0.499
1.092
0.771
0.562
0.938
0.277
0.856
0.097
0.728
0.334
0.425
1.648
0.556
0.759
0.64
0.95
1.22
1.993
0.668
0.497
0.25
0.508
0.656
1.57
0.388
3.389
0.975
0.979
1.178
0.682
0.505
0.601
0.223
0.17
1.379

0.355
0.561
0.333
0.31
0.867
3.862
0.696
0.77
0.322
0.82
1.185
0.299
0.317
0.723
0.816
1.227
0.369
2.439
0.086
1.937
0.059
0.544
0.922
0.307
0.983
0.343
0.607
0.441
0.552
2.358
2.741
0.456
1.359
0.906
0.345
0.471
0.984
0.25
6.42
1.901
1.792
0.834
0.319
0.35
0.408
0.93
0.633
0.967

1.47
0.601
1.453
1.639
2.176
0.331
0.751
1.53
2.028
1.4
0.454
1.515
1.713
0.69
1.338
0.628
1.523
0.385
3.221
0.442
1.644
1.338
0.362
1.384
1.677
1.621
1.25
1.451
1.721
0.517
0.727
1.465
0.366
0.276
1.472
1.393
1.596
1.552
0.528
0.513
0.546
1.412
2.138
1.443
1.473
0.24
0.269
1.426
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A_44_P290905
A_44_P340977
A_44_P698581
A_44_P199482
A_43_P16650
A_43_P12612
A_44_P1059422
A_44_P606810
A_44_P304752
A_44_P329688
A_43_P11613
A_44_P192364
A_42_P780097
A_44_P553980
A_44_P193221
A_44_P482595
A_42_P487031
A_44_P745617
A_42_P751720
A_44_P400591
A_43_P16774
A_42_P839036
A_44_P853879
A_44_P271643
A_44_P343303
A_44_P867677
A_43_P10477
A_44_P482749
A_44_P1054708
A_44_P834734
A_44_P853685
A_44_P339867
A_44_P434859
A_44_P158079
A_44_P523261
A_44_P389243
A_43_P12047
A_44_P1002452
A_42_P799113
A_44_P363090
A_44_P992854
A_42_P512252
A_42_P674598
A_44_P361504
A_42_P596503
A_44_P1018098
A_44_P449108
A_44_P325376

ENSRNOT00000049230
ENSRNOT00000047510
A_44_P698581
XR_005657
XM_214107
Y12259
NM_001009268
TC593084
XR_008958
XM_240915
NM_012903
ENSRNOT00000057412
NM_001008280
ENSRNOT00000047510
CK471009
NM_053796
NM_001009539
TC603676
XR_009563
A_44_P400591
NM_001006995
ENSRNOT00000013359
TC624399
NM_053970
NM_019367
XR_005504
CF108377
XR_008366
NM_001009538
AB026259
TC589959
NM_017199
BC090353
BI395434
ENSRNOT00000049805
ENSRNOT00000000433
NM_019380
NM_001009271
NM_139104
NM_001008725
NM_057132
NM_201421
NM_013067
ENSRNOT00000036109
NM_053334
ENSRNOT00000019724
AI043579
XM_574706

0.0001265
0.0001267
0.0001273
0.0001292
0.0001293
0.00013
0.000131
0.0001314
0.0001331
0.0001364
0.0001369
0.0001378
0.0001378
0.0001384
0.0001386
0.0001404
0.0001434
0.0001444
0.0001445
0.0001446
0.0001461
0.0001487
0.00015
0.0001504
0.0001515
0.0001528
0.0001537
0.0001545
0.0001564
0.0001565
0.0001573
0.0001594
0.0001647
0.0001653
0.0001655
0.0001674
0.0001682
0.0001685
0.0001701
0.0001703
0.0001708
0.0001709
0.0001718
0.0001723
0.0001727
0.0001739
0.0001765
0.0001765

0.651
3.05
0.732
0.659
1.729
3.517
1.014
0.592
1.498
0.577
0.286
1.616
0.966
1.38
1.122
1.302
1.186
0.06
1.093
0.769
2.655
0.661
0.519
0.8
0.673
0.848
5.155
1.18
0.339
0.535
0.474
2.009
0.453
1.04
1.678
2.593
2.156
0.667
1.918
0.621
1.326
0.754
0.721
79.722
6.952
0.922
0.138
0.912

0.939
7.281
0.408
0.41
0.534
1.958
0.544
0.39
2.948
1.342
0.659
6.76
1.964
2.301
2.241
10.509
0.786
0.026
0.806
0.392
1.521
0.44
0.331
0.527
1.313
0.479
1.245
0.638
0.141
1.129
0.879
1.049
0.305
2.104
0.851
3.827
1.4
0.292
0.856
0.436
0.949
1.847
0.415
9.691
1.625
1.539
0.558
0.618

0.693
0.419
1.794
1.607
3.238
1.796
1.864
1.518
0.508
0.43
0.434
0.239
0.492
0.6
0.501
0.124
1.509
2.308
1.356
1.962
1.746
1.502
1.568
1.518
0.513
1.77
4.141
1.85
2.404
0.474
0.539
1.915
1.485
0.494
1.972
0.678
1.54
2.284
2.241
1.424
1.397
0.408
1.737
8.226
4.278
0.599
0.247
1.476
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A_44_P1059334
A_44_P278113
A_44_P959692
A_42_P827124
A_44_P125226
A_44_P667648
A_44_P728932
A_44_P301863
A_44_P337606
A_44_P820184
A_44_P187830
A_44_P254016
A_44_P992854
A_44_P436528
A_44_P261450
A_42_P631453
A_44_P427523
A_44_P400494
A_43_P12732
A_44_P450149
A_42_P660068
A_43_P17696
A_44_P536545
A_42_P552233
A_43_P22613
A_42_P675659
A_44_P921710
A_43_P10614
A_44_P786208
A_44_P196933
A_44_P442733
A_44_P329357
A_44_P182913
A_44_P154245
A_43_P13146
A_44_P876215
A_43_P12438
A_44_P483888
A_44_P583151
A_44_P222865
A_43_P16523
A_44_P1059789
A_44_P185138
A_42_P669388
A_43_P15602
A_44_P264988
A_44_P900178
A_44_P1051965

NM_133398
ENSRNOT00000043693
XM_001066878
ENSRNOT00000007351
AW532988
ENSRNOT00000010055
ENSRNOT00000028742
ENSRNOT00000007403
ENSRNOT00000016804
AI030973
ENSRNOT00000002851
NM_016992
NM_057132
ENSRNOT00000014310
ENSRNOT00000009894
XM_216941
NM_057140
NM_053976
NM_033097
ENSRNOT00000042609
NM_031350
NM_001004257
XM_001055461
XM_213765
ENSRNOT00000018266
NM_001004276
A_44_P921710
TC600099
CF111551
NM_001014031
NM_022386
NM_017112
XR_008450
ENSRNOT00000003146
NM_131907
CF109454
NM_024387
XM_001060262
A_44_P583151
ENSRNOT00000005711
XM_341861
ENSRNOT00000010118
A_44_P185138
NM_001039011
NM_134391
ENSRNOT00000016784
TC584409
NM_053877

0.0001815
0.0001816
0.0001828
0.0001831
0.0001843
0.0001867
0.0001884
0.0001884
0.0001902
0.0001914
0.0001925
0.0001928
0.000193
0.0001952
0.0002013
0.0002062
0.0002067
0.0002067
0.0002096
0.0002105
0.0002112
0.0002143
0.0002161
0.0002176
0.0002187
0.0002198
0.0002214
0.0002236
0.0002255
0.0002268
0.0002277
0.000232
0.0002321
0.0002328
0.0002348
0.0002359
0.0002366
0.0002384
0.0002443
0.0002464
0.0002469
0.0002472
0.0002482
0.0002483
0.0002486
0.00025
0.0002505
0.0002521

2.15
0.904
2.017
1.209
0.162
0.624
0.147
0.87
2.419
3.919
2.125
1.157
3.994
0.409
1.53
0.143
2.292
0.504
0.502
0.708
2.561
0.19
0.584
3.499
0.345
0.412
1
5.698
0.147
0.507
11.947
3.682
0.506
0.246
0.619
1.098
0.976
1.809
2.253
5.152
0.506
0.631
0.187
0.787
0.985
0.286
0.486
0.955

4.277
1.848
3.39
0.791
0.082
0.356
0.945
1.917
1.013
8.831
6.128
2.057
8.596
0.273
0.82
0.553
1.435
0.345
0.369
0.488
5.391
0.938
0.446
6.148
2.9
0.313
1.42
3.824
0.818
0.34
19.659
2.729
0.854
0.43
0.409
0.215
1.851
1.245
5.507
18.322
0.289
0.43
0.547
0.504
0.654
0.172
0.305
1.426

0.503
0.489
0.595
1.528
1.976
1.753
0.156
0.454
2.388
0.444
0.347
0.562
0.465
1.498
1.866
0.259
1.597
1.461
1.36
1.451
0.475
0.203
1.309
0.569
0.119
1.316
0.704
1.49
0.18
1.491
0.608
1.349
0.593
0.572
1.513
5.107
0.527
1.453
0.409
0.281
1.751
1.467
0.342
1.562
1.506
1.663
1.593
0.67
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A_44_P466108
A_44_P551919
A_44_P536282
A_43_P10634
A_44_P236187
A_42_P604121
A_44_P590051
A_44_P884555
A_44_P975513
A_44_P1043059
A_44_P463064
A_44_P1044499
A_44_P685899
A_44_P226029
A_44_P704874
A_44_P824467
A_42_P563553
A_44_P432139
A_44_P473449
A_43_P15307
A_44_P792220
A_44_P251787
A_44_P222865
A_44_P668313
A_44_P901264
A_44_P337088
A_42_P642507
A_43_P10709
A_44_P959890
A_44_P232113
A_44_P333010
A_44_P561113
A_44_P245665
A_44_P532389
A_44_P100996
A_44_P913155
A_44_P261874
A_44_P138347
A_44_P463071
A_44_P177704
A_42_P644278
A_44_P283941
A_43_P19515
A_42_P506402
A_44_P132470
A_44_P928928
A_44_P537303
A_44_P238257

AB012231
ENSRNOT00000057681
NM_001013130
NM_001025123
NM_022582
NM_001012144
AW917697
BE113337
TC588827
NM_001013130
ENSRNOT00000043693
ENSRNOT00000006333
TC601880
ENSRNOT00000016184
AA963844
TC599815
XM_001081219
NM_031099
XM_227913
NM_030859
TC590891
AW142969
ENSRNOT00000005711
ENSRNOT00000017233
TC607281
NM_133609
ENSRNOT00000037829
XM_215728
AABR03000060
A_44_P232113
ENSRNOT00000014193
TC615156
NM_053311
CF110666
NM_017150
AW915016
NM_175761
NM_001034958
ENSRNOT00000043693
AF370889
NM_001037349
NM_001009600
NM_001014207
NM_145677
NM_022511
ENSRNOT00000044499
NM_022510
NM_053920

0.0002547
0.0002628
0.0002628
0.0002634
0.000264
0.0002649
0.0002671
0.0002683
0.0002704
0.0002726
0.000273
0.0002735
0.0002739
0.0002755
0.0002793
0.0002822
0.0002859
0.0002863
0.0002899
0.0002909
0.0002968
0.0002974
0.0003003
0.0003037
0.0003084
0.0003151
0.0003151
0.000317
0.00032
0.0003219
0.0003236
0.0003237
0.0003257
0.0003319
0.0003362
0.0003365
0.0003413
0.000342
0.000346
0.0003462
0.0003479
0.0003516
0.0003551
0.0003557
0.0003559
0.0003598
0.0003698
0.0003701

0.709
0.178
0.935
0.198
1.182
0.787
0.954
1.508
0.232
0.966
2.021
0.244
0.456
0.657
1.032
1.115
10.514
1.527
6.676
36.413
1.585
0.558
0.585
0.184
0.738
0.934
2.559
0.621
0.637
0.792
0.618
2.451
0.638
0.716
0.149
0.488
0.941
1.123
0.944
1.128
0.228
0.663
3.825
1.527
0.496
0.733
3.122
0.684

0.999
0.824
1.239
0.733
2.933
0.565
0.599
1.103
0.63
0.519
2.922
0.659
1.464
0.468
1.751
0.882
34.313
0.974
12.342
141.416
0.897
0.217
0.373
0.145
0.455
0.626
1.51
2.902
0.277
0.964
0.766
4.11
1.024
1.052
0.698
0.348
1.493
0.849
0.69
1.574
0.125
0.318
1.003
1.108
0.329
1.223
1.846
0.547

0.71
0.216
0.755
0.27
0.403
1.393
1.593
1.367
0.368
1.861
0.692
0.37
0.311
1.404
0.589
1.264
0.306
1.568
0.541
0.257
1.767
2.571
1.568
1.269
1.622
1.492
1.695
0.214
2.3
0.822
0.807
0.596
0.623
0.681
0.213
1.402
0.63
1.323
1.368
0.717
1.824
2.085
3.814
1.378
1.508
0.599
1.691
1.25
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A_44_P976320
A_44_P978172
A_42_P726994
A_44_P458987
A_43_P21507
A_44_P116172
A_44_P271416
A_44_P1033023
A_44_P670611
A_44_P248083
A_42_P516640
A_43_P11261
A_44_P1012333
A_44_P1003072
A_44_P416633
A_44_P213392
A_44_P320617
A_44_P1046705
A_43_P16895
A_42_P832832
A_44_P555042
A_44_P714409
A_44_P455065
A_44_P143567
A_43_P11682
A_44_P760650
A_44_P988460
A_44_P140378
A_44_P1042876
A_44_P396522
A_44_P227361
A_44_P790431
A_43_P11241
A_42_P760177
A_44_P420869
A_44_P203746
A_42_P548791
A_44_P291060
A_44_P991484
A_44_P741147
A_44_P531129
A_44_P319256
A_44_P219447
A_44_P1033023_781
A_44_P168184
A_44_P313431
A_44_P358361
A_42_P519910

TC593051
TC602645
XM_001072149
AY325145
ENSRNOT00000049300
ENSRNOT00000019107
NM_138708
NM_013063
TC632008
XM_221978
NM_019124
XM_234572
BC090353
NM_001025650
NM_175754
NM_057122
NM_019131
ENSRNOT00000025008
XM_224672
NM_012530
NM_001000169
NM_001047907
ENSRNOT00000045295
NM_031840
NM_013050
ENSRNOT00000024085
AW142021
ENSRNOT00000015232
NM_031971
NM_021840
ENSRNOT00000008741
ENSRNOT00000060252
ENSRNOT00000055970
XM_342906
BM391518
XM_344416
NM_021762
ENSRNOT00000015257
CA510796
AW917588
M12822
ENSRNOT00000056171
BM986234
NM_013063
AF507943
ENSRNOT00000009755
NM_001002821
ENSRNOT00000021017

0.0003711
0.0003724
0.0003761
0.0003781
0.0003797
0.0003873
0.0003898
0.0003921
0.0004022
0.0004052
0.000406
0.0004067
0.0004081
0.0004191
0.0004193
0.0004206
0.0004286
0.000432
0.0004337
0.0004367
0.0004393
0.0004399
0.0004401
0.0004435
0.0004462
0.000449
0.0004502
0.0004569
0.0004598
0.0004599
0.0004624
0.0004634
0.0004683
0.0004689
0.0004718
0.0004743
0.0004832
0.000487
0.000488
0.0004887
0.0004887
0.00049
0.0004909
0.0004926
0.0004966
0.0004978
0.0004985
0.000499

3.307
0.923
1.487
1.5
5.77
0.722
10.847
0.539
0.809
12.474
2.185
1.068
1.399
0.636
6.874
1.752
0.652
1.416
3.073
1.827
1.694
5.044
1.384
1.067
1.389
0.474
0.697
0.759
0.194
2.978
1.187
1.279
0.945
0.963
1.103
0.759
1.048
0.09
0.33
0.665
0.677
0.553
1.338
3.139
0.672
1.531
1.186
0.625

0.461
0.7
2.525
0.986
12.365
0.432
19.02
0.369
0.569
1.408
1.357
1.407
1.003
0.441
57.055
0.77
0.435
0.984
1.522
3.496
0.462
7.923
2.066
1.575
2.253
0.303
0.479
0.478
0.629
5.425
0.715
0.637
0.537
0.494
0.797
0.561
0.68
0.044
0.732
0.465
0.464
0.413
0.723
1.996
1.102
1.322
1.542
0.444

7.174
1.319
0.589
1.521
0.467
1.671
0.57
1.461
1.422
8.859
1.61
0.759
1.395
1.442
0.12
2.275
1.499
1.439
2.019
0.523
3.667
0.637
0.67
0.677
0.617
1.564
1.455
1.588
0.308
0.549
1.66
2.008
1.76
1.949
1.384
1.353
1.541
2.045
0.451
1.43
1.459
1.339
1.851
1.573
0.61
1.158
0.769
1.408
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A_44_P299109
A_44_P1025944
A_44_P622978
A_44_P457447
A_42_P588944
A_44_P278829
A_44_P1007347
A_44_P535706
A_42_P699937
A_44_P510951
A_44_P460797
A_44_P745393
A_43_P13808
A_44_P222865
A_44_P353708
A_44_P289312
A_44_P458241
A_42_P770458
A_43_P12741
A_44_P1031034
A_42_P577938
A_44_P505180
A_44_P309215
A_44_P351563
A_43_P15794
A_44_P397495
A_44_P457053
A_44_P522482
A_44_P261444
A_44_P137187
A_43_P10498
A_44_P605194
A_44_P281457
A_44_P1020018
A_42_P645110
A_44_P461944
A_44_P288826
A_44_P154298
A_44_P714885
A_44_P112237
A_44_P311247
A_44_P318941
A_44_P941132
A_44_P318029
A_44_P1006988
A_44_P494483
A_44_P311945
A_44_P222865

DV723665
NM_147140
TC590816
CF112427
NM_012862
XR_006025
NM_019386
ENSRNOT00000017422
NM_001034134
ENSRNOT00000028443
AF020046
ENSRNOT00000023274
NM_001017477
ENSRNOT00000005711
ENSRNOT00000016663
CB567518
ENSRNOT00000024406
NM_134414
NM_052798
NM_031745
NM_001014218
NM_057202
NM_001024771
A_44_P351563
NM_053766
NM_024359
XR_007987
NM_001013928
XM_343065
ENSRNOT00000042098
XM_237039
XM_340890
XM_001054883
ENSRNOT00000016882
NM_001029919
NM_001007714
ENSRNOT00000025491
XM_573787
TC589847
ENSRNOT00000052249
NM_212515
XM_225467
ENSRNOT00000030569
ENSRNOT00000035618
ENSRNOT00000025335
XM_215528
ENSRNOT00000013471
ENSRNOT00000005711

0.0005041
0.0005044
0.0005062
0.0005085
0.0005109
0.0005193
0.0005209
0.0005241
0.0005308
0.0005309
0.0005328
0.0005329
0.0005337
0.000536
0.0005408
0.0005419
0.0005452
0.0005461
0.0005473
0.00055
0.0005565
0.0005579
0.000562
0.0005674
0.0005693
0.0005738
0.0005842
0.0005852
0.0005871
0.0005956
0.0006055
0.0006068
0.0006188
0.0006236
0.0006237
0.0006247
0.0006283
0.0006297
0.0006318
0.0006338
0.0006366
0.0006397
0.0006409
0.0006414
0.0006515
0.0006579
0.0006591
0.0006702

0.333
0.58
5.765
0.739
50.115
1.844
0.245
1.352
3.899
0.61
3.973
0.09
0.658
1.501
1.369
1.076
0.239
0.885
0.812
0.564
0.894
0.664
0.364
1.57
0.588
0.125
1.138
0.071
2.911
0.849
0.706
1.143
1.096
0.662
0.347
0.614
0.694
1.096
0.23
2.896
1.549
2.824
0.492
0.895
0.916
0.5
0.78
1.206

0.232
0.375
10.524
0.382
140.76
0.455
0.151
0.88
6.584
1.014
6.483
0.179
0.405
0.349
0.858
1.693
0.152
0.388
0.474
0.754
0.466
0.323
0.675
1.118
1.221
0.523
1.517
0.014
4.225
0.339
0.55
2.011
1.32
0.495
0.233
0.177
1.011
0.664
0.887
1.439
5.636
0.699
0.342
0.581
1.599
0.327
0.56
0.809

1.435
1.547
0.548
1.935
0.356
4.053
1.623
1.536
0.592
0.602
0.613
0.503
1.625
4.301
1.596
0.636
1.572
2.281
1.713
0.748
1.918
2.056
0.539
1.404
0.482
0.239
0.75
5.071
0.689
2.504
1.284
0.568
0.83
1.337
1.489
3.469
0.686
1.651
0.259
2.013
0.275
4.04
1.439
1.54
0.573
1.529
1.393
1.491
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A_43_P10069
A_43_P12406
A_44_P451627
A_44_P503579
A_44_P1021630
A_44_P394119
A_44_P183694
A_44_P243604
A_44_P299247
A_44_P477446
A_44_P299247
A_44_P233080
A_44_P121682
A_44_P822078
A_44_P494652
A_44_P258751
A_42_P710738
A_44_P157045
A_44_P194925
A_44_P105791
A_42_P561580
A_44_P1042876
A_44_P808557
A_44_P1033023
A_44_P505500
A_44_P1016061
A_44_P302012
A_44_P975250
A_44_P748217
A_43_P17988
A_43_P11046
A_42_P489167
A_44_P1040854
A_44_P116176
A_44_P370645
A_44_P1042876
A_42_P638128
A_42_P592059
A_44_P741769
A_44_P556586
A_44_P152290
A_43_P15470
A_44_P165918
A_44_P1006655
A_44_P217774
A_44_P461657
A_44_P948037
A_43_P11040

DV717672
NM_024151
XM_237286
NM_201415
ENSRNOT00000058312
BG663439
AB072614
ENSRNOT00000055588
NM_012778
ENSRNOT00000043942
NM_012778
NM_012551
XM_230870
XM_576832
NM_001013431
NM_031081
NM_031620
ENSRNOT00000045196
ENSRNOT00000043365
BF548544
NM_031113
NM_031971
TC604543
NM_013063
ENSRNOT00000052393
DV729072
ENSRNOT00000007173
BC099121
ENSRNOT00000046038
NM_001025018
TC581726
XM_224963
NM_153628
ENSRNOT00000019107
ENSRNOT00000008329
NM_031971
NM_012893
ENSRNOT00000001922
AI555513
BC086580
ENSRNOT00000007761
NM_012701
ENSRNOT00000061986
NM_053597
NM_001009698
XM_001071880
NM_001039196
NM_001009639

0.0006711
0.0006715
0.0006795
0.0006824
0.0006851
0.0006855
0.0006931
0.0006933
0.0006943
0.0006943
0.0007009
0.0007016
0.0007019
0.0007079
0.0007097
0.00071
0.0007128
0.0007163
0.0007208
0.0007215
0.0007277
0.000728
0.0007292
0.0007296
0.0007313
0.0007316
0.0007354
0.0007392
0.000741
0.0007431
0.0007464
0.0007495
0.0007501
0.0007565
0.0007576
0.0007586
0.0007637
0.0007641
0.0007686
0.0007756
0.0007756
0.0007863
0.0007939
0.0007996
0.0007998
0.0008021
0.0008066
0.0008103

0.734
2.514
3.769
0.611
1.209
0.269
0.392
1.588
1.143
0.871
0.931
0.083
1.991
0.87
1.127
3.671
0.656
1.589
0.635
3.918
0.646
0.681
1.008
1.423
0.331
0.908
0.78
2.26
0.068
1.82
9.266
2.262
1.181
0.756
0.23
0.551
0.886
0.803
0.815
2.185
1.032
7.244
0.482
38.447
1.712
0.087
0.473
12.067

1.822
2.11
1.25
0.413
0.795
0.709
0.286
3.094
0.762
0.682
0.151
0.169
0.684
0.602
0.75
7.301
0.445
2.327
0.964
6.476
0.851
1.338
0.765
0.757
0.6
1.477
0.389
3.308
0.038
1.003
23.758
1.529
0.874
1.17
0.12
0.707
0.502
0.61
0.46
2.991
0.673
10.812
0.35
159.751
3.107
0.197
1.037
2.062

0.403
1.191
3.015
1.479
1.521
0.379
1.371
0.513
1.5
1.277
6.166
0.491
2.911
1.445
1.503
0.503
1.474
0.683
0.659
0.605
0.759
0.509
1.318
1.88
0.552
0.615
2.005
0.683
1.789
1.815
0.39
1.479
1.351
0.646
1.917
0.779
1.765
1.316
1.772
0.731
1.533
0.67
1.377
0.241
0.551
0.442
0.456
5.852
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A_44_P1037886
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A_44_P433367
A_44_P1022403
A_44_P175786
A_44_P233080
A_43_P11951
A_43_P11423
A_44_P158216
A_44_P463069
A_44_P454993
A_44_P159191
A_43_P10601
A_44_P299247
A_44_P153206
A_44_P239985
A_44_P390454
A_44_P515360
A_43_P14802
A_44_P386840
A_44_P944832
A_43_P11924
A_44_P416695
A_44_P220301
A_44_P489468
A_44_P716323
A_43_P15303
A_44_P411362
A_44_P461130
A_44_P822616
A_44_P100565
A_44_P1046566
A_44_P194928
A_44_P607486
A_44_P520509
A_43_P21455
A_44_P393422
A_44_P994686
A_44_P615732
A_44_P233080
A_44_P651794
A_44_P424218

NM_001047087
ENSRNOT00000061430
XM_223116
NM_001011911
NM_001033685
ENSRNOT00000002523
XR_006077
ENSRNOT00000022583
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NM_001004204
XM_228865
NM_012551
NM_019150
XM_342470
NM_022185
ENSRNOT00000043693
XM_346127
ENSRNOT00000025756
XM_220207
NM_012778
NM_031515
NM_013217
NM_017276
L22079
ENSRNOT00000024714
NM_001013209
BG671311
NM_017338
NM_001004022
ENSRNOT00000061270
ENSRNOT00000030661
TC591828
NM_030836
NM_001039026
NM_183333
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A_44_P100565
ENSRNOT00000004150
XM_213602
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ENSRNOT00000014917
NM_001013188
NM_012676
ENSRNOT00000017156
NM_012551
ENSRNOT00000034463
ENSRNOT00000017151

0.0008159
0.0008183
0.0008223
0.0008245
0.0008271
0.0008273
0.0008282
0.0008457
0.0008476
0.0008498
0.0008532
0.0008595
0.0008611
0.0008641
0.0008691
0.0008726
0.0008742
0.0008769
0.0008791
0.0008836
0.000884
0.000886
0.0008876
0.0008878
0.0008896
0.000898
0.0009006
0.0009066
0.0009075
0.0009099
0.0009113
0.0009123
0.0009146
0.0009199
0.0009207
0.0009226
0.0009235
0.0009309
0.0009324
0.0009348
0.0009367
0.0009367
0.0009437
0.0009481
0.0009491
0.0009521
0.0009522
0.0009556

1.181
2.309
0.912
1.483
0.881
3.685
0.613
1.202
1.465
0.57
0.663
19.682
0.717
2.707
3.961
0.242
0.531
0.464
0.791
0.466
0.537
3.275
1.052
0.173
0.181
1.185
1.381
1.43
1.158
2.08
1.891
0.787
0.992
0.488
0.576
0.301
1.072
0.372
0.804
0.574
0.303
2.121
4.067
0.72
0.863
0.08
2.17
0.353

2.543
1.108
0.491
2.58
0.563
7.419
0.422
0.786
3.048
1.239
1.022
2.38
0.488
1.324
6.366
0.493
0.354
0.991
0.468
1.036
0.904
2.127
0.794
0.66
0.398
0.787
0.916
6.28
1.518
0.966
0.339
1.106
0.73
0.363
0.405
0.79
0.652
0.295
1.355
1.476
1.137
1.49
6.81
0.393
0.643
0.506
0.77
0.163

0.464
2.084
1.857
0.575
1.565
0.497
1.453
1.529
0.481
0.46
0.649
8.27
1.469
2.045
0.622
0.491
1.5
0.468
1.69
0.45
0.594
1.54
1.325
0.262
0.455
1.506
1.508
0.228
0.763
2.153
5.578
0.712
1.359
1.344
1.422
0.381
1.644
1.261
0.593
0.389
0.266
1.423
0.597
1.832
1.342
0.158
2.818
2.166

275

A_44_P801044
A_44_P1060444
A_44_P280410
A_44_P492321
A_44_P374011
A_44_P851230
A_44_P603427
A_44_P336714
A_44_P649177
A_43_P16715
A_43_P11226
A_44_P533672
A_44_P473220
A_43_P22696
A_44_P299247
A_44_P160113
A_44_P992404
A_44_P994454
A_44_P266340
A_44_P252417
A_44_P836445
A_43_P16740
A_42_P525962
A_44_P652332
A_44_P542887
A_43_P17564
A_44_P510659
A_43_P16346
A_44_P309052
A_43_P10593
A_44_P473020
A_42_P800669
A_44_P1054213
A_44_P494862
A_42_P544965
A_44_P352123
A_44_P334709
A_44_P149036
A_44_P533778
A_44_P747226
A_44_P639148
A_43_P10326
A_44_P299247
A_44_P200630
A_44_P191784
A_44_P730758
A_44_P190226
A_42_P641234

NM_001025775
XM_216368
NM_183325
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AW918729
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NM_022281
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NM_013083
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NM_017138
NM_030830
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NM_012778
AA851208
NM_031969
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0.0009583
0.0009585
0.0009597
0.0009631
0.0009668
0.0009714
0.000974
0.0009758
0.000983
0.0009837
0.0009876
0.00099
0.0009937
0.0009963
0.0009988

0.627
1.394
1.368
2.75
0.221
0.625
1.862
1.034
0.868
0.982
1.968
0.592
3.106
0.615
2.723

0.389
1.004
0.74
4.731
0.512
0.444
0.905
2.247
0.597
3.155
5.095
0.853
1.057
0.407
1.304

1.612
1.388
1.849
0.581
0.432
1.408
2.057
0.46
1.454
0.311
0.386
0.694
2.939
1.511
2.088
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